<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>ES2873075T3 - 
  Lactobacillus plantarum probiotic strains for urinary tract infections
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/ES2873075T3/en">
    <meta name="description" content="
   
    A composition comprising an effective amount of at least one strain of Lactobacillus plantarum, wherein at least one strain of Lactobacillus plantarum is selected from the group consisting of: strain CECT8675, strain CECT8676, strain CECT8677, strain CECT8678 and a mutant of any of the deposited strains, wherein the mutant was obtained by using the deposited strain as a starting material and by mutagenesis, and wherein the obtained mutant retains or at least enhances the ability of the deposited strain to antagonize the pathogen urogenital Staphylococcus saprophyticus.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Lactobacillus plantarum probiotic strains for urinary tract infections
 
     ">
    <meta name="DC.date" content="2016-02-09" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    A composition comprising an effective amount of at least one strain of Lactobacillus plantarum, wherein at least one strain of Lactobacillus plantarum is selected from the group consisting of: strain CECT8675, strain CECT8676, strain CECT8677, strain CECT8678 and a mutant of any of the deposited strains, wherein the mutant was obtained by using the deposited strain as a starting material and by mutagenesis, and wherein the obtained mutant retains or at least enhances the ability of the deposited strain to antagonize the pathogen urogenital Staphylococcus saprophyticus.
   
 
   ">
    <meta name="citation_patent_application_number" content="ES:16704579T">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/d8/ff/7d/55ef6b50200564/ES2873075T3.pdf">
    <meta name="citation_patent_number" content="ES:2873075:T3">
    <meta name="DC.date" content="2021-11-03" scheme="issue">
    <meta name="DC.contributor" content="Gutierrez Jonathan Santas" scheme="inventor">
    <meta name="DC.contributor" content="Castellana Jordi Cune" scheme="inventor">
    <meta name="DC.contributor" content="Mallen Elisabet Lazaro" scheme="inventor">
    <meta name="DC.contributor" content="AB Biotics SA" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Lactobacillus plantarum probiotic strains for urinary tract infections
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA500586788" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composicin que comprende una cantidad eficaz de al menos una cepa de Lactobacillus plantarum, en donde al menos la cepa de Lactobacillus plantarum se selecciona del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677, la cepa CECT8678 y un mutante de cualquiera de las cepas depositadas, en donde el mutante se obtuvo mediante el uso de la cepa depositada como material de partida y mediante mutagnesis, y en donde el mutante obtenido retiene o potencia al menos la capacidad de la cepa depositada de antagonizar el patgeno urogenital Staphylococcus saprophyticus.</span>A composition comprising an effective amount of at least one strain of Lactobacillus plantarum, wherein at least one strain of Lactobacillus plantarum is selected from the group consisting of: strain CECT8675, strain CECT8676, strain CECT8677, strain CECT8678 and a mutant of any of the deposited strains, wherein the mutant was obtained by using the deposited strain as a starting material and by mutagenesis, and wherein the obtained mutant retains or at least enhances the ability of the deposited strain to antagonize the pathogen urogenital Staphylococcus saprophyticus.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/741"><a id="link" href="#" class="style-scope state-modifier">A61K35/741</a></state-modifier>
                  <span class="description style-scope classification-tree">Probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/744"><a id="link" href="#" class="style-scope state-modifier">A61K35/744</a></state-modifier>
                  <span class="description style-scope classification-tree">Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K35/747"><a id="link" href="#" class="style-scope state-modifier">A61K35/747</a></state-modifier>
                  <span class="description style-scope classification-tree">Lactobacilli, e.g. L. acidophilus or L. brevis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L"><a id="link" href="#" class="style-scope state-modifier">A23L</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/00"><a id="link" href="#" class="style-scope state-modifier">A23L33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/10"><a id="link" href="#" class="style-scope state-modifier">A23L33/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/135"><a id="link" href="#" class="style-scope state-modifier">A23L33/135</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria or derivatives thereof, e.g. probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/66"><a id="link" href="#" class="style-scope state-modifier">A61K31/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Phosphorus compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/665"><a id="link" href="#" class="style-scope state-modifier">A61K31/665</a></state-modifier>
                  <span class="description style-scope classification-tree">Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P41/00"><a id="link" href="#" class="style-scope state-modifier">A61P41/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2400/00"><a id="link" href="#" class="style-scope state-modifier">A23V2400/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Lactic or propionic acid bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2400/11"><a id="link" href="#" class="style-scope state-modifier">A23V2400/11</a></state-modifier>
                  <span class="description style-scope classification-tree">Lactobacillus</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2400/169"><a id="link" href="#" class="style-scope state-modifier">A23V2400/169</a></state-modifier>
                  <span class="description style-scope classification-tree">Plantarum</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2300/00"><a id="link" href="#" class="style-scope state-modifier">A61K2300/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00&nbsp;-&nbsp;A61K41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02"><a id="link" href="#" class="style-scope state-modifier">Y02</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A"><a id="link" href="#" class="style-scope state-modifier">Y02A</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A50/00"><a id="link" href="#" class="style-scope state-modifier">Y02A50/00</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y02A50/30"><a id="link" href="#" class="style-scope state-modifier">Y02A50/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 6 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">ES2873075T3</h2>
                  <p class="tagline style-scope patent-result">Spain</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Translation of granted European patent ( former B3)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/d8/ff/7d/55ef6b50200564/ES2873075T3.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;strain&quot;,&quot;strains&quot;,&quot;treatment&quot;,&quot;composition&quot;,&quot;probiotic&quot;]" data-before="20150211"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/ES2873075T3"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2873075T3/es"><a id="link" href="#" class="style-scope state-modifier">Spanish</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Gutierrez Jonathan Santas"><a id="link" href="#" class="style-scope state-modifier">Gutierrez Jonathan Santas</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Castellana Jordi Cune"><a id="link" href="#" class="style-scope state-modifier">Castellana Jordi Cune</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Mallen Elisabet Lazaro"><a id="link" href="#" class="style-scope state-modifier">Mallen Elisabet Lazaro</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    AB Biotics SA
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2015</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3064072A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP15382051.9A</div>
                <div class="style-scope application-timeline">Filing date: 2015-02-11</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2016</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2016128414A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2016/052747</div>
                <div class="style-scope application-timeline">Filing date: 2016-02-09</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3261723B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP16704579.8A</div>
                <div class="style-scope application-timeline">Filing date: 2016-02-09</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2873075T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES16704579T</div>
                <div class="style-scope application-timeline">Filing date: 2016-02-09</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application ES16704579T events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2016-02-09</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="AB Biotics SA"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by AB Biotics SA</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2021-11-03</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2021-11-03</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2873075T3/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of ES2873075T3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2036-02-09</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (5)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (5)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=ES&amp;NR=2873075T3&amp;KC=T3&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/ES/2873075/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/ES2873075T3">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES312452369" lang="EN" load-source="google" class="style-scope patent-text">
  
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIN</span>DESCRIPTION</span>
  </p>
  <p id="p0001" num="0001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas probiticas de Lactobacillus plantarum para las infecciones del tracto urinario</span>Lactobacillus plantarum probiotic strains for urinary tract infections</span>
  </p>
  <p id="p0002" num="0002" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La presente invencin se refiere a los campos de la medicina y la microbiologa y, en particular, a nuevas cepas de Lactobacillus plantarum para su uso como probitico en beneficio de la salud humana y animal. La presente invencin incluye una formulacin probitica mejorada que se usa como producto alimenticio, suplemento alimenticio, alimento mdico, medicamento, producto farmacutico, producto veterinario y producto de higiene personal, y los usos de los mismos.</span>The present invention relates to the fields of medicine and microbiology and, in particular, to new strains of Lactobacillus plantarum for use as a probiotic for the benefit of human and animal health. The present invention includes an improved probiotic formulation for use as a food product, food supplement, medical food, drug, pharmaceutical product, veterinary product, and personal hygiene product, and the uses thereof.</span>
  </p>
  <p id="p0003" num="0003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antecedentes de la tcnica</span>Background of the technique</span>
  </p>
  <p id="p0004" num="0004" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Probiticos</span>Probiotics</span>
  </p>
  <p id="p0005" num="0005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El concepto de microorganismos probiticos naci de la hiptesis del Premio Nobel Elie Metchnikoff, quien sugiri que el consumo de bacterias capaces de fermentar (comnmente bacterias productoras de cido lctico) tiene un efecto positivo sobre la microbiota del colon, al reducir la presencia de toxinas bacterianas y otras actividades microbianas, las cuales tienen un impacto negativo en la salud humana.</span>The concept of probiotic microorganisms was born from the hypothesis of the Nobel Prize winner Elie Metchnikoff, who suggested that the consumption of bacteria capable of fermenting (commonly lactic acid producing bacteria) has a positive effect on the microbiota of the colon, by reducing the presence of bacterial toxins. and other microbial activities, which have a negative impact on human health.</span>
  </p>
  <p id="p0006" num="0006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Los probiticos son microorganismos vivos los cuales, administrados en cantidades adecuadas, confieren un beneficio para la salud del hospedero". En la actualidad, existen muchas referencias sobre la utilidad de los probiticos para tratar varios trastornos gastrointestinales. Adems, algunos estudios sugieren que los probiticos pueden modular el sistema inmunolgico, prevenir las alergias y las enfermedades relacionadas.</span>"Probiotics are live microorganisms which, when administered in adequate quantities, confer a benefit for the health of the host." Today, there are many references to the usefulness of probiotics in treating various gastrointestinal disorders. In addition, some studies suggest that probiotics can modulate the immune system, prevent allergies and related diseases.</span>
  </p>
  <p id="p0007" num="0007" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las bacterias probiticas deben cumplir diferentes requisitos relacionados con la ausencia de toxicidad, viabilidad, capacidad de colonizacin y los efectos beneficiosos. Las propiedades de cada cepa bacteriana son nicas y no pueden extrapolarse a otras cepas de la misma especie (ARAYA, M., y otros, Guidelines for the Evaluation of Probiotics in Food - Joint FAO/WHO Working Group, FAO/WhO, Editor 2002, Food and Agriculture Organization of the United Nations and World Health Organization: Ontario, Canada). Por tanto, es importante encontrar aquellas cepas que tengan un mejor desempeo en todos los requerimientos de los probiticos.</span>Probiotic bacteria must meet different requirements related to the absence of toxicity, viability, colonization capacity and beneficial effects. The properties of each bacterial strain are unique and cannot be extrapolated to other strains of the same species (ARAYA, M., et al., Guidelines for the Evaluation of Probiotics in Food - Joint FAO / WHO Working Group, FAO / WhO, Editor 2002 , Food and Agriculture Organization of the United Nations and World Health Organization: Ontario, Canada). Therefore, it is important to find those strains that perform better in all probiotic requirements.</span>
  </p>
  <p id="p0008" num="0008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aunque el concepto de probiticos se asoci con la flora microbiana intestinal, los estudios realizados ya en 1987 mostraron que este concepto tambin podra extenderse al tracto urinario. Algunos grupos cientficos han desarrollado esta idea desde hace algunos aos, lo cual culmin con la identificacin de algunas cepas de Lactobacillus las cuales son tiles para tratar complicaciones del tracto urinario [REID, G. y otros. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J. Urol. 1987, Vol.</span>Although the concept of probiotics was associated with the intestinal microbial flora, studies carried out as early as 1987 showed that this concept could also be extended to the urinary tract. Some scientific groups have developed this idea for some years, which culminated in the identification of some Lactobacillus strains which are useful to treat urinary tract complications [REID, G. and others. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J. Urol. 1987, Vol.</span>
  </p>
  <p id="p0009" num="0009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">138, pginas 330-335].</span>138, pages 330-335].</span>
  </p>
  <p id="p0010" num="0010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">C istitis o infeccin del tracto urinario (ITU)</span>Cystitis or urinary tract infection (UTI)</span>
  </p>
  <p id="p0011" num="0011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Informacin general</span>General information</span>
  </p>
  <p id="p0012" num="0012" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cistitis es una infeccin aguda de la vejiga urinaria o del rin, la cual es ms comn en las mujeres que en los hombres. Existen diferentes entidades clnicas relacionadas con la cistitis, a saber, la cistitis aguda, pielonefritis aguda (o infeccin del rin), ITU no complicada (o cistitis aguda o pielonefritis que ocurren en las mujeres premenopusicas sanas, no embarazadas sin antecedentes de tracto urinario anormal), las llamadas ITU complicadas (o infeccin en pacientes con enfermedades funcionales, metablicas o anatmicas, como la obstruccin, el embarazo, la diabetes, vejiga neurognica, insuficiencia renal, la inmunosupresin, las cuales pueden aumentar el riesgo de fracaso del tratamiento o resultados graves) y la ITU recurrente (ITUr) [HOOTON, T.M. Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, Vol. 366, No. 11, pginas 1028-1037; GRABE, M. y otros. European Association of Urology (EAU). Guidelines on urological infections. EAU. Marzo de 2013]. La recurrencia de ITU (o ITU recurrente) ocurre debido a una recada o una reinfeccin. Una recada es cuando no se ha podido curar la infeccin original con (o sin) tratamiento. La reinfeccin es cuando la infeccin original se elimin mediante el tratamiento (por ejemplo, antibiticos) pero vuelve a ocurrir en unas semanas. Una recada es causada por el mismo microorganismo infeccioso que estaba presente antes del tratamiento inicial, generalmente debido a una resistencia del microorganismo al tratamiento farmacolgico. Una reinfeccin es un nuevo episodio de bacteriuria con un microorganismo diferente al original (por ejemplo, bacteriuria con especies de S. saprophyticus cuando la infeccin original fue causada por E. coli), aunque tambin puede ocurrir una reinfeccin con el mismo organismo que caus la infeccin original. En este ltimo caso, la caracterstica principal que diferencia una reinfeccin de una recada es que los episodios individuales de reinfeccin suelen estar separados por un intervalo libre de sntomas de al menos un mes despus de que se suspenden los antibiticos y la orina no muestra un crecimiento bacteriano. [SALVATORE, S. y otros. Urinary Tract Infections in Women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, Vol. 156, pginas 131-136]. 
</span>Cystitis is an acute infection of the urinary bladder or kidney, which is more common in women than in men. There are different clinical entities associated with cystitis, namely acute cystitis, acute pyelonephritis (or kidney infection), uncomplicated UTI (or acute cystitis or pyelonephritis that occur in healthy, non-pregnant premenopausal women with no history of abnormal urinary tract ), so-called complicated UTIs (or infection in patients with functional, metabolic or anatomical diseases, such as obstruction, pregnancy, diabetes, neurogenic bladder, kidney failure, immunosuppression, which can increase the risk of treatment failure or results severe) and recurrent UTI (rUTI) [HOOTON, TM Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, Vol. 366, No. 11, pages 1028-1037; GRABE, M. and others. European Association of Urology (EAU). Guidelines on urological infections. UAE. March 2013]. UTI recurrence (or recurrent UTI) occurs due to relapse or reinfection. A relapse is when the original infection has not been cured with (or without) treatment. Re-infection is when the original infection was cleared by treatment (for example, antibiotics) but reoccurs within a few weeks. A relapse is caused by the same infectious organism that was present before the initial treatment, usually due to a resistance of the organism to drug treatment. A reinfection is a new episode of bacteriuria with a different organism than the original (for example, bacteriuria with S. saprophyticus species when the original infection was caused by E. coli), although a reinfection with the same organism that caused the infection may also occur. original infection. In the latter case, the main characteristic that differentiates a reinfection from a relapse is that the individual episodes of reinfection are usually separated by a symptom-free interval of at least one month after antibiotics are stopped and the urine shows no growth. bacterial. [SALVATORE, S. and others. Urinary Tract Infections in Women. Eur. J. Obstet. Gynecol. Play Biol. 2011, Vol. 156, pages 131-136]. </span>
  </p>
  <p id="p0013" num="0013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Epidemiologa</span>epidemiology</span>
  </p>
  <p id="p0014" num="0014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En cuanto a la incidencia o prevalencia de ITU, se encuentran entre las ms frecuentes las infecciones bacterianas en las mujeres. Se estima que alrededor del 40-60 % de las mujeres premenopusicas desarrollaran al menos una ITU en su vida. En general, la incidencia media estimada por ao de una ITU en las mujeres es de 2,1 % en la infancia, 3 % en la niez, 15,2 % para las mujeres adultas de 17-39 aos, 11,4 % para las mujeres premenopusicas (de 40-59 aos) y 9,7 % para las mujeres posmenopusicas (de 60-79 aos) [FOX<sup class="style-scope patent-text">m</sup>A<sup class="style-scope patent-text">n </sup>, B. y B<sup class="style-scope patent-text">r</sup>O<sup class="style-scope patent-text">w </sup>N. P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect. Dis. Clin. North. Am. 2003, Vol. 17, No. 2, pginas 227-241]. En mujeres jvenes sexualmente activas y en mujeres posmenopusicas, la incidencia de ITU no complicada se estima entre 0,5-0,7 y 0,07 por persona-ao, respectivamente [HOOTON, T.M. y otros. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 1996, Vol. 335, No. 7, pginas 468-474; JACKSON, S. L. y otros. Predictors of urinary tract infection after menopause: a prospective study. Am. J. Med. 2004, Vol. 117, No. 12, pginas 903-11]. En trminos generales, la prevalencia de la cistitis en hombres es menor que en mujeres, y es ms comn en mujeres que en hombres durante la juventud y la edad adulta. Sin embargo, la prevalencia de ITU en los hombres y mujeres de edad avanzada es casi igual. Se estima una incidencia anual de 6-8 ITU por cada 10000 hombres de 21-50 aos [ULLERYD, P. y otros. Febrile urinary tract infection in men. Int. J. Antimicrob. Agents. 2003, Vol. 22, Suppl. 2, pginas 89-93].</span>Regarding the incidence or prevalence of UTI, bacterial infections in women are among the most frequent. It is estimated that around 40-60% of premenopausal women would develop at least one UTI in their lifetime. In general, the estimated average incidence per year of a UTI in women is 2.1% in infancy, 3% in childhood, 15.2% for adult women aged 17-39 years, 11.4% for premenopausal women (40-59 years) and 9.7% for postmenopausal women (60-79 years) [FOX <sup class="style-scope patent-text">m</sup> A <sup class="style-scope patent-text">n</sup> , B. and B <sup class="style-scope patent-text">r</sup> O <sup class="style-scope patent-text">w</sup> NP Epidemiology of urinary tract infections: transmission and risk factors , incidence, and costs. Infect. Dis. Clin. North. Am. 2003, Vol. 17, No. 2, pages 227-241]. In sexually active young women and postmenopausal women, the incidence of uncomplicated UTI is estimated to be between 0.5-0.7 and 0.07 per person-year, respectively [HOOTON, TM et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 1996, Vol. 335, No. 7, pages 468-474; JACKSON, SL and others. Predictors of urinary tract infection after menopause: a prospective study. Am. J. Med. 2004, Vol. 117, No. 12, pages 903-11]. Generally speaking, the prevalence of cystitis in men is lower than in women, and it is more common in women than in men during youth and adulthood. However, the prevalence of UTI in elderly men and women is about the same. An annual incidence of 6-8 UTIs is estimated for every 10,000 men aged 21-50 years [ULLERYD, P. et al. Febrile urinary tract infection in men. Int. J. Antimicrob. Agents. 2003, Vol. 22, Suppl. 2, pages 89-93].</span>
  </p>
  <p id="p0015" num="0015" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etiologa</span>Etiology</span>
  </p>
  <p id="p0016" num="0016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De acuerdo con la Sociedad de Enfermedades Infecciosas de Amrica y la Sociedad Europea de Microbiologa y Enfermedades Infecciosas, en general, el espectro microbiano de cistitis y pielonefritis no complicadas en las mujeres consiste en Escherichia coli (75-95 %) [GUPTA, K. y otros. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases.</span>According to the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases, in general, the microbial spectrum of uncomplicated cystitis and pyelonephritis in women consists of Escherichia coli (75-95%) [GUPTA, K. and others. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases.</span>
  </p>
  <p id="p0017" num="0017" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1 Marzo 2011, Vol. 52, No. 1, e103-e120].</span>March 1, 2011, Vol. 52, No. 1, e103-e120].</span>
  </p>
  <p id="p0018" num="0018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aunque los datos pueden variar considerablemente en funcin de la poblacin en estudio, en particular del pas, y del sexo y la edad, se proponen microorganismos tales como Staphylococcus saprophyticus, Proteus mirabilis y Klebsiella pneumoniae como los segundos agentes causales ms frecuentes de ITU. Por ejemplo, en las ITU que afectan a mujeres suecas en el rango de 15-29 aos, se ha propuesto que S. saprophyticus est presente en el 14,7 % de los episodios de ITU, lo cual es especialmente relevante en mujeres sexualmente activas [ERIKSSON, A. y otros. The relative importance of Staphylococcus saprophyticus as a urinary tract pathogen: distribution of bacteria among urinary samples analyzed during 1 year at a major Swedish laboratory. APMIS. 2012, Vol. 121, pginas 72 78]. Tambin se ha reportado que P. mirabilis y K. pneumoniae, pueden estar presentes en el 3 % y el 5,9 % de los casos en la poblacin sueca en general. En otros pases europeos, los datos tambin apoyan la relevancia de estos microorganismos como los segundos agentes causantes ms frecuentes de ITU [GARC<sup class="style-scope patent-text"></sup>A-GARC<sup class="style-scope patent-text"></sup>A, M.I. y otros. In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J. Chemotherapy. 2007, Vol. 19, pginas 263-270].</span>Although the data may vary considerably depending on the study population, in particular the country, and on sex and age, microorganisms such as Staphylococcus saprophyticus, Proteus mirabilis and Klebsiella pneumoniae are proposed as the second most frequent causative agents of UTI. For example, in UTIs that affect Swedish women in the range 15-29 years, it has been proposed that S. saprophyticus is present in 14.7% of UTI episodes, which is especially relevant in sexually active women [ERIKSSON, A. and others. The relative importance of Staphylococcus saprophyticus as a urinary tract pathogen: distribution of bacteria among urinary samples analyzed during 1 year at a major Swedish laboratory. APMIS. 2012, Vol. 121, pages 72-78]. It has also been reported that P. mirabilis and K. pneumoniae may be present in 3% and 5.9% of cases in the general Swedish population. In other European countries, data also support the relevance of these microorganisms as the second most frequent causative agents of UTI [GARC <sup class="style-scope patent-text"></sup> A-GARC <sup class="style-scope patent-text"></sup> A, MI and others. In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J. Chemotherapy. 2007, Vol. 19, pages 263-270].</span>
  </p>
  <p id="p0019" num="0019" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de ITU</span>UTI treatment</span>
  </p>
  <p id="p0020" num="0020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los agentes recomendados con ms frecuencia para el tratamiento de la ITU no complicada en las mujeres incluyen los siguientes antibiticos [GUPTA, K. y otros, supra; GRABE, M. y otros, supra],</span>The most commonly recommended agents for the treatment of uncomplicated UTI in women include the following antibiotics [GUPTA, K. et al., Supra; GRABE, M. and others, supra],</span>
  </p>
  <p id="p0021" num="0021" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. - cotrimoxazol, tambin conocido como trimetoprim-sulfametoxazol (TMP-SMX), 160/800 mg (1 tableta de doble concentracin) por va oral dos veces al da durante 3 das;</span>1. - cotrimoxazole, also known as trimethoprim-sulfamethoxazole (TMP-SMX), 160/800 mg (1 double strength tablet) orally twice a day for 3 days;</span>
  </p>
  <p id="p0022" num="0022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. - nitrofurantona monohidrato/macrocristales, 100 mg por va oral dos veces al da durante 5-7 das; y, 3. - fosfomicina-trometamol, 3 g por va oral en dosis nica.</span>2. - nitrofurantoin monohydrate / macrocrystals, 100 mg orally twice a day for 5-7 days; and 3. - fosfomycin-trometamol, 3 g orally in a single dose.</span>
  </p>
  <p id="p0023" num="0023" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sin embargo, en general, el uso de los antibiticos conduce a una mayor presencia de microorganismos resistentes a los frmacos, lo cual no es una excepcin en el caso de las ITU.</span>However, in general, the use of antibiotics leads to an increased presence of drug-resistant microorganisms, which is no exception in the case of UTIs.</span>
  </p>
  <p id="p0024" num="0024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por ejemplo, las relaciones de resistencia de TMP-SMX estn en aumento, especialmente fuera de los Estados Unidos. De hecho, la Asociacin Europea de Urologa ya no lo recomienda como agente de tratamiento de primera lnea, especialmente si las tasas de resistencia local son &lt; 20 %, si se sabe que la cepa infectante es susceptible a ella o si se ha utilizado para el tratamiento de la ITU en los 3 meses anteriores. Se estima que en Espaa solo el 66,1 % de las muestras clnicas de E. coli son sensibles a este antibitico [ANDREU, A., y otros. Etiologa y sensibilidad a los antimicrobianos de los uropatgenos causantes de la infeccin urinaria baja adquirida en la comunidad. Estudio nacional multicntrico. Enferm. Infecc. Microbiol. Clin. 2005, Vol. 23, No. 1, pginas 4-9].</span>For example, TMP-SMX resistance ratios are on the rise, especially outside of the United States. In fact, the European Association of Urology no longer recommends it as a first-line treatment agent, especially if local resistance rates are &lt;20%, if the infecting strain is known to be susceptible to it, or if it has been used for UTI treatment in the previous 3 months. It is estimated that in Spain only 66.1% of clinical samples of E. coli are sensitive to this antibiotic [ANDREU, A., and others. Etiology and antimicrobial sensitivity of the uropathogens causing community-acquired lower urinary tract infection. National multicenter study. Sick Infecc. Microbiol. Clin. 2005, Vol. 23, No. 1, pages 4-9].</span>
  </p>
  <p id="p0025" num="0025" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por otro lado, la nitrofurantona no puede considerarse un tratamiento til a corto plazo (hasta 3 das) y solo se recomienda para tratamientos entre 5 a 7 das, lo cual pueden comprometer la adhesin al tratamiento. Aunque se reporta que la resistencia a la nitrofurantona permanece baja (3-11 %), se considera que no es eficaz contra 
microorganismos tales como P. mirabilis y especies de Klebsiella /KAHLMETER, G. An International survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. Journal of Antimicrobial Chemotherapy. 2003, Vol. 51, pginas 69-76]. Adems, el uso de la nitrofurantona en Europa se discute de manera controvertida debido a sus efectos secundarios potencialmente peligrosos despus de una exposicin prolongada (polineuropata, neumona intersticial y hepatitis) [HUMMERS-PRADIER, E. y otros. Urinary tract infections in adult general practice patients. British Journal of general practice. 2002, Vol. 52, pginas 752-761]. </span>On the other hand, nitrofurantoin cannot be considered a useful short-term treatment (up to 3 days) and is only recommended for treatments between 5 to 7 days, which can compromise adherence to treatment. Although resistance to nitrofurantoin is reported to remain low (3-11%), it is considered to be ineffective against  microorganisms such as P. mirabilis and Klebsiella species / KAHLMETER, G. An International survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. Journal of Antimicrobial Chemotherapy. 2003, Vol. 51, pages 69-76]. Furthermore, the use of nitrofurantoin in Europe is controversially discussed due to its potentially dangerous side effects after prolonged exposure (polyneuropathy, interstitial pneumonia, and hepatitis) [HUMMERS-PRADIER, E. et al. Urinary tract infections in adult general practice patients. British Journal of general practice. 2002, Vol. 52, pages 752-761].</span>
  </p>
  <p id="p0026" num="0026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, la fosfomicina-trometamol se selecciona comnmente como la primera opcin de tratamiento debido a su amplio espectro de accin y su efectividad contra E. coli. Adems, tiene la ventaja de que se administra en una sola dosis, lo cual asegura altas tasas de adhesin al tratamiento y, en consecuencia, disminuye la probabilidad de resistencias a los antibiticos. Sin embargo, una limitacin en el uso de la fosfomicina-trometamol es que, en algunas poblaciones, aunque es muy eficaz contra E. coli, la eficacia contra otros patgenos causantes, como las cepas de S. saprophyticus, es baja. Por ejemplo, GARCA-GARCA MI, y otros supra, reportaron que la tasa de susceptibilidad de S. saprophyticus a fosfomicina en la poblacin espaola fue solo del 56,3 % en 2002 y disminuy a 20,6 % en 2004, mientras que en el mismo perodo la susceptibilidad de E. coli fue superior al 97 % [GARCA-GARCA, MI, y otros supra]. Adems, en comparacin con E. coli, la actividad de la fosfomicina puede ser menor frente a otros agentes responsables de las ITU, como P. mirabilis (76 %) y K. pneumoniae (78,5 %). Esta eficacia reducida puede atribuirse a un aumento de la resistencia a los antibiticos de estos uropatgenos, lo cual puede esperarse que aumente en los prximos aos.</span>Therefore, fosfomycin-trometamol is commonly selected as the first treatment option due to its broad spectrum of action and its effectiveness against E. coli. In addition, it has the advantage that it is administered in a single dose, which ensures high rates of adherence to treatment and, consequently, reduces the probability of resistance to antibiotics. However, a limitation in the use of fosfomycin-trometamol is that, in some populations, although it is highly effective against E. coli, the efficacy against other causative pathogens, such as S. saprophyticus strains, is low. For example, GARCA-GARCA MI, and others supra, reported that the susceptibility rate of S. saprophyticus to fosfomycin in the Spanish population was only 56.3% in 2002 and decreased to 20.6% in 2004, while in the same period, the susceptibility of E. coli was higher than 97% [GARCA-GARCA, MI, and others supra]. Furthermore, compared to E. coli, the activity of fosfomycin may be lower against other agents responsible for UTIs, such as P. mirabilis (76%) and K. pneumoniae (78.5%). This reduced efficacy can be attributed to an increase in the antibiotic resistance of these uropathogens, which can be expected to increase in the coming years.</span>
  </p>
  <p id="p0028" num="0028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En resumen, tanto el riesgo de ITU de por vida como la incidencia de episodios de ITU recurrentes, principalmente entre las mujeres, son altos. En general, el uso de antibiticos conduce a una mayor presencia de microorganismos resistentes a los frmacos, lo cual no es una excepcin en el caso de las ITU. De hecho, como se discuti anteriormente, existe el problema del aumento de los principales patgenos causantes de las ITU que muestran resistencia a los agentes empricos de primera lnea para la cistitis aguda no complicada, a saber, la fosfomicina y el TMP-SMX. Tambin como ya se ha comentado, los episodios de ITUr requieren en la mayora de los casos de ciclos repetidos de tratamiento antimicrobiano. De hecho, la profilaxis antibitica a largo plazo es el mtodo ms comn para el manejo actual de las ITUr, con la importante limitacin de las crecientes resistencias antimicrobianas mencionadas.</span>In summary, both the lifetime risk of UTI and the incidence of recurrent UTI episodes, mainly among women, are high. In general, the use of antibiotics leads to an increased presence of drug-resistant microorganisms, which is no exception in the case of UTIs. In fact, as discussed above, there is the problem of an increase in the main pathogens causing UTIs that show resistance to the first-line empirical agents for acute uncomplicated cystitis, namely fosfomycin and TMP-SMX. Also, as already mentioned, episodes of rUTI require, in most cases, repeated cycles of antimicrobial treatment. In fact, long-term antibiotic prophylaxis is the most common method for the current management of rUTIs, with the important limitation of the increasing antimicrobial resistance mentioned.</span>
  </p>
  <p id="p0030" num="0030" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todos estos factores hacen que el tratamiento y la prevencin de las ITU sean cada vez ms problemticos. En consecuencia, actualmente se necesitan estrategias de tratamiento y prevencin sin antibiticos, novedosas, seguras y eficaces, solas o en combinacin con antibiticos.</span>All of these factors make the treatment and prevention of UTIs increasingly problematic. Consequently, novel, safe and effective non-antibiotic treatment and prevention strategies are currently needed, alone or in combination with antibiotics.</span>
  </p>
  <p id="p0032" num="0032" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamientos alternativos para el manejo de ITU</span>Alternative treatments for the management of UTI</span>
  </p>
  <p id="p0034" num="0034" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La tcnica describe otros productos que se utilizan actualmente para la prevencin y el tratamiento de ITUr, como los extractos de arndano rojo. Estas bayas son ricas en proantocianidinas (PAC), es decir, taninos capaces de prevenir la expresin de las fimbrias P del uropatgeno E. coli, lo cual inhibe la sntesis de la pared celular bacteriana y la expresin celular de molculas de adhesin a la mucosa urogenital. Algunos hallazgos indican que los productos que contienen arndanos podran estar clnicamente asociados con un efecto protector contra las ITU [SENGUPTA, K. y otros. A Randomized, double blind, controlled, dose dependent clinical trial to evaluate the efficacy of a proanthocyanidin standardized whole cranberry (Vaccinium macrocarpon) powder on infections of the urinary tract. Current Bioactive Compounds. Marzo de 2011, Vol. 7, No 1, pginas 39-42]. Sin embargo, estas observaciones no estn respaldadas por los resultados de algunos ensayos clnicos [BARBOSA-CESNIK, C. y otros. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clinical Infectious Diseases. 2011, Vol. 52, No. 1, pginas 23-30]. Entonces, la evidencia cientfica general est lejos de ser concluyente.</span>The technique describes other products that are currently used for the prevention and treatment of rUTIs, such as cranberry extracts. These berries are rich in proanthocyanidins (PAC), that is, tannins capable of preventing the expression of the P fimbriae of the uropathogen E. coli, which inhibits the synthesis of the bacterial cell wall and the cellular expression of adhesion molecules to the mucosa urogenital. Some findings indicate that blueberry-containing products could be clinically associated with a protective effect against UTIs [SENGUPTA, K. et al. A Randomized, double blind, controlled, dose dependent clinical trial to evaluate the efficacy of a proanthocyanidin standardized whole cranberry (Vaccinium macrocarpon) powder on infections of the urinary tract. Current Bioactive Compounds. March 2011, Vol. 7, No 1, pages 39-42]. However, these observations are not supported by the results of some clinical trials [BARBOSA-CESNIK, C. et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clinical Infectious Diseases. 2011, Vol. 52, No. 1, pages 23-30]. So the general scientific evidence is far from conclusive.</span>
  </p>
  <p id="p0036" num="0036" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los lactobacilos estn presentes en la flora vaginal, en donde desarrollan diversas funciones esenciales para el mantenimiento del equilibrio fisiolgico vaginal y la prevencin de las infecciones. La flora "normal" del tracto reproductivo est dominada numricamente por especies de Lactobacillus que mantienen el pH cido natural de la vagina, actan como una barrera natural contra los patgenos y producen compuestos antimicrobianos que inhiben la colonizacin y/o el crecimiento excesivo de los microorganismos patgenos. Sin embargo, se reconoce que la composicin de la microbiota puede variar de un da a otro incluso en mujeres sin indicacin de infecciones, debido a la influencia de varios factores tales como: los cambios hormonales (es decir, los ciclos menstruales), la anticoncepcin orientada a biomateriales, el contacto sexual, las prcticas de higiene femenina, el consumo de antibiticos, el estado nutricional, la competencia microbiana interespecfica o el comensalismo. Las enfermedades urogenitales en las mujeres a menudo se caracterizan por una alteracin en la flora local desde el predominio de lactobacilos hasta los patgenos oportunistas. Las enfermedades urogenitales incluyen la vaginosis, vaginitis o ITU. Por ejemplo, la vaginosis bacteriana es una enfermedad comn caracterizada por un cambio en la microbiota vaginal de lactobacilos protectores a bacterias patgenas como Gardnerella vaginalis y Mycoplasma hominis. De manera similar, la vaginitis es una alteracin de la flora vaginal, generalmente causada por un crecimiento excesivo o una infeccin de las especies de Candida o Trichomonas. La vaginitis en comparacin con la vaginosis da lugar adems a una inflamacin vulvovaginal. 
</span>Lactobacilli are present in the vaginal flora, where they perform various essential functions for maintaining vaginal physiological balance and preventing infections. The "normal" flora of the reproductive tract is numerically dominated by Lactobacillus species that maintain the natural acidic pH of the vagina, act as a natural barrier against pathogens, and produce antimicrobial compounds that inhibit the colonization and / or overgrowth of microorganisms. pathogens. However, it is recognized that the composition of the microbiota can vary from day to day even in women with no indication of infections, due to the influence of various factors such as: hormonal changes (i.e. menstrual cycles), contraception oriented to biomaterials, sexual contact, feminine hygiene practices, antibiotic consumption, nutritional status, interspecific microbial competition or commensalism. Urogenital diseases in women are often characterized by an alteration in the local flora from the predominance of lactobacilli to opportunistic pathogens. Urogenital diseases include vaginosis, vaginitis, or UTI. For example, bacterial vaginosis is a common disease characterized by a change in the vaginal microbiota from protective lactobacilli to pathogenic bacteria such as Gardnerella vaginalis and Mycoplasma hominis. Similarly, vaginitis is an alteration of the vaginal flora, usually caused by an overgrowth or infection of the Candida or Trichomonas species. Vaginitis compared to vaginosis also leads to vulvovaginal inflammation. </span>
  </p>
  <p id="p0037" num="0037" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha postulado que los lactobacilos pueden usarse para el tratamiento de las enfermedades vaginales. Por ejemplo, se han estudiado formulaciones probiticas para su uso en el tratamiento de la vaginosis bacteriana (VB) [LARSSON, P.G. y otros. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infectious Diseases. 2011. Vol. 11, pgina 223]. El estudio muestra que el tratamiento agresivo de la paciente con un tratamiento antibitico repetido con clindamicina y metronidazol junto con cpsulas de gelatina vaginal que contienen diferentes cepas de lactobacilos, puede proporcionar una cura duradera. Sin embargo, en este estudio no hay control sin probiticos, por lo cual no se pueden evaluar las diferencias en la eficacia y en el riesgo de recada entre el tratamiento combinado y el uso de antibiticos habituales.</span>Lactobacilli have been postulated to be used for the treatment of vaginal diseases. For example, probiotic formulations have been studied for use in the treatment of bacterial vaginosis (BV) [LARSSON, P.G. and others. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infectious Diseases. 2011. Vol. 11, page 223]. The study shows that aggressive treatment of the patient with repeated antibiotic treatment with clindamycin and metronidazole along with vaginal gelatin capsules containing different strains of lactobacilli, can provide a long-lasting cure. However, in this study there is no control without probiotics, so the differences in efficacy and risk of relapse between combined treatment and the use of standard antibiotics cannot be evaluated.</span>
  </p>
  <p id="p0039" num="0039" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sin embargo, existe incertidumbre sobre si la aplicacin vaginal de lactobacilos reduce la tasa de infeccin en mujeres propensas a la cistitis [BAERHEIM, A. y otros. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand. J. Prim. Health Care. 1994. Vol. 12, pginas 239-243].</span>However, there is uncertainty as to whether vaginal application of lactobacilli reduces the rate of infection in women prone to cystitis [BAERHEIM, A. et al. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand. J. Prim. Health Care. 1994. Vol. 12, pages 239-243].</span>
  </p>
  <p id="p0041" num="0041" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AQUILEA INTIMUS es un probitico oral compuesto por dos cepas de lactobacilos, es decir, Lactobacillus rhamnosus GR-1, aislado a partir de la uretra de una mujer sana, y Lactobacillus reuteri RC-14, aislado a partir de la vagina de una mujer sana. Se ha demostrado una vez ms que estas dos cepas probiticas son eficaces para el tratamiento de la vaginosis bacteriana [MARTINEZ, R.C.R. y otros. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double blind, placebo control trial. Canadian Journal of Microbiology. 2009, Vol. 55, pginas 133-138]. Otro estudio report que una composicin oral que comprende las mismas cepas aument el efecto de la terapia con metronidazol para la vaginosis bacteriana [ANUKAM, K. y otros. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, doubleblind, placebo controlled trial. Microbes and infection. 2006. Vol. 8. pginas 1450-1454].</span>AQUILEA INTIMUS is an oral probiotic composed of two strains of lactobacilli, that is, Lactobacillus rhamnosus GR-1, isolated from the urethra of a healthy woman, and Lactobacillus reuteri RC-14, isolated from the vagina of a healthy woman. These two probiotic strains have been shown once again to be effective for the treatment of bacterial vaginosis [MARTINEZ, R.C.R. and others. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double blind, placebo control trial. Canadian Journal of Microbiology. 2009, Vol. 55, pages 133-138]. Another study reported that an oral composition comprising the same strains increased the effect of metronidazole therapy for bacterial vaginosis [ANUKAM, K. et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, doubleblind, placebo controlled trial. Microbes and infection. 2006. Vol. 8. pages 1450-1454].</span>
  </p>
  <p id="p0043" num="0043" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sin embargo, estas cepas no demostraron eficacia en la reduccin de la incidencia de ITUr como se report en un ensayo aleatorizado, doble ciego, de no inferioridad en 252 mujeres posmenopusicas con ITUr [BEEREPOT, M.A. y otros. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in post-menopausal women. Archives of Internal Medicine. 2012, Vol. 172, No. 9, pginas 704-712]. Como se muestra en la Tabla 2 del artculo de referencia, no se observ diferencia estadsticamente significativa entre la incidencia de ITUr en las mujeres despus de 12 meses de profilaxis con L. reuteri RC-14 y L. rhamnosus GR-1 vs profilaxis con TMP-SMX. La cepa Lactobacillus rhamnosus GR-1 tambin se describe en la Patente europea EP 1137423 B1, en una composicin probitica junto con al menos otra cepa probitica de Lactobacillus, a saber, Lactobacillus fermentum B-54 (ATCC55884). En particular, el documento EP 1137423 B1 ilustra cmo la ingestin oral de lactobacilos por una mujer que presenta una ITU sintomtica crnica puede reducir la presencia de Enterococcus faecalis en la orina y los exudados vaginales. Sin embargo, el estudio se realiz en una sola persona y no hubo ningn grupo de control que consumiera placebo. Adems, no hay informacin sobre si la administracin de lactobacilos puede reducir la presencia de los principales agentes causantes de la ITU, a saber, E. coli, S. saprophyticus y/o P. mirabillis. Por lo tanto, la eficacia de la composicin de lactobacilos para el tratamiento de la ITU es cuestionable.</span>However, these strains did not demonstrate efficacy in reducing the incidence of rUTI as reported in a randomized, double-blind, non-inferiority trial in 252 postmenopausal women with rUTI [BEEREPOT, M.A. and others. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in post-menopausal women. Archives of Internal Medicine. 2012, Vol. 172, No. 9, pages 704-712]. As shown in Table 2 of the reference article, no statistically significant difference was observed between the incidence of rUTI in women after 12 months of prophylaxis with L. reuteri RC-14 and L. rhamnosus GR-1 vs prophylaxis. with TMP-SMX. The Lactobacillus rhamnosus GR-1 strain is also described in European Patent EP 1137423 B1, in a probiotic composition together with at least one other probiotic Lactobacillus strain, namely Lactobacillus fermentum B-54 (ATCC55884). In particular, EP 1137423 B1 illustrates how oral ingestion of lactobacilli by a woman presenting with a chronic symptomatic UTI can reduce the presence of Enterococcus faecalis in urine and vaginal exudates. However, the study was conducted on a single person and there was no control group that took a placebo. Furthermore, there is no information on whether the administration of lactobacilli can reduce the presence of the main causative agents of UTI, namely E. coli, S. saprophyticus and / or P. mirabillis. Therefore, the efficacy of the lactobacilli composition for the treatment of UTI is questionable.</span>
  </p>
  <p id="p0045" num="0045" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La tcnica tambin describe los resultados de un estudio de caso, sin grupo de placebo, realizado en 9 mujeres y de un ensayo de fase 2 aleatorizado, controlado con placebo, con 100 mujeres con antecedentes de ITUr (es decir, uno o ms episodios de ITU en los 12 meses anteriores) para evaluar la seguridad y eficacia de los supositorios vaginales de Lactobacillus crispatus cepa GAI 98332 [UEHARA, S. y otros. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. International Journal of Antimicrobial Agents. 2006. Vol. 28, No. 1, pginas S30-S34; STAPLETON, A.E. y otros. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. Mayo de 2011. Vol. 52, No. 10, pginas: 1212-1217, respectivamente]. La cepa GAI 98332 de L. crispatus se aisl a partir de la vagina de mujeres sanas. En ambos estudios, se observ una reduccin significativa en el nmero de ITUr causadas por E. coli. Sin embargo, ambos estudios guardan silencio con respecto a las recurrencias causadas por otros patgenos de la ITU, as como al antibitico utilizado para el tratamiento convencional.</span>The technique also describes the results of a case study, without a placebo group, conducted in 9 women and a randomized, placebo-controlled phase 2 trial of 100 women with a history of rUTI (i.e., one or more episodes of UTI in the previous 12 months) to evaluate the safety and efficacy of vaginal suppositories of Lactobacillus crispatus strain GAI 98332 [UEHARA, S. et al. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. International Journal of Antimicrobial Agents. 2006. Vol. 28, No. 1, pages S30-S34; STAPLETON, A.E. and others. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. May 2011. Vol. 52, No. 10, pages: 1212-1217, respectively]. L. crispatus strain GAI 98332 was isolated from the vagina of healthy women. In both studies, a significant reduction in the number of rUTIs caused by E. coli was observed. However, both studies are silent regarding recurrences caused by other UTI pathogens, as well as the antibiotic used for conventional treatment.</span>
  </p>
  <p id="p0047" num="0047" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otro probitico comercializado es Isadin a Barcilus, un probitico vaginal de cpsula blanda con excipientes emolientes y lubricantes, que se utiliza en pacientes con candidiasis vulvovaginal e infecciones vaginales de diversas causas. Isadin a Barcilus est compuesto por la cepa P17630 de Lactobacillus plantarum. No se han encontrado reportes sobre su eficacia para el tratamiento de la ITU.</span>Another probiotic marketed is Isadin a Barcilus, a soft capsule vaginal probiotic with emollient and lubricating excipients, which is used in patients with vulvovaginal candidiasis and vaginal infections of various causes. Isadin a Barcilus is composed of Lactobacillus plantarum strain P17630. No reports have been found on its efficacy for the treatment of UTI.</span>
  </p>
  <p id="p0049" num="0049" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, aunque podra esperarse que las cepas de lactobacilos puedan ser efectivas en la prevencin y el tratamiento de las enfermedades vaginales, su efectividad en el manejo de las ITU est lejos de haber sido demostrada. 
</span>Therefore, although it might be expected that strains of lactobacilli may be effective in the prevention and treatment of vaginal diseases, their effectiveness in the management of UTIs is far from being demonstrated. </span>
  </p>
  <p id="p0050" num="0050" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Descripcin detallada de la invencin</span>Detailed description of the invention</span>
  </p>
  <p id="p0051" num="0051" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El problema a resolver por la presente invencin es proporcionar composiciones y remedios tiles para la prevencin y/o el tratamiento de las infecciones del tracto urinario.</span>The problem to be solved by the present invention is to provide compositions and remedies useful for the prevention and / or treatment of urinary tract infections.</span>
  </p>
  <p id="p0052" num="0052" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se mencion anteriormente, la tcnica anterior ha descrito cepas probiticas que pueden ser tiles para tratar enfermedades urogenitales tales como la vaginosis bacteriana, pero no la UTI. Los inventores encontraron cepas de bacterias del cido lctico que son tiles para el tratamiento de las infecciones del tracto urinario y tambin pueden combinarse con tratamientos antimicrobianos convencionales.</span>As mentioned above, the prior art has described probiotic strains that may be useful for treating urogenital diseases such as bacterial vaginosis, but not UTI. The inventors found strains of lactic acid bacteria that are useful for treating urinary tract infections and can also be combined with conventional antimicrobial treatments.</span>
  </p>
  <p id="p0053" num="0053" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invencin es como se define en las reivindicaciones. Por tanto, en un aspecto, la presente invencin proporciona una composicin para su uso en la prevencin y/o tratamiento de las infecciones del tracto urinario que comprende (i) una cantidad eficaz de al menos un agente antimicrobiano que es activo contra patgenos del tracto urogenital, y (ii) una cantidad eficaz de al menos una cepa de bacterias del cido lctico, en donde la cepa tiene resistencia no transmisible al agente antimicrobiano y en donde (i) y (ii) se formulan en una forma de administracin nica o separada.</span>The invention is as defined in the claims. Thus, in one aspect, the present invention provides a composition for use in the prevention and / or treatment of urinary tract infections comprising (i) an effective amount of at least one antimicrobial agent that is active against pathogens of the tract. urogenital, and (ii) an effective amount of at least one strain of lactic acid bacteria, wherein the strain has non-transmissible resistance to the antimicrobial agent and wherein (i) and (ii) are formulated in a single or single administration form. separated.</span>
  </p>
  <p id="p0054" num="0054" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "cantidad eficaz" (o "cantidad teraputicamente eficaz") como se usa en este documento, significa una cantidad del agente lo suficientemente alta para proporcionar el beneficio deseado, es decir, prevenir, retrasar el inicio o reducir la progresin, pero lo suficientemente baja para evitar efectos secundarios graves dentro del alcance del juicio mdico, administrada sola o en combinacin con un agente teraputico adicional a una clula, tejido o sujeto. Cuando se aplica a un ingrediente activo individual (o agente activo) administrado solo, una dosis teraputicamente eficaz se refiere a ese ingrediente solo. Cuando se aplica a una combinacin, una dosis teraputicamente eficaz se refiere a cantidades combinadas de los ingredientes activos que dan como resultado el efecto teraputico, ya sea que se administren en combinacin, en serie o simultneamente.</span>The term "effective amount" (or "therapeutically effective amount") as used herein, means an amount of the agent high enough to provide the desired benefit, ie, prevent, delay the onset, or reduce progression, but not low enough to avoid serious side effects within the scope of medical judgment, administered alone or in combination with an additional therapeutic agent to a cell, tissue or subject. When applied to a single active ingredient (or active agent) administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether they are administered in combination, serially or simultaneously.</span>
  </p>
  <p id="p0055" num="0055" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "antimicrobiano" tiene en la presente invencin el significado normal en el campo, a saber, un agente que elimina los microorganismos o inhibe su crecimiento. Adems, pueden agruparse de acuerdo con los microorganismos contra los que actan principalmente, por ejemplo, contra las bacterias (antibacterianos) y contra los hongos (antifngicos).</span>The term "antimicrobial" has in the present invention the normal meaning in the field, namely, an agent that kills microorganisms or inhibits their growth. Furthermore, they can be grouped according to the microorganisms against which they mainly act, for example, against bacteria (antibacterial) and against fungi (antifungal).</span>
  </p>
  <p id="p0056" num="0056" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se entiende por "resistencia al agente antimicrobiano" la capacidad de un microorganismo de crecer en presencia del agente antimicrobiano. En general, la resistencia puede tomar la forma de una mutacin gentica espontnea o inducida, o la adquisicin de genes de resistencia a partir de otras especies bacterianas mediante la transferencia horizontal de genes por conjugacin, transduccin o transformacin. La resistencia se considera "no transmisible", como se usa en la presente descripcin, cuando el riesgo potencial de propagacin lateral u horizontal de esta resistencia a otros microorganismos es mnimo.</span>By "antimicrobial agent resistance" is meant the ability of a microorganism to grow in the presence of the antimicrobial agent. In general, resistance can take the form of a spontaneous or induced genetic mutation, or the acquisition of resistance genes from other bacterial species through horizontal gene transfer by conjugation, transduction or transformation. Resistance is considered "non-transmissible", as used in the present description, when the potential risk of lateral or horizontal spread of this resistance to other microorganisms is minimal.</span>
  </p>
  <p id="p0057" num="0057" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, al menos un agente antimicrobiano comprende un compuesto adecuado para prevenir y/o tratar ITU. Los agentes para prevenir y/o tratar las ITU son antibiticos e ingredientes naturales con efecto antimicrobiano. Los antibiticos de eleccin comn para el tratamiento de las ITU son, sin limitacin, la nitrofurantona, trimetoprim-sulfametoxazol, pivmecilinam, fosfomicina, nitrofurantona, quinolonas, tetraciclinas, penicilinas y betalactmicos. En una modalidad de preferencia, al menos un agente antimicrobiano es la fosfomicina. En una modalidad de preferencia, al menos un agente antimicrobiano es una fluoroquinonolona y, particularmente, la norfloxacina.</span>In a particular embodiment, at least one antimicrobial agent comprises a compound suitable for preventing and / or treating UTI. The agents to prevent and / or treat UTIs are antibiotics and natural ingredients with antimicrobial effect. The antibiotics of common choice for the treatment of UTIs are, without limitation, nitrofurantoin, trimethoprim-sulfamethoxazole, pivmecillinam, fosfomycin, nitrofurantoin, quinolones, tetracyclines, penicillins, and beta-lactams. In a preferred embodiment, at least one antimicrobial agent is fosfomycin. In a preferred embodiment, at least one antimicrobial agent is a fluoroquinonolone and, particularly, norfloxacin.</span>
  </p>
  <p id="p0058" num="0058" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra modalidad particular, al menos un agente antimicrobiano es un producto o un ingrediente natural para tratar ITU. Los productos e ingredientes naturales para tratar ITU incluyen, sin limitacin, los extractos, jugos y compuestos aislados a partir de materiales vegetales, como por ejemplo, las frutas y hierbas. En una modalidad particular, el ingrediente natural se obtiene a partir de arndanos (Vaccinum macrocarpon), arndano (V. myrtilis), arndano Europeo (V. oxycoccus), arndanos (V. corymbosum), arndano rojo (V. vitis-idaea), otras hierbas o frutas, y extractos y zumos de uva (por ejemplo, a partir del caf, t, hibisco, Orthoshipon sp., Juniperus sp., Aloe sp., salvia, Equisetum sp., Lavandula sp., betula, manosa), berberina, arbutina y/o vitaminas, en particular, la vitamina C o B. En una modalidad particular, al menos una cepa de bacterias del cido lctico tiene la capacidad de antagonizar al patgeno urogenital Staphylococcus saprophyticus, en donde la capacidad de la cepa de antagonizar al patgeno urogenital se determina mediante las siguientes etapas:</span>In another particular embodiment, at least one antimicrobial agent is a natural product or ingredient for treating UTIs. Natural products and ingredients for treating UTIs include, without limitation, extracts, juices, and compounds isolated from plant materials, such as fruits and herbs. In a particular modality, the natural ingredient is obtained from blueberries (Vaccinum macrocarpon), blueberries (V. myrtilis), European blueberries (V. oxycoccus), blueberries (V. corymbosum), lingonberries (V. vitis-idaea) , other herbs or fruits, and grape extracts and juices (for example, from coffee, tea, hibiscus, Orthoshipon sp., Juniperus sp., Aloe sp., sage, Equisetum sp., Lavandula sp., betula, mannose ), berberine, arbutin and / or vitamins, in particular, vitamin C or B. In a particular embodiment, at least one strain of lactic acid bacteria has the ability to antagonize the urogenital pathogen Staphylococcus saprophyticus, where the ability to Strain of antagonizing the urogenital pathogen is determined by the following steps:</span>
  </p>
  <p id="p0059" num="0059" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(i) frotar uniformemente la cepa patgena urogenital en placas que contienen el medio Tripticasa Soya Agar y hacerla crecer hasta la confluencia en una incubadora de CO<sup class="style-scope patent-text">2 </sup>a 37 C y 5 % de CO<sup class="style-scope patent-text">2 </sup>;</span>(i) evenly rub the urogenital pathogenic strain on plates containing Trypticase Soya Agar medium and grow it to confluence in a CO <sup class="style-scope patent-text">2</sup> incubator at 37  C and 5% CO <sup class="style-scope patent-text">2</sup> ;</span>
  </p>
  <p id="p0060" num="0060" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(ii) colocar dos secciones cilndricas de 6 mm de dimetro de una placa de agar confluente sembrada uniformemente con las clulas en contacto con la placa sembrada con el patgeno urogenital, al confrontar tanto (a) el lado crecido de la seccin de un cilindro contra la placa sembrada con el patgeno urogenital; y (b) el lado no crecido de la otra seccin del cilindro contra la placa sembrada con el patgeno urogenital; e incubar durante la noche a 37 C;</span>(ii) place two 6 mm diameter cylindrical sections of a uniformly seeded confluent agar plate with the cells in contact with the plate seeded with the urogenital pathogen, by confronting both (a) the grown side of the section of a cylinder against the plaque seeded with the urogenital pathogen; and (b) the ungrown side of the other section of the cylinder against the plate seeded with the urogenital pathogen; and incubate overnight at 37  C;</span>
  </p>
  <p id="p0061" num="0061" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(iii) medir al da siguiente las zonas de inhibicin al colocar la placa de agar sobre una regla plana; y, 
</span>(iii) measure the zones of inhibition the next day by placing the agar plate on a flat ruler; and, </span>
  </p>
  <p id="p0062" num="0062" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(iv) calcular la actividad inhibidora del crecimiento (IC) al restar el dimetro del cilindro (DC) al dimetro de la zona de inhibicin (DZI) medido en centmetros y dividir esta diferencia por 2, de acuerdo con la frmula IC = (DZI-DC)/ 2.</span>(iv) calculate the growth inhibitory activity (IC) by subtracting the diameter of the cylinder (DC) from the diameter of the zone of inhibition (DZI) measured in centimeters and dividing this difference by 2, according to the formula IC = (DZI -DC) / 2.</span>
  </p>
  <p id="p0063" num="0063" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "zona de inhibicin", como se usa en este documento, se refiere a una zona alrededor de la cepa de bacterias del cido lctico de inters donde el crecimiento del patgeno se reduce parcial o totalmente en comparacin con el crecimiento del patgeno en ausencia de la cepa de bacterias del cido lctico de inters.</span>The term "zone of inhibition", as used herein, refers to a zone around the lactic acid bacteria strain of interest where the growth of the pathogen is partially or totally reduced compared to the growth of the pathogen in the absence. of the lactic acid bacteria strain of interest.</span>
  </p>
  <p id="p0064" num="0064" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se considera que las cepas de bacterias del cido lctico tienen la capacidad de antagonizar al patgeno urogenital Staphylococcus saprophyticus, en donde esta capacidad est determinada por las etapas descritas anteriormente, cuando la cepa de bacterias del cido lctico tiene una actividad inhibidora del crecimiento (IC) que puede medirse mediante la inspeccin visual. En una modalidad particular, la IC de las bacterias del cido lctico de inters es de 0,5 mm. En otras modalidades particulares, la IC es de 1 mm, 2 mm, 3 mm o ms.</span>Lactic acid bacteria strains are considered to have the ability to antagonize the urogenital pathogen Staphylococcus saprophyticus, where this ability is determined by the steps described above, when the lactic acid bacteria strain has growth inhibitory activity (IC) which can be measured by visual inspection. In a particular embodiment, the IC of the lactic acid bacteria of interest is 0.5 mm. In other particular modalities, the CI is 1mm, 2mm, 3mm or more.</span>
  </p>
  <p id="p0065" num="0065" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sabe que otros patgenos distintos de S. saprophyticus son los principales agentes causantes de las infecciones del tracto urogenital, es decir, Proteus mirabilis, Escherichia coli y Klebsiella pneumonia. La composicin de la invencin tambin es til para prevenir y/o tratar infecciones del tracto urinario causadas por estos patgenos.</span>Pathogens other than S. saprophyticus are known to be the main causative agents of urogenital tract infections, ie Proteus mirabilis, Escherichia coli, and Klebsiella pneumonia. The composition of the invention is also useful for preventing and / or treating urinary tract infections caused by these pathogens.</span>
  </p>
  <p id="p0066" num="0066" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por tanto, en una modalidad particular, al menos una cepa de bacterias del cido lctico tambin tiene la capacidad de antagonizar los patgenos urogenitales Proteus mirabilis, Escherichia coli o Klebsiella pneumonia. El EJEMPLO 4 de trabajo de este documento proporciona una descripcin detallada de un ensayo adecuado para medir la capacidad de la cepa de bacterias del cido lctico de inters de antagonizar estos patgenos.</span>Thus, in a particular embodiment, at least one strain of lactic acid bacteria also has the ability to antagonize the urogenital pathogens Proteus mirabilis, Escherichia coli or Klebsiella pneumonia. WORKING EXAMPLE 4 of this document provides a detailed description of a suitable assay to measure the ability of the lactic acid bacteria strain of interest to antagonize these pathogens.</span>
  </p>
  <p id="p0067" num="0067" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular de ms preferencia an, al menos una cepa de bacterias del cido lctico tiene tambin la capacidad de antagonizar los patgenos urogenitales Proteus mirabilis, Escherichia coli y Klebsiella pneumonia. El EJEMPLO 4 de trabajo de este documento proporciona una descripcin detallada de un ensayo adecuado para medir la capacidad de la cepa de bacterias del cido lctico de inters de antagonizar estos patgenos.</span>In a still more preferred particular embodiment, at least one strain of lactic acid bacteria also has the ability to antagonize the urogenital pathogens Proteus mirabilis, Escherichia coli and Klebsiella pneumonia. WORKING EXAMPLE 4 of this document provides a detailed description of a suitable assay to measure the ability of the lactic acid bacteria strain of interest to antagonize these pathogens.</span>
  </p>
  <p id="p0068" num="0068" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se prefiere que la cepa de bacterias del cido lctico como se describe en este documento sea una cepa de bacterias del cido lctico aislada.</span>It is preferred that the lactic acid bacteria strain as described herein is an isolated lactic acid bacteria strain.</span>
  </p>
  <p id="p0069" num="0069" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como entender el experto en el presente contexto, el trmino "aislado" se refiere a que la cepa de bacterias del cido lctico est aislada de su entorno natural, es decir, no est presente en su entorno natural.</span>As the skilled person will understand in the present context, the term "isolated" refers to the fact that the lactic acid bacteria strain is isolated from its natural environment, that is, it is not present in its natural environment.</span>
  </p>
  <p id="p0070" num="0070" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En base al ensayo detallado descrito en este documento (vase el EJEMPLO 4 para el ensayo de actividad antagonista), el experto en la materia puede repetir rutinariamente este ensayo para determinar objetivamente si una cepa de bacterias del cido lctico de inters antagoniza los patgenos urogenitales. Es importante sealar que las descripciones y condiciones del ensayo de actividad antagonista descritas en las etapas (i)-(iv) anteriores y en el EJEMPLO 4 no limitan el alcance de la invencin. El ensayo es adecuado para probar la capacidad de las cepas de bacterias del cido lctico de inters de antagonizar los patgenos urogenitales Staphylococcus saprophyticus, Proteus mirabillis, Escherichia coli o Pseudomonas pneumoniae. Los expertos en la tcnica saben que los patgenos pueden mostrar una tolerancia diferente a la actividad inhibidora de las bacterias del cido lctico en dependencia de la cepa patgena utilizada para realizar los ensayos y su resistencia. Por tanto, el alcance de la invencin incluye cepas de bacterias del cido lctico que muestran una actividad inhibidora contra cualquier cepa de Staphylococcus saprophyticus, Proteus mirabillis, Escherichia coli o Pseudomonas pneumoniae.</span>Based on the detailed assay described herein (see EXAMPLE 4 for antagonist activity assay), one of ordinary skill in the art can routinely repeat this assay to objectively determine whether a lactic acid bacteria strain of interest antagonizes urogenital pathogens. It is important to note that the descriptions and conditions of the antagonist activity assay described in steps (i) - (iv) above and in EXAMPLE 4 do not limit the scope of the invention. The assay is suitable for testing the ability of the lactic acid bacteria strains of interest to antagonize the urogenital pathogens Staphylococcus saprophyticus, Proteus mirabillis, Escherichia coli or Pseudomonas pneumoniae. Those skilled in the art know that pathogens may show different tolerance to the inhibitory activity of lactic acid bacteria depending on the pathogenic strain used for testing and its resistance. Thus, the scope of the invention includes strains of lactic acid bacteria that show inhibitory activity against any strain of Staphylococcus saprophyticus, Proteus mirabillis, Escherichia coli or Pseudomonas pneumoniae.</span>
  </p>
  <p id="p0071" num="0071" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa de bacterias del cido lctico es la cepa de Lactobacillus plantarum seleccionada del grupo que consisten en: la cepa depositada en la Coleccin Espaola de Cultivos Tipo (CECT) con el nmero de acceso CECT8675, la cepa depositada con el nmero de acceso CECT8676, la cepa depositada con el nmero de acceso CECT8677; la cepa depositada con el nmero de acceso CECT8678, y un mutante de cualquiera de las cepas depositadas, en donde el mutante se ha obtenido mediante el uso de la cepa depositada como material de partida y al aplicar mutagnesis, y en donde el mutante obtenido retiene o mejora al menos la capacidad de la cepa depositada de antagonizar el patgeno urogenital Staphylococcus saprophyticus. En modalidades particulares, la composicin comprende combinaciones de dos, tres o cuatro cepas, seleccionadas del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677, la cepa CECT8678 y mutantes de las mismas. En otra modalidad particular ms, la composicin comprende una cantidad eficaz de L. plantarum CECT8675 y L. plantarum CECT8677.</span>The lactic acid bacteria strain is the Lactobacillus plantarum strain selected from the group consisting of: the strain deposited in the Spanish Type Culture Collection (CECT) with the accession number CECT8675, the strain deposited with the accession number CECT8676, the strain deposited with accession number CECT8677; the deposited strain with accession number CECT8678, and a mutant of any of the deposited strains, where the mutant has been obtained by using the deposited strain as starting material and applying mutagenesis, and where the mutant obtained retains or at least improves the ability of the deposited strain to antagonize the urogenital pathogen Staphylococcus saprophyticus. In particular embodiments, the composition comprises combinations of two, three or four strains, selected from the group consisting of: the CECT8675 strain, the CECT8676 strain, the CECT8677 strain, the CECT8678 strain and mutants thereof. In yet another particular embodiment, the composition comprises an effective amount of L. plantarum CECT8675 and L. plantarum CECT8677.</span>
  </p>
  <p id="p0072" num="0072" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores proporcionan nuevas cepas de bacterias del cido lctico, particularmente del gnero Lactobacillus. La provisin de estas cepas es el resultado de extensos estudios de diferentes cepas de bacterias del cido lctico aisladas a partir de seres humanos sanos. La cepa de Lactobacillus plantarum F2032, Lactobacillus plantarum cepa F3164, Lactobacillus plantarum cepa F1034 y Lactobacillus plantarum cepa F2070, se depositaron el 17 de julio de 2014, el 15 de julio de 2014, el 15 de julio de 2014 y el 15 de julio de 2014, respectivamente, en la Coleccin Espaola de Cultivos Tipo (Coleccin Espaola de Cultivos Tipo, CECT, Edificio 3 CUE, Parc Cientfic, Universitat de Valencia, Catedrtico Agustn Escardino, 9, 46980-Paterna, Valencia, Espaa), por el depositante AB-Biotics, SA, con domicilio en Parc de Recerca UAB, Edifici Eureka, Campus UAB, despacho P2M1, 08193-Bellaterra (Espaa). 
</span>The inventors provide new strains of lactic acid bacteria, particularly of the genus Lactobacillus. The provision of these strains is the result of extensive studies of different strains of lactic acid bacteria isolated from healthy humans. Lactobacillus plantarum strain F2032, Lactobacillus plantarum strain F3164, Lactobacillus plantarum strain F1034 and Lactobacillus plantarum strain F2070, were deposited on July 17, 2014, July 15, 2014, July 15, 2014, and July 15, 2014. 2014, respectively, in the Spanish Collection of Type Cultures (Spanish Collection of Type Cultures, CECT, Building 3 CUE, Parc Cientfic, University of Valencia, Catedrtico Agustn Escardino, 9, 46980-Paterna, Valencia, Spain), by depositor AB -Biotics, SA, with address at Parc de Recerca UAB, Edifici Eureka, Campus UAB, office P2M1, 08193-Bellaterra (Spain). </span>
  </p>
  <p id="p0073" num="0073" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas de L. plantarum recibieron los nmeros de acceso CECT8677, CECT8675, CECT8678 y CECT8676, respectivamente, despus de que la Autoridad Internacional de Depsito declarara la cepa como viable.</span>The L. plantarum strains received accession numbers CECT8677, CECT8675, CECT8678, and CECT8676, respectively, after the International Depository Authority declared the strain viable.</span>
  </p>
  <p id="p0074" num="0074" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas de la presente invencin se seleccionaron debido a las siguientes propiedades/capacidades distintivas:</span>The strains of the present invention were selected due to the following distinctive properties / capabilities:</span>
  </p>
  <p id="p0075" num="0075" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de inhibir el crecimiento de S. saprophyticus, por lo cual muestra un espectro de actividad ms amplio en comparacin con otros probiticos disponibles comercialmente para ayudar a controlar la ITU, especialmente en donde el agente causal es este patgeno. Como se indica en la tcnica anterior y en la seccin de EJEMPLOS, se han usado algunas cepas de lactobacilos para el tratamiento y/o la prevencin de ITU. Sin embargo, dichas cepas no muestran actividad antagonista significativa contra varios aislamientos de S. saprohyticus (ver EJEMPLO 4.1). De manera notable, las cepas CECT8677, CECT8675, CECT8678 y CECT8676 mostraron una actividad notablemente antagonista contra las tres cepas de S. saprophyticus ensayadas. De este modo, como corroboran los datos divulgados en el EJEMPLO 4.1, la capacidad de inhibir S. saprohyticus no es una caracterstica inherente del gnero Lactobacillus, ni siquiera de las cepas de lactobacilos de origen uretral o vaginal, como las cepas comerciales L. rhamnosus GR-1 y L. reuteri RC-14, respectivamente, y mucho menos una caracterstica inherente de las cepas de L. plantarum como L. plantarum P17630, una cepa comercial probitica. Por tanto, la presente invencin proporciona cepas de bacterias de cido lctico que tienen la capacidad de antagonizar Staphylococcus saprophyticus.</span> The ability to inhibit the growth of S. saprophyticus, thus showing a broader spectrum of activity compared to other commercially available probiotics to help control UTI, especially where the causative agent is this pathogen. As indicated in the prior art and in the EXAMPLES section, some strains of lactobacilli have been used for the treatment and / or prevention of UTI. However, these strains do not show significant antagonistic activity against various isolates of S. saprohyticus (see EXAMPLE 4.1). Notably, the strains CECT8677, CECT8675, CECT8678, and CECT8676 showed markedly antagonistic activity against all three S. saprophyticus strains tested. Thus, as corroborated by the data disclosed in EXAMPLE 4.1, the ability to inhibit S. saprohyticus is not an inherent characteristic of the genus Lactobacillus, not even of the lactobacilli strains of urethral or vaginal origin, such as the commercial strains L. rhamnosus GR-1 and L. reuteri RC-14, respectively, much less an inherent characteristic of L. plantarum strains such as L. plantarum P17630, a commercial probiotic strain. Thus, the present invention provides strains of lactic acid bacteria that have the ability to antagonize Staphylococcus saprophyticus.</span>
  </p>
  <p id="p0076" num="0076" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de inhibir el crecimiento de otros patgenos del tracto urinario, a saber, Proteus mirabilis, Escherichia coli y Klebsiella pneumoniae, muestra un espectro de actividad an ms amplio contra los uropatgenos en comparacin con otros probiticos disponibles comercialmente para ayudar a controlar la ITU. Como ya se mencion anteriormente, algunas cepas de Lactobacillus se han utilizado para el tratamiento y/o la prevencin de ITU. Sin embargo, dichas cepas no muestran una actividad antagonista significativa contra los aislamientos de P. mirabilis, E. coli y K. pneumoniae (vase los EJEMPLOS 4.2-4.3). De manera sorprendente, las cepas CECT8677, CECT8675, CECT8678 y CECT8676 mostraron una actividad notablemente antagnica contra ellas. Por lo tanto, como lo respaldan los datos revelados en los EJEMPLOS 4.2-4.3, la capacidad de inhibir P. mirabilis, E. coli y K. pneumoniae no es una caracterstica inherente del gnero Lactobacillus, ni siquiera de las cepas de lactobacilos de origen uretral o vaginal, tales como las cepas comerciales L. rhamnosus GR-1 y L. reuteri RC-14, respectivamente, y mucho menos una caracterstica inherente de las cepas de L. plantarum tales como el probitico comercial L. plantarum P17630.</span> The ability to inhibit the growth of other urinary tract pathogens, namely Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae, shows an even broader spectrum of activity against uropathogens compared to other commercially available probiotics to help control UTI . As already mentioned above, some Lactobacillus strains have been used for the treatment and / or prevention of UTIs. However, these strains do not show significant antagonistic activity against P. mirabilis, E. coli and K. pneumoniae isolates (see EXAMPLES 4.2-4.3). Surprisingly, the strains CECT8677, CECT8675, CECT8678 and CECT8676 showed markedly antagonistic activity against them. Therefore, as supported by the data revealed in EXAMPLES 4.2-4.3, the ability to inhibit P. mirabilis, E. coli, and K. pneumoniae is not an inherent characteristic of the genus Lactobacillus, not even of the lactobacillus strains of origin. urethral or vaginal strains, such as the commercial L. rhamnosus GR-1 and L. reuteri RC-14 strains, respectively, much less an inherent characteristic of L. plantarum strains such as the commercial probiotic L. plantarum P17630.</span>
  </p>
  <p id="p0077" num="0077" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de sobrevivir a altas concentraciones de fosfomicina, antibitico que se usa tpicamente para controlar las ITU. Como se muestra en el EJEMPLO 5, el crecimiento de las cepas CECT8677, CECT8675, CECT8678 y CECT8676 no se inhibe incluso al usar concentraciones saturadas de fosfomicina. En otras palabras, incluso cuando se utilizan altas concentraciones de fosfomicina junto con dichas cepas, la eficacia de la combinacin resultante no se ve comprometida y, por tanto, puede ejercer tanto la funcin probitica como la antimicrobiana. En resumen, las cepas de la presente invencin pueden coadministrarse con el antibitico fosfomicina.</span> The ability to survive high concentrations of fosfomycin, an antibiotic typically used to control UTIs. As shown in EXAMPLE 5, the growth of strains CECT8677, CECT8675, CECT8678 and CECT8676 is not inhibited even when using saturated concentrations of fosfomycin. In other words, even when high concentrations of fosfomycin are used in conjunction with such strains, the efficacy of the resulting combination is not compromised and therefore it can exert both probiotic and antimicrobial function. In summary, the strains of the present invention can be co-administered with the antibiotic fosfomycin.</span>
  </p>
  <p id="p0078" num="0078" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de sobrevivir a altas concentraciones de otros antibiticos utilizados para el tratamiento de la ITU como la norfloxacina (EJEMPLO 5).</span> The ability to survive high concentrations of other antibiotics used to treat UTI such as norfloxacin (EXAMPLE 5).</span>
  </p>
  <p id="p0079" num="0079" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de sobrevivir en presencia de ingredientes activos naturales comnmente prescritos para tratar ITU tales como los extractos de arndano y/o arndano rojo, lo cual permite que las cepas bacterianas de la presente invencin sean coadministradas con dichos ingredientes activos a ITU (ver EJEMPLO 6).</span> The ability to survive in the presence of natural active ingredients commonly prescribed to treat UTI such as bilberry and / or lingonberry extracts, which allows the bacterial strains of the present invention to be co-administered with said active ingredients to UTI (see EXAMPLE 6).</span>
  </p>
  <p id="p0080" num="0080" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Una capacidad mejorada de agregacin, como se muestra en el EJEMPLO 7, lo cual es uno de los pasos iniciales que conducen a la formacin de biopelculas protectoras contra (uro)patgenos. La biopelcula permite formar una barrera protectora o 'pelcula' que dificulta la colonizacin de (uro)patgenos debido a la competencia para los sitios de adhesin.</span> An improved aggregation capacity, as shown in EXAMPLE 7, which is one of the initial steps leading to the formation of protective biofilms against (uro) pathogens. The biofilm allows to form a protective barrier or 'film' that hinders the colonization of (uro) pathogens due to competition for adhesion sites.</span>
  </p>
  <p id="p0081" num="0081" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de producir cidos grasos de cadena corta (AGCC), como se muestra en el EJEMPLO 8. La produccin de AGCC a partir de fibras no digeribles es un rasgo probitico interesante. Este rasgo es deseable en un probitico porque los AGCC producidos muestran varias propiedades beneficiosas en el hospedero. Entre sus diversas propiedades, hay muy buena evidencia que respalda que el aumento de las concentraciones de AGCC potencia el crecimiento de bacterias protectoras al tiempo que limita el crecimiento de patgenos y puede mejorar la funcin de la barrera intestinal, especialmente en el caso del butirato [KOBOZIEV, I. y otros. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radical Biology &amp; Medicine. 2014, Vol. 68, pginas 122 133]. Como resultado, los AGCC pueden mejorar los sntomas asociados a enfermedades gastrointestinales adversas como la diarrea, que es un factor de riesgo importante de contaminacin cruzada de patgenos intestinales a la vagina que favorece las infecciones vaginales y las ITU.</span> The ability to produce short chain fatty acids (SCFA), as shown in EXAMPLE 8. Production of SCFA from indigestible fibers is an interesting probiotic trait. This trait is desirable in a probiotic because the SCFAs produced show several beneficial properties in the host. Among its various properties, there is very good evidence to support that increasing SCFA concentrations enhance the growth of protective bacteria while limiting the growth of pathogens and may improve intestinal barrier function, especially in the case of butyrate [ KOBOZIEV, I. and others. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radical Biology &amp; Medicine. 2014, Vol. 68, pages 122-133]. As a result, SCFAs can improve symptoms associated with adverse gastrointestinal diseases such as diarrhea, which is a major risk factor for cross-contamination of intestinal pathogens into the vagina that promotes vaginal infections and UTIs.</span>
  </p>
  <p id="p0082" num="0082" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La tolerancia a las condiciones ambientales de los tractos gastrointestinal y genitourinario y, por tanto, la capacidad para ejercer su efecto beneficioso en las ubicaciones deseadas del cuerpo, como se muestra en el EJEMPLO 9. 
</span> Tolerance to the environmental conditions of the gastrointestinal and genitourinary tracts and, therefore, the ability to exert their beneficial effect in the desired locations of the body, as shown in EXAMPLE 9. </span>
  </p>
  <p id="p0083" num="0083" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> La capacidad de las cepas probiticas de la presente invencin para aumentar la eficacia de la fosfomicina para inhibir patgenos asociados con ITU. Como se muestra en el EJEMPLO 10 y la FIG. 9, la combinacin de fosfomicina con las cepas de la presente invencin, reduce significativamente la concentracin de Staphylococcus saprophyticus. Por lo tanto, el uso combinado de antibiticos y probiticos puede considerarse una opcin de manejo eficaz para tratar las infecciones por S. saprophyticus.</span> The ability of the probiotic strains of the present invention to increase the efficacy of fosfomycin to inhibit pathogens associated with UTI. As shown in EXAMPLE 10 and FIG. 9, the combination of fosfomycin with the strains of the present invention significantly reduces the concentration of Staphylococcus saprophyticus. Therefore, the combined use of antibiotics and probiotics can be considered an effective management option to treat S. saprophyticus infections.</span>
  </p>
  <p id="p0084" num="0084" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Una amplia variedad de especies de bacterias del cido lctico tienen una larga historia de uso aparentemente seguro. La Autoridad Europea de Seguridad Alimentaria ha desarrollado un sistema que otorga el estado de "Presuncin Cualificada de Seguridad" (QPS) a las unidades taxonmicas con una larga historia probada de uso aparentemente seguro. Las cepas de la invencin pertenecen a una especie bacteriana que tiene estado QPS (ANDREOLETTI, O. y otros. The maintenance of the list of QPS microorganisms intentionally added to food or feed. Question no: EFSA-Q-2008-006. The EFSA Journal. 2008, Vol. 923, pginas 1-48).</span> A wide variety of lactic acid bacteria species have a long history of apparently safe use. The European Food Safety Authority has developed a system that grants "Qualified Presumption of Safety" (QPS) status to taxonomic units with a long proven history of apparently safe use. The strains of the invention belong to a bacterial species that has QPS status (ANDREOLETTI, O. et al. The maintenance of the list of QPS microorganisms intentionally added to food or feed. Question no: EFSA-Q-2008-006. The EFSA Journal. 2008, Vol. 923, pages 1-48).</span>
  </p>
  <p id="p0085" num="0085" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En resumen, se cree que ninguna tcnica anterior describe cepas de Lactobacillus y particularmente cepas de Lactobacillus plantarum con las caractersticas mencionadas anteriormente. Es de destacar que las cepas de Lactobacillus plantarum CECT8677, CECT8675, CECT8678 y CECT8676 renen juntas todas las propiedades mencionadas anteriormente, por lo cual son adecuadas para el tratamiento de la ITU.</span>In summary, it is believed that no prior art describes Lactobacillus strains and particularly Lactobacillus plantarum strains with the aforementioned characteristics. It is noteworthy that the Lactobacillus plantarum strains CECT8677, CECT8675, CECT8678 and CECT8676 have together all the properties mentioned above, making them suitable for the treatment of UTI.</span>
  </p>
  <p id="p0086" num="0086" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De manera notable, todas las cepas de la invencin tienen la capacidad de antagonizar todos los siguientes patgenos urogenitales Staphylococcus saprophyticus, Escherichia coli, Klebsiella pneumoniae y Proteus mirabilis. y se pueden combinar con agentes antimicrobianos, es decir, antibiticos, que se usan de forma rutinaria para tratar la ITU. Adems, la cepa de la invencin tuvo buena tolerancia y se puede combinar con tratamientos alternativos basados en productos e ingredientes naturales, por ejemplo, jugos y compuestos aislados a partir de materiales vegetales (frutas y hierbas) como los que pertenecen al gnero Vaccinum (por ejemplo, arndano); y vitaminas (por ejemplo, la vitamina C)</span>Notably, all of the strains of the invention have the ability to antagonize all of the following urogenital pathogens Staphylococcus saprophyticus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. and they can be combined with antimicrobial agents, that is, antibiotics, that are used routinely to treat UTI. Furthermore, the strain of the invention had good tolerance and can be combined with alternative treatments based on natural products and ingredients, for example, juices and compounds isolated from plant materials (fruits and herbs) such as those belonging to the genus Vaccinum (for example example, blueberry); and vitamins (for example, vitamin C)</span>
  </p>
  <p id="p0087" num="0087" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otro aspecto, la presente invencin proporciona una composicin que comprende una cantidad eficaz de al menos una cepa de Lactobacillus plantarum, en donde la cepa tiene la capacidad de antagonizar al patgeno urogenital Staphylococcus saprophyticus, y en donde la capacidad de la cepa de L. plantarum de antagonizar los patgenos urogenitales se determinan mediante las siguientes etapas: (i) frotar uniformemente las cepas de patgenos urogenitales en placas que contienen el medio Tripticasa Soya Agar y se hacen crecer hasta la confluencia en una incubadora de CO<sup class="style-scope patent-text">2 </sup>a 37 C y 5 % de CO<sup class="style-scope patent-text">2 </sup>; (ii) colocar dos secciones cilndricas de 6 mm de dimetro de una placa de agar confluente sembrada uniformemente con las clulas de L. plantarum en contacto con la placa sembrada con el patgeno urogenital, al enfrentar tanto (a) el lado crecido de una seccin del cilindro contra la placa sembrada del patgeno urogenital; y (b) el lado no crecido de la otra seccin del cilindro contra la placa sembrada del patgeno urogenital; e incubar durante la noche a 37 C; (iii) medir al da siguiente las zonas de inhibicin al colocar la placa de agar sobre una regla plana; y (iv) calcular la actividad inhibidora del crecimiento al restar el dimetro del cilindro (DC) al dimetro de la zona de inhibicin (DZI) medido en centmetros y dividir esta diferencia por 2, de acuerdo con la frmula IC = (DZI-DC)/ 2.</span>In another aspect, the present invention provides a composition comprising an effective amount of at least one Lactobacillus plantarum strain, wherein the strain has the ability to antagonize the urogenital pathogen Staphylococcus saprophyticus, and wherein the ability of the L. plantarum to antagonize urogenital pathogens are determined by the following steps: (i) uniformly rub the strains of urogenital pathogens on plates containing Trypticase Soya Agar medium and grow to confluence in a CO <sup class="style-scope patent-text">2</sup> incubator at 37  C and 5% CO <sup class="style-scope patent-text">2</sup> ; (ii) place two 6 mm diameter cylindrical sections of a confluent agar plate uniformly seeded with the L. plantarum cells in contact with the plate seeded with the urogenital pathogen, facing both (a) the grown side of a section of the cylinder against the plaque seeded of the urogenital pathogen; and (b) the ungrown side of the other section of the cylinder against the seeded plate of the urogenital pathogen; and incubate overnight at 37  C; (iii) measure the zones of inhibition the next day by placing the agar plate on a flat ruler; and (iv) calculate the growth inhibitory activity by subtracting the diameter of the cylinder (DC) from the diameter of the zone of inhibition (DZI) measured in centimeters and dividing this difference by 2, according to the formula IC = (DZI-DC )/ 2.</span>
  </p>
  <p id="p0088" num="0088" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, la actividad inhibidora del crecimiento (IC) de al menos una cepa de Lactobacillus plantarum es de 0,5 mm. En otras modalidades particulares, la IC es de 1 mm, 2 mm, 3 mm o ms.</span>In a particular embodiment, the growth inhibitory activity (IC) of at least one Lactobacillus plantarum strain is 0.5 mm. In other particular modalities, the CI is 1mm, 2mm, 3mm or more.</span>
  </p>
  <p id="p0089" num="0089" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, al menos una cepa de Lactobacillus plantarum, tambin tiene la capacidad de antagonizar los patgenos urogenitales Proteus mirabilis, Escherichia coli o Klebsiella pneumoniae, en donde la capacidad de la cepa de antagonizar los patgenos urogenitales est determinada por las etapas definidas anteriormente.</span>In a particular embodiment, at least one Lactobacillus plantarum strain also has the ability to antagonize the urogenital pathogens Proteus mirabilis, Escherichia coli or Klebsiella pneumoniae, where the ability of the strain to antagonize urogenital pathogens is determined by the stages defined above. .</span>
  </p>
  <p id="p0090" num="0090" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular de ms preferencia, al menos una cepa de Lactobacillus plantarum, tambin tiene la capacidad de antagonizar los patgenos urogenitales Proteus mirabilis, Escherichia coli y Klebsiella pneumoniae, en donde la capacidad de la cepa de antagonizar los patgenos urogenitales est determinada por las etapas definidas anteriormente.</span>In a particular more preferred embodiment, at least one Lactobacillus plantarum strain also has the ability to antagonize the urogenital pathogens Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae, where the ability of the strain to antagonize urogenital pathogens is determined by the stages defined above.</span>
  </p>
  <p id="p0091" num="0091" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se discuti anteriormente, se prefiere que la cepa de bacterias de cido lctico discutida en este documento sea una cepa de bacterias de cido lctico aislada, es decir, se prefiere que el Lactobacillus plantarum como se discuti en este documento sea una cepa de bacterias de cido lctico aislada.</span>As discussed above, it is preferred that the lactic acid bacteria strain discussed herein be an isolated lactic acid bacteria strain, that is, it is preferred that Lactobacillus plantarum as discussed herein be a lactic acid bacteria strain. isolated lactic acid.</span>
  </p>
  <p id="p0092" num="0092" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, la presente invencin proporciona la composicin del aspecto anterior, en donde al menos cepa de L. plantarum se selecciona del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677, la cepa CECT8678 y mutantes de la misma, en donde el mutante se ha obtenido mediante el uso de la cepa depositada como material de partida y al aplicar mutagnesis, y en donde el mutante obtenido retiene o potencia al menos la capacidad de la cepa depositada de antagonizar el patgeno urogenital Staphylococcus saprophyticus. En una modalidad ms particular, al menos una cepa de Lactobacillus plantarum se selecciona del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677 y la cepa CECT8678. En modalidades particulares, la composicin comprende combinaciones de dos, tres o cuatro cepas, seleccionadas del 
grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677, la cepa CECT8678 y mutantes de las mismas. En otra modalidad particular ms, la composicin comprende una cantidad eficaz de L. plantarum CECT8675 y L. plantarum CECT8677.</span>In a particular embodiment, the present invention provides the composition of the previous aspect, wherein at least the L. plantarum strain is selected from the group consisting of: the CECT8675 strain, the CECT8676 strain, the CECT8677 strain, the CECT8678 strain and mutants of the same, where the mutant has been obtained by using the deposited strain as starting material and by applying mutagenesis, and where the mutant obtained retains or enhances at least the capacity of the deposited strain to antagonize the urogenital pathogen Staphylococcus saprophyticus . In a more particular embodiment, at least one Lactobacillus plantarum strain is selected from the group consisting of: the CECT8675 strain, the CECT8676 strain, the CECT8677 strain and the CECT8678 strain. In particular embodiments, the composition comprises combinations of two, three or four strains, selected from  group consisting of: strain CECT8675, strain CECT8676, strain CECT8677, strain CECT8678 and mutants thereof. In yet another particular embodiment, the composition comprises an effective amount of L. plantarum CECT8675 and L. plantarum CECT8677.</span>
  </p>
  <p id="p0093" num="0093" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El uso generalizado de las cepas es en forma de clulas viables. Sin embargo, tambin se puede extender a clulas no viables tales como los cultivos muertos o los lisados celulares (obtenidos, por ejemplo, por exposicin a pH alterado, sonicacin, radiacin, temperatura, presin o entre otros medios para matar o lisar bacterias) o composiciones que contienen beneficiosos producidos por cualquiera de las cepas.</span>The widespread use of the strains is in the form of viable cells. However, it can also be extended to non-viable cells such as dead cultures or cell lysates (obtained, for example, by exposure to altered pH, sonication, radiation, temperature, pressure or among other means to kill or lyse bacteria) or compositions containing beneficials produced by either strain.</span>
  </p>
  <p id="p0094" num="0094" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas de la invencin se producen al cultivar (o fermentar) las bacterias en un medio artificial adecuado y en condiciones adecuadas. Por la expresin "medio artificial" para microorganismos se entiende un medio que contiene sustancias naturales y, opcionalmente, productos qumicos sintticos como el polmero polivinil alcohol que puede reproducir algunas de las funciones de los sueros. El medio artificial se esteriliza adecuadamente una vez que se mezclan las sustancias. Por consiguiente, entre las sustancias naturales, los medios artificiales adecuados habituales son los caldos nutritivos que contienen los elementos que incluyen una fuente de carbono (por ejemplo, glucosa), una fuente de nitrgeno (por ejemplo, aminocidos y protenas), agua y sales necesarias para el crecimiento bacteriano. Los medios de crecimiento pueden estar en forma lquida o, a menudo, mezclados con agar u otro agente gelificante para obtener un medio slido. Los medios de crecimiento tambin pueden considerarse cualquier matriz alimentaria en donde las bacterias puedan crecer en condiciones adecuadas, como los ingredientes para hacer yogur.</span>The strains of the invention are produced by cultivating (or fermenting) the bacteria in a suitable artificial medium and under suitable conditions. By the term "artificial medium" for microorganisms is meant a medium that contains natural substances and, optionally, synthetic chemicals such as polyvinyl alcohol polymer that can reproduce some of the functions of sera. The artificial medium is properly sterilized once the substances are mixed. Therefore, among the natural substances, the usual suitable artificial media are nutrient broths containing the elements including a carbon source (eg glucose), a nitrogen source (eg amino acids and proteins), water and salts. necessary for bacterial growth. The growth media can be in liquid form or often mixed with agar or other gelling agent to obtain a solid medium. Growth media can also be considered any food matrix where bacteria can grow under suitable conditions, such as ingredients for making yogurt.</span>
  </p>
  <p id="p0095" num="0095" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas pueden cultivarse solas para formar un cultivo puro, o como un cultivo mixto junto con otros microorganismos, o al cultivar bacterias de diferentes tipos por separado y luego combinarlas en las proporciones deseadas. Despus del cultivo, y en dependencia de la formulacin final, las cepas pueden usarse como bacterias purificadas o, alternativamente, puede usarse el cultivo bacteriano o la suspensin celular, como tal o despus de un postratamiento apropiado. En esta descripcin, se entiende por "biomasa" el cultivo de cepas bacterianas obtenido tras el cultivo (o la fermentacin como sinnimo de cultivo).</span>The strains can be grown alone to form a pure culture, or as a mixed culture together with other microorganisms, or by growing bacteria of different types separately and then combining them in the desired proportions. After culturing, and depending on the final formulation, the strains can be used as purified bacteria or, alternatively, the bacterial culture or cell suspension can be used, as such or after an appropriate post-treatment. In this description, "biomass" is understood as the culture of bacterial strains obtained after cultivation (or fermentation as a synonym for cultivation).</span>
  </p>
  <p id="p0096" num="0096" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por el trmino "postratamiento" se entiende en el contexto de la presente invencin, cualquier procesamiento realizado sobre la biomasa con el objetivo de obtener clulas bacterianas almacenables. El objetivo del postratamiento es disminuir la actividad metablica de las clulas en la biomasa y, por tanto, ralentizar la tasa de reacciones celulares deletreas. Como resultado del postratamiento, las clulas bacterianas pueden estar en forma slida o lquida. En forma slida, las clulas bacterianas almacenadas pueden ser un polvo o grnulos. En cualquier caso, tanto la forma slida como la lquida que contienen las clulas bacterianas no estn presentes en la naturaleza, por lo tanto, no son de origen natural, ya que son el resultado de proceso(s) artificial(es) de postratamiento. Los procesos de postratamiento pueden requerir en modalidades particulares el uso de uno o ms de los denominados agentes de postratamiento. En el contexto de la presente invencin, la expresin "agente de postratamiento" se refiere a un compuesto utilizado para realizar los procesos de postratamiento descritos en el presente documento. Entre los agentes de postratamiento se incluirn, sin limitacin, los agentes deshidratantes, agentes bacteriostticos, agentes crioprotectores (crioprotectores), aditivos inertes (tambin conocidos como lioprotectores), material portador (tambin conocido como material de ncleo), etc, solos o en combinacin.</span>By the term "post-treatment" is understood in the context of the present invention, any processing carried out on biomass with the aim of obtaining storable bacterial cells. The goal of post-treatment is to decrease the metabolic activity of cells in biomass and thus slow down the rate of deleterious cellular reactions. As a result of post-treatment, the bacterial cells can be in solid or liquid form. In solid form, the stored bacterial cells can be a powder or granules. In any case, both the solid and the liquid form that the bacterial cells contain are not present in nature, therefore, they are not of natural origin, since they are the result of artificial post-treatment process (s). Post-treatment processes may require in particular modalities the use of one or more of so-called post-treatment agents. In the context of the present invention, the term "post-treatment agent" refers to a compound used to carry out the post-treatment processes described herein. Post-treatment agents will include, without limitation, dehydrating agents, bacteriostatic agents, cryoprotective agents (cryoprotectants), inert additives (also known as lyoprotectants), carrier material (also known as core material), etc., alone or in combination. .</span>
  </p>
  <p id="p0097" num="0097" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Existen dos enfoques bsicos para disminuir la actividad metablica de las clulas bacterianas y, por tanto, dos enfoques para realizar el postratamiento. El primero es disminuir la velocidad de todas las reacciones qumicas. Esto puede realizarse al reducir la temperatura por refrigeracin o congelacin mediante frigorficos, congeladores mecnicos y congeladores de nitrgeno lquido. Alternativamente, tambin puede disminuirse la velocidad de todas las reacciones qumicas al agregar sustancias que inhiben el crecimiento de las clulas bacterianas, a saber, un agente bacteriosttico, abreviado Bstatic, el cual es un agente biolgico o qumico que detiene la reproduccin de las bacterias, sin daarlas, entre ellos los antibiticos bacteriostticos y conservantes. Esto contrasta con los bactericidas, que matan las bacterias. El experto en la materia conoce el bacteriosttico apropiado a utilizar. Como ejemplo de antibiticos bacteriostticos, y sin limitacin, los bacteriostticos que limitan el crecimiento de las bacterias al interferir con la produccin de protenas bacterianas, la replicacin del ADN u otros aspectos del metabolismo celular bacteriano, en las concentraciones adecuadas para mantener solo su actividad bacteriosttica. Tambin puede entenderse por agente bacteriosttico cualquier agente que se aada para modificar las condiciones ambientales como el pH, la concentracin de sales o el estado redox.</span>There are two basic approaches to lowering the metabolic activity of bacterial cells, and therefore two approaches to post-treatment. The first is to slow down all chemical reactions. This can be done by reducing the temperature by refrigeration or freezing using refrigerators, mechanical freezers, and liquid nitrogen freezers. Alternatively, the speed of all chemical reactions can also be slowed by adding substances that inhibit the growth of bacterial cells, namely a bacteriostatic agent, abbreviated Bstatic, which is a biological or chemical agent that stops the reproduction of bacteria, without damaging them, including bacteriostatic antibiotics and preservatives. This is in contrast to bactericides, which kill bacteria. The person skilled in the art knows the appropriate bacteriostat to use. As an example of bacteriostatic antibiotics, and without limitation, bacteriostats that limit the growth of bacteria by interfering with the production of bacterial proteins, DNA replication, or other aspects of bacterial cell metabolism, in the proper concentrations to maintain only their bacteriostatic activity. . Bacteriostatic agent can also be understood as any agent that is added to modify environmental conditions such as pH, salt concentration or redox state.</span>
  </p>
  <p id="p0098" num="0098" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El segundo enfoque para realizar el postratamiento es eliminar el agua a partir de la biomasa, proceso que puede implicar la sublimacin del agua mediante un liofilizador. Las tcnicas adecuadas para eliminar el agua a partir de la biomasa son el secado, la liofilizacin, el secado por aspersin o el secado en lecho fluido.</span>The second approach to post-treatment is to remove the water from the biomass, a process that may involve sublimation of the water using a lyophilizer. Suitable techniques for removing water from biomass are drying, lyophilization, spray drying, or fluid bed drying.</span>
  </p>
  <p id="p0099" num="0099" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los tratamientos posteriores que dan como resultado una forma slida pueden ser el secado, la congelacin, la liofilizacin, el secado en lecho fluido o el secado por aspersin.</span>Post treatments that result in a solid form can be drying, freezing, lyophilization, fluid bed drying, or spray drying.</span>
  </p>
  <p id="p0100" num="0100" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El postratamiento tras el cultivo de las cepas puede consistir en la congelacin. En este caso, deben agregarse uno o ms agentes crioprotectores. Las expresiones "agente (o aditivo) crioprotector" y "crioprotector" se utilizan indistintamente en la presente invencin, y se refieren a los productos qumicos que protegen las clulas durante la 
congelacin y minimizan al mismo tiempo los efectos perjudiciales del aumento de la concentracin de solutos y la formacin de cristales de hielo que provocan una cada en el nmero de clulas viables y las consiguientes prdidas en la produccin industrial. Los agentes crioprotectores ms comnmente usados son el dimetilsulfxido (DMSO) y el glicerol, ya sean solos o en combinacin; aunque otros crioprotectores que se han usado ocasionalmente, ya sean solos o en combinacin, incluyen: el polietilenglicol, propilenglicol, glicerina, betana (o glicina betana), polivinilpirrolidona, sorbitol, dextrano y trehalosa. Los crioprotectores clasificados por familias son: los sulfxidos, alcoholes monohdricos y derivados, dioles y derivados, trioles, polialcoholes, mono-, di-, tri-, polisacridos, amidas, N-alquilamidas, imidas, compuestos heterocclicos, aminocidos y cidos carbnicos, protenas, pptidos, polipptidos, glicoprotenas y surfactantes no inicos. Los protocolos para congelar bacterias y la seleccin de crioprotectores adecuados son la eleccin y el conocimiento de los expertos en la tcnica. Bsicamente, las bacterias pueden cultivarse o recolectarse convenientemente a partir de placas o inclinaciones de agar, o de cultivo en caldo y recolectarse por centrifugacin. En cualquier caso, las clulas se suspenden generalmente en medio de crecimiento fresco que contiene el o los agentes crioprotectores. Las bacterias tambin pueden concentrarse por centrifugacin, pero a menudo se suspenden en el medio usado y luego se diluyen al agregar un volumen igual de medio de crecimiento fresco que contiene el(los) agente(s) crioprotector(es). Luego, la mezcla de clulas y crioprotectores se deja durante al menos 15 minutos pero no ms de 45-60 minutos para que se equilibre antes del proceso de enfriamiento. La suspensin se distribuye en viales y se enfra a una velocidad de enfriamiento adecuada.</span>Post-treatment after culturing the strains may consist of freezing. In this case, one or more cryoprotective agents must be added. The terms "cryoprotective agent (or additive)" and "cryoprotective" are used interchangeably in the present invention, and refer to chemicals that protect cells during  freezing while minimizing the detrimental effects of increased solute concentration and ice crystal formation that cause a drop in the number of viable cells and consequent losses in industrial production. The most commonly used cryoprotective agents are dimethyl sulfoxide (DMSO) and glycerol, either alone or in combination; although other cryoprotectants that have been used occasionally, either alone or in combination, include: polyethylene glycol, propylene glycol, glycerin, betaine (or glycine betaine), polyvinylpyrrolidone, sorbitol, dextran, and trehalose. Cryoprotectants classified by families are: sulfoxides, monohydric alcohols and derivatives, diols and derivatives, triols, polyalcohols, mono-, di-, tri-, polysaccharides, amides, N-alkylamides, imides, heterocyclic compounds, amino acids and carbonic acids, nonionic proteins, peptides, polypeptides, glycoproteins and surfactants. The protocols for freezing bacteria and the selection of suitable cryoprotectants are the choice and knowledge of those skilled in the art. Basically, the bacteria can be conveniently cultured or harvested from agar plates or slants, or from broth culture and harvested by centrifugation. In either case, the cells are generally suspended in fresh growth medium containing the cryoprotective agent (s). Bacteria can also be concentrated by centrifugation, but are often suspended in the used medium and then diluted by adding an equal volume of fresh growth medium containing the cryoprotective agent (s). The mixture of cells and cryoprotectants is then left for at least 15 minutes but no more than 45-60 minutes to equilibrate before the cooling process. The suspension is dispensed into vials and cooled to a suitable cooling rate.</span>
  </p>
  <p id="p0102" num="0102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando el postratamiento luego del cultivo de las cepas es el secado, bsicamente consiste en secar en un desecador al vaco sobre agentes deshidratantes como el H<sup class="style-scope patent-text">2</sup>SO <sup class="style-scope patent-text">4 </sup>o P<sup class="style-scope patent-text">2</sup>O<sup class="style-scope patent-text">5</sup>, los microorganismos suspendidos en el fluido de cultivo o resuspendidos en suero fisiolgico.</span>When the post-treatment after the cultivation of the strains is drying, it basically consists of drying in a vacuum desiccator over dehydrating agents such as H <sup class="style-scope patent-text">2</sup> SO <sup class="style-scope patent-text">4</sup> or P <sup class="style-scope patent-text">2</sup> O <sup class="style-scope patent-text">5</sup> , the microorganisms suspended in the culture fluid or resuspended in physiological serum. .</span>
  </p>
  <p id="p0104" num="0104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El postratamiento tras el cultivo de las cepas puede consistir en la liofilizacin, como mtodo de eliminacin de agua. La liofilizacin implica la eliminacin del agua a partir de las suspensiones bacterianas congeladas mediante sublimacin a presin reducida. Los cultivos liofilizados se mantienen mejor a 4 C o menos. La sublimacin ocurre cuando un lquido congelado pasa directamente a un estado gaseoso sin entrar en una fase lquida. El proceso de liofilizacin da como resultado un producto estable y fcilmente rehidratado. Este proceso consta de tres pasos: precongelar el producto para formar una estructura congelada, el secado primario para eliminar la mayor parte del agua y el secado secundario para eliminar el agua unida. Los medios y mtodos para la liofilizacin son conocidos en la tcnica y estn a disposicin del experto. Debido a la variabilidad objetiva y esperada de los procesos industriales para la fabricacin y aislamiento de los cultivos bacterianos liofilizados, estos ltimos comnmente contienen cierta cantidad de aditivo inerte tambin conocido como lioprotector. Su funcin es estandarizar el contenido de bacterias probiticas vivas en el producto. Se utilizan los siguientes aditivos inertes en los cultivos liofilizados disponibles comercialmente: la sacarosa, sacarosa, lactosa, trehalosa, glucosa, maltosa, maltodextrina, almidn de maz, inulina y otros aditivos no higroscpicos farmacuticamente aceptables. Opcionalmente, tambin se utilizan otros agentes estabilizantes o protectores de la congelacin, como el cido ascrbico, para formar una pasta viscosa, el cual se somete a liofilizacin. En cualquier caso, el material as obtenido puede triturarse hasta obtener un tamao apropiado, incluso hasta obtener un polvo.</span>Post-treatment after culturing the strains may consist of lyophilization, as a method of removing water. Lyophilization involves the removal of water from frozen bacterial suspensions by sublimation under reduced pressure. Freeze-dried cultures are best kept at 4  C or below. Sublimation occurs when a frozen liquid goes directly to a gaseous state without entering a liquid phase. The lyophilization process results in a stable and easily rehydrated product. This process consists of three steps: pre-freezing the product to form a frozen structure, primary drying to remove most of the water, and secondary drying to remove bound water. The means and methods for lyophilization are known in the art and are available to the skilled person. Due to the objective and expected variability of industrial processes for the manufacture and isolation of lyophilized bacterial cultures, the latter commonly contain a certain amount of inert additive also known as lyoprotectant. Its function is to standardize the content of live probiotic bacteria in the product. The following inert additives are used in commercially available lyophilized cultures: sucrose, sucrose, lactose, trehalose, glucose, maltose, maltodextrin, cornstarch, inulin, and other pharmaceutically acceptable non-hygroscopic additives. Optionally, other stabilizing or freeze-protecting agents, such as ascorbic acid, are also used to form a viscous paste, which is lyophilized. In any case, the material thus obtained can be ground to a suitable size, even to a powder.</span>
  </p>
  <p id="p0106" num="0106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El postratamiento tras el cultivo de las cepas puede consistir en un secado por aspersin. El secado por aspersin es un proceso mediante el cual una formulacin lquida se convierte en un polvo seco en un solo paso. El proceso se realiza tpicamente atomizando primero la solucin en gotitas artificialmente finas tan pequeas como sea posible, lo cual maximiza la transferencia de calor y la tasa de vaporizacin del agua. El tamao de las gotas puede variar de 20 a 180 pm en dependencia de la boquilla. Hay dos tipos principales de boquillas: la boquilla de fluido nico de alta presin (50 a 300 bares) y boquillas de dos fluidos: un fluido es el lquido a secar y el segundo es gas comprimido (generalmente aire de 1 a 7 bares). A continuacin, las gotitas se secan rpidamente en una cmara grande mediante el uso de gas caliente. Las partculas secas resultantes se recogen con un cicln.</span>Post-treatment after culturing the strains may consist of spray drying. Spray drying is a process by which a liquid formulation is turned into a dry powder in one step. The process is typically performed by first atomizing the solution into artificially fine droplets as small as possible, which maximizes the heat transfer and vaporization rate of the water. The size of the drops can vary from 20 to 180 pm depending on the nozzle. There are two main types of nozzles: the high pressure single fluid nozzle (50-300 bar) and two-fluid nozzles: one fluid is the liquid to be dried and the second is compressed gas (generally 1-7 bar air). The droplets are then quickly dried in a large chamber using hot gas. The resulting dry particles are collected with a cyclone.</span>
  </p>
  <p id="p0108" num="0108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El postratamiento tras el cultivo de las cepas puede consistir en un secado en lecho fluido. En el proceso de lecho fluido, en primer lugar, se necesita un material portador (tambin conocido como material de ncleo) como base para el sustrato que debe secarse. El material portador puede ser, sin limitacin, la celulosa. Este material portador se mantiene en el aire para permitir la aplicacin del sustrato a travs de una boquilla de pulverizacin. En comparacin con el secado por aspersin, las temperaturas son ms bajas. Las bacterias se pulverizan sobre el material portador disperso en forma de gotitas finas. El agua contenida privada del aire seco fluye de abajo hacia arriba a travs del lecho fluido. Al mismo tiempo, la corriente de aire es responsable de la fluidizacin de las partculas. Posteriormente se aplica una capa protectora de la misma materia sobre el portador que est recubierto con bacterias. El revestimiento protector utilizado debe prevenir el dao celular de las bacterias al estabilizar los componentes de la membrana celular, por ejemplo, al crear una estructura porosa en el producto seco que facilita la rehidratacin y contiene protenas que proporcionan un revestimiento protector para las clulas. El material de revestimiento protector puede ser, sin limitacin, leche desnatada y alginato de calcio. La estructura de un producto encapsulado que se logra mediante el recubrimiento de lecho fluido consta de al menos tres partes: dentro el portador o material del ncleo (esfrico), la capa de recubrimiento protectora uniforme, en el exterior y entre el ingrediente activo recubierto de inters, a saber, las bacterias. A veces, se requieren mltiples capas de diferentes materiales de recubrimiento para obtener las propiedades deseadas del producto. El tamao de las microcpsulas resultantes vara entre 200 pm y 2 mm. 
</span>Post-treatment after culturing the strains can consist of fluid bed drying. In the fluid bed process, first of all, a carrier material (also known as core material) is needed as a base for the substrate to be dried. The carrier material can be, without limitation, cellulose. This carrier material is held in the air to allow application of the substrate through a spray nozzle. Compared to spray drying, the temperatures are lower. The bacteria are sprayed onto the dispersed carrier material in the form of fine droplets. Contained water deprived of dry air flows from the bottom up through the fluidized bed. At the same time, the air stream is responsible for the fluidization of the particles. Subsequently, a protective layer of the same material is applied on the carrier that is coated with bacteria. The protective coating used should prevent cell damage from bacteria by stabilizing the components of the cell membrane, for example by creating a porous structure in the dry product that facilitates rehydration and contains proteins that provide a protective coating for the cells. The protective coating material can be, without limitation, skim milk and calcium alginate. The structure of an encapsulated product that is achieved by fluid bed coating consists of at least three parts: inside the carrier or core material (spherical), the uniform protective coating layer, outside and between the active ingredient coated with interest, namely bacteria. Sometimes multiple layers of different coating materials are required to obtain the desired product properties. The size of the resulting microcapsules varies between 200 m and 2 mm. </span>
  </p>
  <p id="p0109" num="0109" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente a conservar la biomasa en forma slida, la biomasa tambin puede conservarse en forma lquida. Esto se puede hacer al agregar un agente bacteriosttico como se describi anteriormente para detener el crecimiento de las bacterias en el medio de cultivo o con un paso intermedio de recoleccin de clulas, al resuspender el sedimento en la solucin salina con un agente bacteriosttico y opcionalmente refrigerarlo.</span>As an alternative to preserving the biomass in solid form, the biomass can also be preserved in liquid form. This can be done by adding a bacteriostatic agent as described above to stop the growth of bacteria in the culture medium or with an intermediate cell harvesting step, by resuspending the pellet in the saline with a bacteriostatic agent and optionally refrigerating it. .</span>
  </p>
  <p id="p0110" num="0110" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A veces, como se describe, por ejemplo, anteriormente en el proceso de secado en lecho fluido, la preparacin probitica se somete a un proceso de inmovilizacin y/o recubrimiento, o encapsulacin con el fin de mejorar la vida til y/o las funcionalidades. En la tcnica se conocen varias tcnicas para la inmovilizacin, el recubrimiento o la encapsulacin de las bacterias.</span>Sometimes, as described, for example, above in the fluid bed drying process, the probiotic preparation is subjected to an immobilization and / or coating process, or encapsulation in order to improve shelf life and / or functionalities. . Various techniques for immobilization, coating, or encapsulation of bacteria are known in the art.</span>
  </p>
  <p id="p0111" num="0111" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En consecuencia, una modalidad particular de la presente invencin se refiere a al menos una cepa como se define anteriormente, por lo tanto, que incluye Lactobacillus plantarum CECT8677 o un mutante del mismo, L. plantarum CECT8675 o un mutante del mismo, L. plantarum CECT8678 o un mutante del mismo, y L. plantarum CECT8676 o un mutante del mismo, en donde la cepa o mutante del mismo ha sido fermentado en un medio artificial y sometido a un postratamiento despus de la fermentacin, para obtener clulas bacterianas, y donde las clulas bacterianas resultantes estn en un medio lquido o en forma slida.</span>Consequently, a particular embodiment of the present invention refers to at least one strain as defined above, therefore, including Lactobacillus plantarum CECT8677 or a mutant thereof, L. plantarum CECT8675 or a mutant thereof, L. plantarum CECT8678 or a mutant thereof, and L. plantarum CECT8676 or a mutant thereof, wherein the strain or mutant thereof has been fermented in an artificial medium and subjected to post-treatment after fermentation, to obtain bacterial cells, and where the resulting bacterial cells are in a liquid medium or in solid form.</span>
  </p>
  <p id="p0112" num="0112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, el postratamiento se selecciona del grupo que consiste en: el secado, congelacin, liofilizacin, secado en lecho fluido, secado por aspersin y refrigeracin en medio lquido. En una modalidad particular, el postratamiento es la liofilizacin.</span>In a particular embodiment, the post-treatment is selected from the group consisting of: drying, freezing, lyophilization, fluid bed drying, spray drying and cooling in a liquid medium. In a particular embodiment, the post-treatment is lyophilization.</span>
  </p>
  <p id="p0113" num="0113" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Est claro que al usar las cepas depositadas como material de partida, el experto en la tcnica puede, de forma rutinaria, mediante mutagnesis convencional o tcnicas de re-aislamiento, obtener mutantes adicionales de las mismas que retengan o mejoren las caractersticas y ventajas relevantes aqu descritas de las cepas que forman la composicin de la invencin. En una modalidad particular, los mutantes se obtienen al utilizar tecnologa de ADN recombinante. En otra modalidad, los mutantes se obtienen mediante mutagnesis aleatoria. Por tanto, otro aspecto de la descripcin se refiere a un mtodo para obtener un mutante de al menos una cepa de Lactobacillus plantarum, en donde la cepa de L. plantarum se selecciona del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677 o la cepa CECT8678, en donde el mtodo comprende usar la cepa depositada como material de partida y aplicar mutagnesis, y en donde el mutante obtenido retiene o mejora adicionalmente al menos la capacidad de la cepa depositada de antagonizar el patgeno urogenital Staphylococcus saprophyticus as como otros patgenos ITU como Escherichia coli, Klebsiella pneumoniae y/o Proteus mirabilis.</span>It is clear that by using the deposited strains as starting material, the person skilled in the art can, routinely, by conventional mutagenesis or re-isolation techniques, obtain additional mutants thereof that retain or enhance the characteristics and advantages relevant here. described of the strains that form the composition of the invention. In a particular embodiment, mutants are made using recombinant DNA technology. In another embodiment, mutants are obtained by random mutagenesis. Therefore, another aspect of the description refers to a method to obtain a mutant of at least one Lactobacillus plantarum strain, wherein the L. plantarum strain is selected from the group consisting of: the CECT8675 strain, the CECT8676 strain, the strain CECT8677 or the strain CECT8678, wherein the method comprises using the deposited strain as starting material and applying mutagenesis, and wherein the obtained mutant retains or further enhances at least the ability of the deposited strain to antagonize the urogenital pathogen Staphylococcus saprophyticus as well as other UTI pathogens such as Escherichia coli, Klebsiella pneumoniae and / or Proteus mirabilis.</span>
  </p>
  <p id="p0114" num="0114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De acuerdo con las caractersticas beneficiosas descritas anteriormente de las cepas CECT8677, CECT8675, CECT8678 y/o CECT8676, otro aspecto de la invencin se refiere a cualquiera de las composiciones definidas anteriormente para su uso como medicamento o como probitico.</span>In accordance with the beneficial characteristics described above of the CECT8677, CECT8675, CECT8678 and / or CECT8676 strains, another aspect of the invention relates to any of the compositions defined above for use as a medicine or as a probiotic.</span>
  </p>
  <p id="p0115" num="0115" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otro aspecto de la invencin se refiere a las composiciones definidas anteriormente para su uso en la prevencin y/o tratamiento de una enfermedad relacionada con alteraciones de la microbiota urogenital. Este aspecto puede formularse alternativamente como el uso de cualquiera de las composiciones de la invencin para la fabricacin de un producto farmacutico, un producto veterinario, un medicamento, un producto alimenticio, un suplemento alimenticio, un alimento mdico o un producto de higiene personal para la prevencin y/o el tratamiento de una enfermedad relacionada con alteraciones de la microbiota urogenital. Este tambin puede formularse alternativamente como un mtodo para la prevencin y/o tratamiento de una enfermedad relacionada con alteraciones de la microbiota urogenital, que comprende administrar al sujeto que lo necesite una cantidad eficaz de cualquiera de las composiciones de la invencin. En incluso otras modalidades particulares, la enfermedad relacionada con alteraciones de la microbiota urogenital mencionada en todos los aspectos anteriores es la infeccin del tracto urinario. En incluso otras modalidades particulares, la infeccin del tracto urinario es la cistitis aguda, pielonefritis aguda, ITU no complicada, ITU complicada o ITU recurrente. Las composiciones de la invencin son particularmente tiles para el tratamiento profilctico de individuos susceptibles a ITU y tambin para el manejo teraputico de individuos con ITU recidivante o reinfeccin. Las composiciones tambin son tiles para prevenir infecciones que ponen en peligro al feto en las mujeres embarazadas y el parto prematuro.</span>Another aspect of the invention relates to the compositions defined above for use in the prevention and / or treatment of a disease related to alterations of the urogenital microbiota. This aspect can alternatively be formulated as the use of any of the compositions of the invention for the manufacture of a pharmaceutical product, a veterinary product, a medicine, a food product, a food supplement, a medical food or a personal hygiene product for the prevention and / or treatment of a disease related to alterations of the urogenital microbiota. It can also alternatively be formulated as a method for the prevention and / or treatment of a disease related to alterations of the urogenital microbiota, which comprises administering to the subject in need thereof an effective amount of any of the compositions of the invention. In even other particular modalities, the disease related to alterations of the urogenital microbiota mentioned in all the above aspects is urinary tract infection. In even other particular modalities, the urinary tract infection is acute cystitis, acute pyelonephritis, uncomplicated UTI, complicated UTI, or recurrent UTI. The compositions of the invention are particularly useful for the prophylactic treatment of individuals susceptible to UTI and also for the therapeutic management of individuals with recurrent or reinfected UTI. The compositions are also useful for preventing fetal endangering infections in pregnant women and premature labor.</span>
  </p>
  <p id="p0116" num="0116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las alteraciones de la microbiota urogenital pueden ser causadas, sin limitacin, por cambios hormonales (es decir, ciclos menstruales), anticoncepcin basada en biomateriales, contacto sexual, prcticas de higiene femenina, consumo de antibiticos, estado nutricional, competencia microbiana interespecfica, comensalismo, etc. En una modalidad particular, tal enfermedad es la vaginosis bacteriana. La vaginosis bacteriana es causada por un crecimiento excesivo de las especies bacterianas que generalmente estn ausentes en la flora vaginal o se encuentran en cantidades muy pequeas. Las especies ms comunes son Gardnerella vaginalis y Atopobium vaginae. Aunque la vaginosis bacteriana puede causar secreciones vaginales inusuales y olor a pescado, la mayora de los casos son asintomticos. Un rasgo tpico de la vaginosis bacteriana es el aumento del pH por encima de 4,5, debido a la desaparicin de Lactobacilli, lo cual facilita an ms el crecimiento de otras especies bacterianas. La vaginosis bacteriana se trata con antibiticos, como el metronidazol y la clindamicina.</span>Urogenital microbiota alterations can be caused, without limitation, by hormonal changes (i.e., menstrual cycles), biomaterial-based contraception, sexual contact, feminine hygiene practices, antibiotic use, nutritional status, interspecific microbial competition, commensalism, etc. In a particular embodiment, such a disease is bacterial vaginosis. Bacterial vaginosis is caused by an overgrowth of bacterial species that are generally absent in the vaginal flora or found in very small amounts. The most common species are Gardnerella vaginalis and Atopobium vaginae. Although bacterial vaginosis can cause unusual vaginal discharge and a fishy odor, most cases are asymptomatic. A typical feature of bacterial vaginosis is an increase in pH above 4.5, due to the disappearance of Lactobacilli, which further facilitates the growth of other bacterial species. Bacterial vaginosis is treated with antibiotics, such as metronidazole and clindamycin.</span>
  </p>
  <p id="p0117" num="0117" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otro aspecto de la invencin se refiere a un producto farmacutico, un producto veterinario, un alimento mdico, un producto alimenticio, un suplemento alimenticio o un producto de higiene personal, que comprende una cantidad 
eficaz de cualquiera de las composiciones descritas en este documento junto con cantidades apropiadas de excipientes aceptables.</span>Another aspect of the invention relates to a pharmaceutical product, a veterinary product, a medical food, a food product, a food supplement or a personal hygiene product, comprising an amount  efficacy of any of the compositions described herein in conjunction with appropriate amounts of acceptable excipients.</span>
  </p>
  <p id="p0118" num="0118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, la composicin de la invencin puede prepararse en cualquier forma adecuada que no afecte negativamente a la viabilidad de las cepas que forman la composicin de la invencin. La seleccin de los excipientes y los mtodos de formulacin ms apropiados en vista del propsito particular de la composicin estn dentro del alcance de los expertos en la tcnica de la tecnologa farmacutica.</span>Accordingly, the composition of the invention can be prepared in any suitable form that does not adversely affect the viability of the strains that make up the composition of the invention. Selection of the most appropriate excipients and formulation methods in view of the particular purpose of the composition is within the purview of those skilled in the art of pharmaceutical technology.</span>
  </p>
  <p id="p0119" num="0119" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composicin puede administrarse por va oral, vaginal o rectal, o al utilizar diferentes formas de administracin simultneamente (por ejemplo, por va oral y vaginal).</span>The composition can be administered orally, vaginally or rectally, or by using different forms of administration simultaneously (for example, orally and vaginally).</span>
  </p>
  <p id="p0120" num="0120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En este sentido, la composicin de la invencin se encuentra en forma slida o lquida y puede estar, entre otras cosas, en forma de polvos, tabletas o grageas, tabletas para chupar, preparaciones de pelculas, soluciones, aerosoles, grnulos, pldoras, suspensiones, emulsiones, cpsulas, comprimidos y cpsulas con revestimiento, jarabes, lquidos, elixires, dulces, chicles, supositorios, microenemas, comprimidos vaginales, cpsulas de gelatina vaginal, cremas, geles, ungentos, lociones, tampones, servilletas, compresas, tiras fundentes, condones, pesarios, aerosoles, duchas vaginales, tintura o extractos fluidos.</span>In this sense, the composition of the invention is in solid or liquid form and may be, among other things, in the form of powders, tablets or dragees, lozenges, film preparations, solutions, aerosols, granules, pills, suspensions. , emulsions, capsules, tablets and coated capsules, syrups, liquids, elixirs, sweets, chewing gums, suppositories, microenemas, vaginal tablets, vaginal gelatin capsules, creams, gels, ointments, lotions, tampons, napkins, compresses, melting strips, condoms, pessaries, sprays, douches, tincture, or fluid extracts.</span>
  </p>
  <p id="p0121" num="0121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, la composicin de la invencin se administra en combinacin con otros ingredientes activos comnmente usados para tratar ITU, en particular con un agente antimicrobiano. En apartados anteriores se define lo que se entiende por agentes antimicrobianos, entre los que habitualmente se incluyen los antibiticos y los productos e ingredientes naturales con efecto antimicrobiano. Algunas modalidades particulares de la invencin son composiciones que comprenden las cepas de la invencin junto con: el arndano; arndano y salvia; arndano, manosa y salvia; arndano y vitamina C; arndano, berberina, arbutina y betula; y arndano, berberina, arbutina, betula y manosa.</span>In a particular embodiment, the composition of the invention is administered in combination with other active ingredients commonly used to treat UTI, in particular with an antimicrobial agent. The previous sections define what is understood by antimicrobial agents, which usually include antibiotics and natural products and ingredients with antimicrobial effect. Some particular embodiments of the invention are compositions comprising the strains of the invention together with: cranberry; blueberry and sage; cranberry, mannose, and sage; cranberry and vitamin C; blueberry, berberine, arbutin and betula; and cranberry, berberine, arbutin, betula and mannose.</span>
  </p>
  <p id="p0122" num="0122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composicin de acuerdo con la invencin puede formularse en una forma en donde las cepas de la invencin sean el nico agente activo. Alternativamente, la composicin de la invencin puede formularse mezclada con uno o ms de otros agentes activos. Alternativamente, las cepas de la invencin solas o formuladas mezcladas con uno o ms de otros agentes activos, tambin pueden formularse con excipientes farmacuticamente o veterinariamente aceptables o aditivos o ingredientes adecuados en el caso de un producto alimenticio. En una modalidad particular de la invencin, la composicin contiene adicionalmente uno o ms agentes activos adicionales. Alternativamente, el agente o agentes activos adicionales son otras bacterias probiticas que no son antagonistas de las cepas que forman la composicin de la invencin. En particular, y debido a la capacidad de las cepas de la invencin para sobrevivir en altas concentraciones de agentes antibiticos a los cuales las cepas de la invencin son resistentes y que se usan tpicamente para manejar la ITU, la composicin de la invencin puede administrarse en combinacin con la fosfomicina en la prevencin y/o el tratamiento de las ITU. Como se muestra en el EJEMPLO 5, ventajosamente, las cepas de la invencin pueden coadministrarse con la fosfomicina, la cual es el tratamiento de primera lnea en muchos pases. Dado que la resistencia de los uropatgenos (por ejemplo, S. saprophyticus) a este antibitico ha aumentado significativamente en los ltimos aos en muchos pases, el uso combinado de la(s) cepa(s) probitica(s) de la invencin con la fosfomicina puede aumentar el espectro inhibidor de este antibitico, lo cual mejora su eficacia.</span>The composition according to the invention can be formulated in a form where the strains of the invention are the only active agent. Alternatively, the composition of the invention can be formulated in admixture with one or more other active agents. Alternatively, the strains of the invention alone or formulated in admixture with one or more other active agents may also be formulated with pharmaceutically or veterinarily acceptable excipients or suitable additives or ingredients in the case of a food product. In a particular embodiment of the invention, the composition additionally contains one or more additional active agents. Alternatively, the additional active agent (s) are other probiotic bacteria that are not antagonists of the strains that make up the composition of the invention. In particular, and due to the ability of the strains of the invention to survive in high concentrations of antibiotic agents to which the strains of the invention are resistant and which are typically used to manage UTI, the composition of the invention can be administered in combination with fosfomycin in the prevention and / or treatment of UTIs. As shown in EXAMPLE 5, advantageously, the strains of the invention can be co-administered with fosfomycin, which is the first-line treatment in many countries. Since the resistance of uropathogens (e.g. S. saprophyticus) to this antibiotic has increased significantly in recent years in many countries, the combined use of the probiotic strain (s) of the invention with the fosfomycin can increase the inhibitory spectrum of this antibiotic, which improves its effectiveness.</span>
  </p>
  <p id="p0123" num="0123" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por tanto, en una modalidad particular, las composiciones de la invencin se utilizan en combinacin con una cantidad eficaz de un agente antimicrobiano; y ms particularmente, el antibitico es la fosmomicina.</span>Therefore, in a particular embodiment, the compositions of the invention are used in combination with an effective amount of an antimicrobial agent; and more particularly, the antibiotic is fosmomycin.</span>
  </p>
  <p id="p0124" num="0124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una modalidad particular, la composicin comprende ms de un agente activo, los agentes activos pueden formularse en una nica forma farmacutica, veterinaria, suplemento alimenticio o alimento mdico, o en formas separadas para ser administradas secuencial o consecutivamente en cualquier orden, en donde la forma que comprende al menos una de las cepas de la presente invencin, se administra antes, sustancialmente de forma simultnea, despus o entre la administracin de(los) otro(s) agente(s) activo(s).</span>In a particular embodiment, the composition comprises more than one active agent, the active agents can be formulated in a single pharmaceutical, veterinary, food supplement or medical food form, or in separate forms to be administered sequentially or consecutively in any order, wherein the A form comprising at least one of the strains of the present invention, is administered before, substantially simultaneously, after or between the administration of the other active agent (s).</span>
  </p>
  <p id="p0125" num="0125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los expertos en la tcnica determinarn las dosis diarias y los regmenes teraputicos. Por ejemplo, la dosis diaria puede ser mayor durante el tratamiento de sntomas activos o puede ser menor con fines profilcticos. Un rgimen teraputico preferente se basar en la administracin simultnea de las bacterias del cido lctico y los agentes antimicrobianos u otros ingredientes activos. Sin embargo, los regmenes teraputicos tambin pueden ser secuenciales, por ejemplo, al administrar primero el agente antimicrobiano o el ingrediente activo de inters y comenzar el tratamiento con la composicin probitica de acuerdo con la presente invencin algunos das despus. Otros regmenes teraputicos tpicos consisten en iniciar el tratamiento con la composicin probitica antes de la administracin del agente antimicrobiano o el principio activo de inters.</span>Those skilled in the art will determine daily dosages and therapeutic regimens. For example, the daily dose may be higher during the treatment of active symptoms or it may be lower for prophylactic purposes. A preferred therapeutic regimen will be based on the simultaneous administration of the lactic acid bacteria and antimicrobial agents or other active ingredients. However, therapeutic regimens can also be sequential, for example by first administering the antimicrobial agent or active ingredient of interest and starting treatment with the probiotic composition according to the present invention a few days later. Other typical therapeutic regimens consist of initiating treatment with the probiotic composition prior to administration of the antimicrobial agent or active ingredient of interest.</span>
  </p>
  <p id="p0126" num="0126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, la administracin puede ser crnica o intermitente, como lo considere apropiado el mdico supervisor, particularmente en vista de cualquier cambio en el estado de la enfermedad o cualquier efecto secundario indeseable. La administracin "crnica" se refiere a la administracin de la composicin de manera continua, mientras que la administracin "intermitente" se refiere al tratamiento que se realiza con interrupcin. 
</span>Furthermore, administration may be chronic or intermittent, as the supervising physician deems appropriate, particularly in view of any change in disease status or any undesirable side effects. "Chronic" administration refers to administration of the composition in a continuous manner, while "intermittent" administration refers to treatment that is carried out with interruption. </span>
  </p>
  <p id="p0127" num="0127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cantidad eficaz de las unidades formadoras de colonias (ufc) para las cepas en la composicin se determinar por los expertos en la tcnica y depender de la formulacin final. Por ejemplo, cuando se administra por va oral sin ningn otro agente activo, la cantidad total de las cepas de la invencin est presente en la composicin en una sola dosis en una cantidad que da una dosis diaria efectiva de 107 a 1012 ufc, de acuerdo con la actual legislacin, preferentemente de 109 a 1011 ufc y, cuando se administra por va vaginal o rectal, en una cantidad que proporcione una dosis diaria eficaz de 103 a 1012 ufc, preferentemente de 105 a 1010 ufc. El trmino "unidad formadora de colonias" ("ufc") se define como el nmero de clulas bacterianas revelado por recuentos microbiolgicos en placas de agar. Los suplementos alimenticios suelen contener cepas probiticas en una cantidad que oscila entre 107 y 1012 ufc/g. En una modalidad particular, la composicin de la invencin es un suplemento alimenticio para dosis diarias que comprenden entre 109-1011 ufc/g.</span>The effective amount of colony forming units (cfu) for the strains in the composition will be determined by those skilled in the art and will depend on the final formulation. For example, when administered orally without any other active agent, the total amount of the strains of the invention is present in the composition in a single dose in an amount that gives an effective daily dose of 107 to 1012 cfu, according to with current legislation, preferably 109-1011 cfu and, when administered vaginally or rectally, in an amount that provides an effective daily dose of 103-1012 cfu, preferably 105-1010 cfu. The term "colony forming unit" ("cfu") is defined as the number of bacterial cells revealed by microbiological counts on agar plates. Food supplements usually contain probiotic strains in an amount ranging between 107 and 1012 cfu / g. In a particular embodiment, the composition of the invention is a food supplement for daily doses comprising between 109-1011 cfu / g.</span>
  </p>
  <p id="p0128" num="0128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "producto farmacutico" se entiende en su amplio significado en esta descripcin, el cual incluye cualquier composicin que comprenda un ingrediente activo, en este caso, las cepas de la invencin preferentemente en forma de composicin, junto con excipientes farmacuticamente aceptables. El trmino "producto farmacutico" no se limita a medicamentos. El trmino "farmacuticamente aceptable", como se usa en este documento, se refiere a compuestos, materiales, composiciones y/o formas farmacolgicas las cuales, dentro del alcance del juicio mdico slido, son adecuados para su uso en contacto con los tejidos de un sujeto (por ejemplo, un ser humano) sin excesos de toxicidad, irritacin, respuesta alrgica u otro problema o complicacin, acorde con una relacin beneficio/riesgo razonable. Cada portador, excipiente, etc. tambin debe ser "aceptable" en el sentido de ser compatible con los dems ingredientes de la formulacin. Los portadores, excipientes, etc. adecuados pueden encontrarse en los textos farmacuticos estndar.</span>The term "pharmaceutical product" is understood in its broad meaning in this description, which includes any composition comprising an active ingredient, in this case, the strains of the invention preferably in composition form, together with pharmaceutically acceptable excipients. The term "pharmaceutical product" is not limited to drugs. The term "pharmaceutically acceptable", as used herein, refers to compounds, materials, compositions, and / or drug forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of a patient. subject (eg, a human) without excess toxicity, irritation, allergic response, or other problem or complication, consistent with a reasonable benefit / risk ratio. Each carrier, excipient, etc. it must also be "acceptable" in the sense of being compatible with the other ingredients in the formulation. Carriers, excipients, etc. Suitable can be found in standard pharmaceutical texts.</span>
  </p>
  <p id="p0129" num="0129" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El trmino "excipiente" se entiende en su amplio significado en esta descripcin, el cual incluye cualquier sustancia natural o sinttica formulada junto con el ingrediente activo de un producto farmacutico, producto veterinario, medicamento, suplemento alimenticio, alimento mdico y producto de higiene personal. El(los) excipiente(s) ms apropiado(s) a utilizar depende(n) de la formulacin final.</span>The term "excipient" is understood in its broad meaning in this description, which includes any natural or synthetic substance formulated together with the active ingredient of a pharmaceutical product, veterinary product, medicine, food supplement, medical food and personal hygiene product. The most appropriate excipient (s) to use depends on the final formulation.</span>
  </p>
  <p id="p0130" num="0130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los excipientes se seleccionan, sin limitacin, del grupo que comprende: aditivos/diluyentes/agentes de carga, aglutinantes, antiadherentes, desintegrantes, recubrimientos, agentes antiaglomerantes, antioxidantes, lubricantes, edulcorantes, aromas, colorantes, surfactantes y otras clases de excipientes farmacutica y veterinariamente aceptables.</span>Excipients are selected, without limitation, from the group comprising: additives / diluents / bulking agents, binders, release agents, disintegrants, coatings, anti-caking agents, antioxidants, lubricants, sweeteners, flavors, colorants, surfactants and other classes of pharmaceutical excipients and veterinarily acceptable.</span>
  </p>
  <p id="p0131" num="0131" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los aditivos se seleccionan, sin limitacin, del grupo que comprende: la inulina, oligofructosa, pectina, pectinas modificadas, celulosa microcristalina, lactosa, almidn, maltodextrina, sacarosa, glucosa, fructosa, manitol, xilitol, sorbitol no cristalizante, carbonato clcico, fosfato diclcico, otros aditivos inertes inorgnicos y orgnicos farmacolgicamente aceptables, y mezclas de estas sustancias. En la forma de dosificacin de suspensin oral, los aditivos o diluyentes se seleccionan del grupo que comprende: el aceite vegetal, cido oleico, alcohol oleico, polietilenglicol lquido, otros lquidos inertes farmacolgicamente aceptables o mezclas de estas sustancias.</span>Additives are selected, without limitation, from the group comprising: inulin, oligofructose, pectin, modified pectins, microcrystalline cellulose, lactose, starch, maltodextrin, sucrose, glucose, fructose, mannitol, xylitol, non-crystallizing sorbitol, calcium carbonate, phosphate dicalcium, other pharmacologically acceptable inert inorganic and organic additives, and mixtures of these substances. In oral suspension dosage form, additives or diluents are selected from the group comprising: vegetable oil, oleic acid, oleic alcohol, liquid polyethylene glycol, other pharmacologically acceptable inert liquids, or mixtures of these substances.</span>
  </p>
  <p id="p0132" num="0132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los aglutinantes se utilizan en formas farmacolgicas slidas, por ejemplo, para mantener juntos los ingredientes de una tableta, para asegurar que las tabletas y los grnulos puedan formarse con la resistencia mecnica requerida y para proporcionar volumen a las tabletas de baja dosis activa. Los aglutinantes en formas farmacuticas slidas como tabletas son: la lactosa, sacarosa, almidn de maz (maz), almidones modificados, celulosa microcristalina, celulosa modificada (por ejemplo, la hidroxipropil metilcelulosa (HPMC) e hidroxietilcelulosa), otros teres de celulosa solubles en agua, la polivinilpirrolidona (PVP) tambin conocida como povidona, el polietilenglicol, sorbitol, maltitol, xilitol y fosfato clcico dibsico; otros aglutinantes farmacolgicamente aceptables adecuados o mezclas de estas sustancias.</span>Binders are used in solid drug forms, for example, to hold the ingredients of a tablet together, to ensure that tablets and granules can be formed with the required mechanical strength, and to provide bulk to low-dose active tablets. Binders in solid dosage forms such as tablets are: lactose, sucrose, cornstarch (corn), modified starches, microcrystalline cellulose, modified cellulose (for example, hydroxypropyl methylcellulose (HPMC) and hydroxyethylcellulose), other cellulose ethers soluble in water, polyvinylpyrrolidone (PVP) also known as povidone, polyethylene glycol, sorbitol, maltitol, xylitol, and dibasic calcium phosphate; other suitable pharmacologically acceptable binders or mixtures of these substances.</span>
  </p>
  <p id="p0133" num="0133" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los antiadherentes se utilizan para reducir la adherencia entre el polvo (grnulos) y las caras del punzn y as evitar que se pegue a los punzones de las tabletas. Tambin se utilizan para ayudar a evitar que las tabletas se peguen. El ms utilizado es el estearato de magnesio.</span>Non-stick agents are used to reduce adhesion between the powder (granules) and the punch faces and thus prevent it from sticking to the tablet punches. They are also used to help prevent tablets from sticking. The most widely used is magnesium stearate.</span>
  </p>
  <p id="p0134" num="0134" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como desintegrantes y superdesintegrantes en formas farmacuticas slidas como las tabletas y cpsulas, se utilizan las siguientes sustancias, sin limitacin: polivinilpirrolidona reticulada, almidn glicolato de sodio, carboximetilcelulosa de sodio, carboximetilcelulosa de calcio y formaldehdo-casena, otro desintegrante y superdesintegrante farmacolgicamente aceptable adecuado, o sus mezclas.</span>As disintegrants and superdisintegrants in solid pharmaceutical forms such as tablets and capsules, the following substances are used, without limitation: cross-linked polyvinylpyrrolidone, sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose and formaldehyde-casein, another pharmacologically acceptable disintegrant and superdisintegrant , or their mixtures.</span>
  </p>
  <p id="p0135" num="0135" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los recubrimientos en el caso de formas farmacuticas slidas, tales como las tabletas y los grnulos para el llenado de cpsulas, protegen los ingredientes del deterioro por la humedad en el aire, hacen que las tabletas grandes y de sabor desagradable sean ms fciles de tragar y/o en el caso de los recubrimientos entricos aseguran que estn intactas al pasar a travs de un medio cido fuerte de jugo gstrico (pH alrededor de 1), y lo cual permite su liberacin en el duodeno o el leon (intestino delgado). Para la mayora de las tabletas recubiertas, se usa un recubrimiento de pelcula de ter de celulosa hidroxipropil metilcelulosa (HPMC). Ocasionalmente, se utilizan otros materiales de recubrimiento, por ejemplo, polmeros sintticos y copolmeros como el ftalato de acetato de polivinilo (PVAP); copolmeros de acrilato de metilo-cido metacrlico; copolmeros de metacrilato de metilo-cido metacrlico; goma laca, zena de protena de maz u otros polisacridos; ceras o sustancias similares a las ceras como la cera de 
abejas, el cido esterico; alcoholes grasos superiores como el alcohol cetlico o estearlico; la parafina slida; el monoestearato de glicerol; el diestearato de glicerol, o sus combinaciones. Las cpsulas estn recubiertas con gelatina o hidroxipropil metilcelulosa.</span>Coatings in the case of solid dosage forms, such as tablets and capsule filling granules, protect ingredients from deterioration by moisture in the air, make large, unpleasant-tasting tablets easier to swallow, and / or in the case of enteric coatings, they ensure that they are intact when passing through a strong acidic medium of gastric juice (pH around 1), and which allows their release in the duodenum or ileum (small intestine). For most coated tablets, a hydroxypropyl methylcellulose cellulose ether (HPMC) film coating is used. Occasionally, other coating materials are used, for example synthetic polymers and copolymers such as polyvinyl acetate phthalate (PVAP); methyl acrylate-methacrylic acid copolymers; methyl methacrylate-methacrylic acid copolymers; Shellac, corn protein zein, or other polysaccharides; waxes or wax-like substances such as wax  bees, stearic acid; higher fatty alcohols such as cetyl or stearyl alcohol; solid paraffin; glycerol monostearate; glycerol distearate, or combinations thereof. The capsules are coated with gelatin or hydroxypropyl methylcellulose.</span>
  </p>
  <p id="p0136" num="0136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los recubrimientos entricos controlan la velocidad de liberacin del frmaco y determinan donde se liberar el frmaco en el tracto digestivo. Los materiales utilizados para los recubrimientos entricos incluyen los cidos grasos, ceras, goma laca, plsticos y fibras vegetales y sus mezclas, tambin en combinacin con otros recubrimientos mencionados anteriormente.</span>Enteric coatings control the rate of drug release and determine where the drug will be released in the digestive tract. The materials used for enteric coatings include fatty acids, waxes, shellac, plastics and vegetable fibers and their mixtures, also in combination with other coatings mentioned above.</span>
  </p>
  <p id="p0137" num="0137" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un antiaglomerante es un aditivo que se coloca en materiales en polvo o granulados para evitar la formacin de grumos (apelmazamiento) y para facilitar el envasado, transporte y el consumo. Como agentes antiaglomerantes en formas farmacolgicas slidas como las tabletas, cpsulas o polvos, se utilizan los siguientes: el estearato de magnesio, dixido de silicio coloidal, talco, otros agentes antiaglomerantes farmacolgicamente aceptables o sus mezclas.</span>An anti-caking agent is an additive that is placed in powdered or granulated materials to prevent lumping (caking) and to facilitate packaging, transportation, and consumption. As anticaking agents in solid pharmacological forms such as tablets, capsules or powders, the following are used: magnesium stearate, colloidal silicon dioxide, talc, other pharmacologically acceptable anticaking agents or their mixtures.</span>
  </p>
  <p id="p0138" num="0138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los lubricantes se utilizan en formas farmacolgicas slidas, en particular en tabletas y cpsulas, para evitar que los ingredientes se agrupen y se peguen a los punzones de tabletas o la mquina de llenado de cpsulas, y tambin en cpsulas duras. Como lubricantes, el talco o la slice y las grasas, por ejemplo, la estearina vegetal, el estearato de magnesio o cido esterico, y sus mezclas, son los lubricantes ms utilizados en las tabletas o cpsulas de gelatina dura.</span>Lubricants are used in solid drug forms, particularly tablets and capsules, to prevent ingredients from clumping together and sticking to tablet punches or capsule filling machine, and also in hard capsules. As lubricants, talc or silica and fats, for example, vegetable stearin, magnesium stearate or stearic acid, and their mixtures, are the most commonly used lubricants in hard gelatin tablets or capsules.</span>
  </p>
  <p id="p0139" num="0139" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se aaden edulcorantes para hacer que los ingredientes sean ms agradables al paladar, especialmente en formas farmacolgicas slidas, por ejemplo, tabletas masticables, as como en formas farmacolgicas lquidas, como el jarabe para la tos. Los edulcorantes pueden seleccionarse entre edulcorantes artificiales, naturales o sintticos o semisintticos; ejemplos no limitantes de edulcorantes son el aspartamo, acesulfamo de potasio, ciclamato, sucralosa, sacarina, azcares o cualquier mezcla de los mismos,</span>Sweeteners are added to make the ingredients more palatable, especially in solid drug forms, eg, chewable tablets, as well as in liquid drug forms, such as cough syrup. The sweeteners can be selected from artificial, natural or synthetic or semi-synthetic sweeteners; non-limiting examples of sweeteners are aspartame, acesulfame potassium, cyclamate, sucralose, saccharin, sugars or any mixture thereof,</span>
  </p>
  <p id="p0140" num="0140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los aromas pueden utilizarse para enmascarar ingredientes activos de sabor desagradable en cualquier forma farmacolgica. Los aromatizantes pueden ser naturales (por ejemplo, el extracto de frutas) o artificiales. Por ejemplo, para mejorar: (1) puede utilizarse un producto amargo, menta, cereza o ans; (2) puede utilizarse un producto salado, melocotn o albaricoque o regaliz; (3) un producto cido, frambuesa; y (4) un producto excesivamente dulce, vainilla.</span>Flavors can be used to mask unpleasant tasting active ingredients in any pharmacological form. Flavorings can be natural (eg fruit extract) or artificial. For example, to improve: (1) a bitter product, mint, cherry or anise can be used; (2) a salty product, peach or apricot or licorice can be used; (3) an acidic product, raspberry; and (4) an excessively sweet product, vanilla.</span>
  </p>
  <p id="p0141" num="0141" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Excepto las sustancias auxiliares de la clase de excipientes, la formulacin de la presente invencin puede contener otras sustancias nutritivas o farmacolgicamente activas seleccionadas del grupo que comprende: antibiticos; jugo de arndano; vitaminas, tales como la vitamina C (o cido ascrbico) en una forma qumica, sal o derivados farmacuticamente aceptables; minerales en la presentacin de una forma qumica nutritiva y farmacolgicamente aceptable; y L-aminocidos. Con respecto a la preparacin de las formulaciones de la presente invencin, est dentro del alcance del experto en la tcnica y depender de la formulacin farmacolgica final. Por ejemplo, y sin limitacin, cuando la forma farmacolgica final es slida oral, como las tabletas, cpsulas, polvo, grnulos, suspensin oral, etc., el proceso para la preparacin de las formas farmacolgicas slidas de la formulacin incluye la homogeneizacin de: (1) el(los) ingrediente(s) o ingrediente(s) activos, que comprenden al menos una o ms bacterias probiticas postratadas de la invencin en una cantidad eficaz; (2) con uno o ms excipientes para formar una mezcla homognea que, por ejemplo, de acuerdo con los requisitos, se somete a lubricacin con estearato de magnesio u otros lubricantes, lo cual produce la forma farmacolgica final en polvo. Dicho polvo homogneo se introduce en cpsulas de gelatina ordinarias o, alternativamente, en cpsulas gastrorresistentes. En el caso de las tabletas, se fabrican mediante la compresin directa o granulacin. En el primer caso, se prepara una mezcla homognea de principios activos y excipientes adecuados como la lactosa anhidra, el sorbitol no cristalizante y otros. En el segundo caso, las tabletas se procesan sobre la mezcla en forma granulada. Los grnulos se preparan mediante un proceso de granulacin de los ingredientes activos de la formulacin con aditivos, aglutinantes, desintegrantes adecuados y una pequea cantidad de agua purificada. Dichos grnulos preparados se tamizan y secan hasta que el contenido de agua sea &lt;1 % p/p.</span>Except auxiliary substances from the excipient class, the formulation of the present invention may contain other nutritive or pharmacologically active substances selected from the group comprising: antibiotics; cranberry juice; vitamins, such as vitamin C (or ascorbic acid) in a pharmaceutically acceptable chemical form, salt or derivatives; minerals in a nutritive and pharmacologically acceptable chemical form; and L-amino acids. With regard to the preparation of the formulations of the present invention, it is within the scope of the person skilled in the art and will depend on the final drug formulation. For example, and without limitation, when the final drug form is an oral solid, such as tablets, capsules, powder, granules, oral suspension, etc., the process for the preparation of the solid drug forms of the formulation includes the homogenization of: (1) the active ingredient (s) or ingredient (s), comprising at least one or more post-treated probiotic bacteria of the invention in an effective amount; (2) with one or more excipients to form a homogeneous mixture which, for example, according to requirements, is lubricated with magnesium stearate or other lubricants, which produces the final powdered drug form. Said homogeneous powder is filled into ordinary gelatin capsules or, alternatively, into gastro-resistant capsules. In the case of tablets, they are made by direct compression or granulation. In the first case, a homogeneous mixture of active principles and suitable excipients such as anhydrous lactose, non-crystallizing sorbitol and others is prepared. In the second case, the tablets are processed on the mixture in granular form. The granules are prepared by a process of granulation of the active ingredients of the formulation with suitable additives, binders, disintegrants and a small amount of purified water. Said prepared granules are sieved and dried until the water content is &lt;1% w / w.</span>
  </p>
  <p id="p0142" num="0142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En cuanto al proceso para la preparacin de las formas farmacolgicas lquidas (por ejemplo, la suspensin oral), implica la homogeneizacin del(los) ingrediente(s) activo(s) de la formulacin que comprende al menos una o ms bacterias probiticas postratadas de la invencin en una cantidad eficaz en un diluyente lquido inerte (aditivo) tal como varios aceites vegetales como por ejemplo el aceite de girasol, soja u oliva; el cido oleico; alcohol oleico; los polietilenglicoles lquidos como el PEG 200, PEG 400 o PEG 600; u otros lquidos inertes farmacolgicamente aceptables. El proceso adems implica el tratamiento de una mezcla homognea con uno o ms procesos seleccionados del grupo que comprende: (1) la estabilizacin de la formulacin, mediante la adicin y la homogenizacin de estabilizadores de la suspensin como la cera de abejas, dixido de silicio coloidal, etc; (2) la edulcoracin de la formulacin; por adicin y homogeneizacin del edulcorante; (3) aromatizar la formulacin, mediante la adicin y homogeneizacin del aromatizante. Tales formas de la formulacin pueden contener tambin otros excipientes o ingredientes, normalmente empleados en la tcnica. 
</span>Regarding the process for the preparation of the liquid pharmacological forms (for example, the oral suspension), it involves the homogenization of the active ingredient (s) of the formulation comprising at least one or more post-treated probiotic bacteria of the invention in an effective amount in an inert liquid diluent (additive) such as various vegetable oils such as sunflower, soy or olive oil; oleic acid; oleic alcohol; liquid polyethylene glycols such as PEG 200, PEG 400 or PEG 600; or other pharmacologically acceptable inert liquids. The process also involves the treatment of a homogeneous mixture with one or more processes selected from the group that comprises: (1) stabilization of the formulation, by adding and homogenizing suspension stabilizers such as beeswax, silicon dioxide colloidal, etc; (2) the sweetening of the formulation; by adding and homogenizing the sweetener; (3) flavoring the formulation, by adding and homogenizing the flavoring. Such forms of the formulation may also contain other excipients or ingredients, normally employed in the art. </span>
  </p>
  <p id="p0143" num="0143" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El producto farmacutico puede adoptar diferentes formas o nombres en dependencia de la va de aprobacin del producto y tambin del pas. Por ejemplo, un medicamento es un producto farmacutico particular. Un alimento mdico es otro producto farmacutico particular. Los trminos "alimento medicinal" o "alimento para fines mdicos especiales" se utilizan en algunos pases para referirse a un alimento especialmente formulado y destinado al manejo diettico de una enfermedad que tiene necesidades nutricionales distintivas que no pueden satisfacerse nicamente con una dieta normal. Estn definidos en las regulaciones como las Enmiendas a la Ley de Medicamentos Hurfanos de 1988 de la Administracin de Alimentos y Medicamentos en los Estados Unidos y la Directiva de la Comisin 1999/21/EC en Europa. Los alimentos medicinales son distintos de la categora ms amplia de suplementos alimenticios y de los alimentos tradicionales que llevan una declaracin de propiedades saludables. De este modo, en una modalidad particular, la composicin de la invencin es un alimento medicinal.</span>The pharmaceutical product can take different forms or names depending on the approval route of the product and also on the country. For example, a drug is a particular pharmaceutical product. A medical food is another particular pharmaceutical product. The terms "medicinal food" or "food for special medical purposes" are used in some countries to refer to a food specially formulated and intended for the dietary management of a disease that has distinctive nutritional needs that cannot be met by a normal diet alone. They are defined in regulations such as the Orphan Drugs Act Amendments of 1988 of the Food and Drug Administration in the United States and Commission Directive 1999/21 / EC in Europe. Medicinal foods are different from the broader category of dietary supplements and traditional foods that carry a health claim. Thus, in a particular embodiment, the composition of the invention is a medicinal food.</span>
  </p>
  <p id="p0144" num="0144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A menudo, las composiciones de bacterias probiticas, como la descrita en este documento, se consideran suplementos alimenticios. Un suplemento alimenticio, tambin conocido como suplemento diettico o suplemento nutricional, se considera otro producto farmacutico particular. Se trata de un preparado o producto destinado a complementar la dieta, elaborado a partir de compuestos habitualmente utilizados en los alimentos, que aportan nutrientes o ingredientes beneficiosos que no suelen ingerirse en la dieta habitual o no pueden consumirse en cantidades suficientes. En su mayora, los suplementos alimenticios se consideran productos alimenticios, pero a veces se definen como medicamentos, productos naturales para la salud o productos nutracuticos. En el sentido de la presente invencin, los suplementos alimenticios tambin incluyen los nutracuticos. Los suplementos alimenticios se venden normalmente "sin receta", es decir, sin prescripcin. Si el suplemento alimenticio adopta la forma de pastilla, cpsula, tableta o polvo, comprende excipientes que son los mismos que se utilizan en los medicamentos. Sin embargo, un suplemento alimenticio tambin puede adoptar la forma de un producto alimenticio enriquecido con algunos nutrientes (por ejemplo, una barra o yogur). De este modo, en una modalidad particular, la composicin de la invencin es un suplemento alimenticio.</span>Probiotic bacteria compositions, such as the one described herein, are often considered food supplements. A food supplement, also known as a dietary supplement or nutritional supplement, is considered another particular pharmaceutical product. It is a preparation or product intended to supplement the diet, made from compounds commonly used in food, which provide nutrients or beneficial ingredients that are not usually ingested in the usual diet or cannot be consumed in sufficient quantities. Food supplements are mostly considered food products, but are sometimes defined as medicines, natural health products, or nutraceuticals. In the sense of the present invention, food supplements also include nutraceuticals. Food supplements are usually sold "without a prescription", that is, without a prescription. If the food supplement is in the form of a pill, capsule, tablet or powder, it includes excipients that are the same as those used in medicines. However, a food supplement can also take the form of a food product enriched with some nutrients (for example, a bar or yogurt). Thus, in a particular embodiment, the composition of the invention is a food supplement.</span>
  </p>
  <p id="p0145" num="0145" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Si la composicin de acuerdo la invencin es un suplemento alimenticio, puede administrarse como tal, puede mezclarse con un lquido potable adecuado, como el agua, yogur, leche o zumo de frutas, o puede mezclarse con alimentos slidos o lquidos. En este contexto, el suplemento alimenticio puede estar en forma de tabletas o pastillas, pldoras, cpsulas, grnulos, polvos, suspensiones, parches, caramelos, barras, jarabes y formas de administracin correspondientes, normalmente en la forma de dosis unitaria. Preferentemente, el suplemento alimenticio que comprende la composicin de la invencin se administra en forma de tabletas, grageas, cpsulas o polvos, fabricados en procesos convencionales de preparacin de complementos dietticos.</span>If the composition according to the invention is a food supplement, it can be administered as such, it can be mixed with a suitable drinking liquid, such as water, yogurt, milk or fruit juice, or it can be mixed with solid or liquid food. In this context, the food supplement may be in the form of tablets or lozenges, pills, capsules, granules, powders, suspensions, patches, candies, bars, syrups and corresponding administration forms, usually in unit dose form. Preferably, the food supplement comprising the composition of the invention is administered in the form of tablets, dragees, capsules or powders, manufactured in conventional processes for the preparation of dietary supplements.</span>
  </p>
  <p id="p0146" num="0146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas de la invencin tambin pueden incluirse en una variedad de productos alimenticios, tales como los productos lcteos (un yogur, un queso, una leche fermentada, una leche en polvo, un producto fermentado a base de leche, un helado, un producto a base de cereal fermentado, un polvo a base de leche), pan, barras, untables, galletas y cereales, una bebida, diferentes tipos de aceite o un aderezo. El trmino "producto alimenticio" se usa en este documento en su significado ms amplio, el cual incluye cualquier tipo de producto, en cualquier forma de presentacin, que pueda ingerirse por un animal, pero excluye los productos farmacuticos y veterinarios. Ejemplos de otros productos alimenticios son los productos crnicos (por ejemplo, las salchichas o pastas para untar), chocolate para untar, rellenos y glaseados, chocolate, confitera, productos horneados (tartas, pasteles), salsas y sopas, jugos de frutas y blanqueadores de caf. Los productos alimenticios particularmente interesantes son los suplementos alimenticios y las frmulas infantiles. El producto alimenticio comprende preferentemente un material portador tal como las gachas de avena, alimentos fermentados con cido lctico, almidn resistente, fibras dietticas, carbohidratos, protenas y protenas glicosiladas. En una modalidad particular, las cepas de la invencin estn encapsuladas o recubiertas. Por tanto, en una modalidad particular, la composicin de la invencin es un producto alimenticio.</span>The strains of the invention can also be included in a variety of food products, such as dairy products (a yogurt, a cheese, a fermented milk, a powdered milk, a fermented milk-based product, an ice cream, a product to fermented cereal base, a milk-based powder), bread, bars, spreads, cookies and cereals, a drink, different types of oil, or a dressing. The term "food product" is used in this document in its broadest meaning, which includes any type of product, in any form of presentation, that can be ingested by an animal, but excludes pharmaceutical and veterinary products. Examples of other food products are meat products (for example, hot dogs or spreads), chocolate spreads, fillings and glazes, chocolate, confectionery, baked goods (cakes, pastries), sauces and soups, fruit juices and whiteners of coffee. Particularly interesting food products are food supplements and infant formulas. The food product preferably comprises a carrier material such as porridge, lactic acid fermented foods, resistant starch, dietary fibers, carbohydrates, proteins and glycosylated proteins. In a particular embodiment, the strains of the invention are encapsulated or coated. Therefore, in a particular embodiment, the composition of the invention is a food product.</span>
  </p>
  <p id="p0147" num="0147" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Algunas de las formas mencionadas anteriormente se consideran dispositivos mdicos en algunos pases; por ejemplo, cpsulas vaginales, tampones u otros tipos de aplicadores. As, en una modalidad particular, la composicin de la invencin es un dispositivo mdico.</span>Some of the forms mentioned above are considered medical devices in some countries; for example, vaginal capsules, tampons, or other types of applicators. Thus, in a particular embodiment, the composition of the invention is a medical device.</span>
  </p>
  <p id="p0148" num="0148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otra modalidad particular, la composicin de la invencin es un producto de higiene personal, el cual puede venderse "sin receta" en un supermercado o en una farmacia. Ejemplos de productos de higiene personal son los tampones, compresas higinicas, toallas higinicas, paales, jabones, champs, geles, ungentos, cremas, aerosoles y lociones.</span>In another particular embodiment, the composition of the invention is a personal hygiene product, which can be sold "without a prescription" in a supermarket or in a pharmacy. Examples of personal hygiene products are tampons, sanitary napkins, sanitary napkins, diapers, soaps, shampoos, gels, salves, creams, sprays, and lotions.</span>
  </p>
  <p id="p0149" num="0149" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En particular, la composicin de la invencin est en forma de tabletas intravaginales mucoadhesivas desintegrables que se aplican intravaginalmente mediante el uso de un dispositivo aplicador.</span>In particular, the composition of the invention is in the form of disintegrable mucoadhesive intravaginal tablets which are applied intravaginally through the use of an applicator device.</span>
  </p>
  <p id="p0150" num="0150" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por tanto, debe entenderse que la composicin de la invencin es til en el tratamiento de la ITU y otras enfermedades relacionadas del tracto urogenital independientemente de la forma de la composicin; es decir, independientemente de que se trate de un producto farmacutico, un medicamento, un producto alimenticio, un suplemento alimenticio, un alimento mdico o un producto de higiene personal. 
</span>Therefore, it should be understood that the composition of the invention is useful in the treatment of UTI and other related diseases of the urogenital tract regardless of the form of the composition; that is, regardless of whether it is a pharmaceutical product, a medicine, a food product, a food supplement, a medical food or a personal hygiene product. </span>
  </p>
  <p id="p0151" num="0151" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A lo largo de la descripcin y las reivindicaciones, la palabra "comprende" y sus variaciones no pretenden excluir otras caractersticas tcnicas, aditivos, componentes o pasos. Los objetos, ventajas y caractersticas adicionales de la invencin resultarn evidentes para los expertos en la tcnica tras el examen de la descripcin o pueden aprenderse mediante la prctica de la invencin. Adems, la presente invencin cubre todas las combinaciones posibles de las modalidades particulares y de preferencia descritas en el presente documento. Los siguientes ejemplos y figuras se proporcionan en el presente documento con fines ilustrativos y sin pretender limitar la presente invencin.</span>Throughout the description and claims, the word "comprise" and its variations are not intended to exclude other technical features, additives, components, or steps. Additional objects, advantages, and features of the invention will be apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. Furthermore, the present invention covers all possible combinations of the particular and preferred embodiments described herein. The following examples and figures are provided herein for illustrative purposes and are not intended to limit the present invention.</span>
  </p>
  <p id="p0152" num="0152" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Breve descripcin de las figuras</span>Brief description of the figures</span>
  </p>
  <p id="p0153" num="0153" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 1. Patrones de electroforesis de campo pulsado de ADN genmico digerido con Sfi-I y Sma-I (de izquierda a derecha): Lactobacillus plantarum P17630, L. plantarum CECT8675, L. plantarum CECT8676, L. plantarum CECT8677, L. plantarum CECT8678, y el marcador molecular de ADN (M).</span>FIG. 1. Pulsed field electrophoresis patterns of genomic DNA digested with Sfi-I and Sma-I (from left to right): Lactobacillus plantarum P17630, L. plantarum CECT8675, L. plantarum CECT8676, L. plantarum CECT8677, L. plantarum CECT8678 , and the DNA molecular marker (M).</span>
  </p>
  <p id="p0154" num="0154" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 2. RAPD de (de izquierda a derecha): L. plantarum CECT8676, L. plantarum CECT8678, la cepa probitica comercial L. plantarum P17630 y el marcador molecular de ADN (Marcador).</span>FIG. 2. RAPD of (from left to right): L. plantarum CECT8676, L. plantarum CECT8678, the commercial probiotic strain L. plantarum P17630 and the DNA molecular marker (Marker).</span>
  </p>
  <p id="p0155" num="0155" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 3. Grfico de Barras con Columnas Apiladas que muestra la actividad acumulativa antagonista de L. plantarum CECT8675, CECT8676, CECT8677, las cepas <sup class="style-scope patent-text">c </sup>E<sup class="style-scope patent-text">c</sup>T8678 y las cepas comerciales de L. plantarum P17630, L. reuteri RC-14 y L. rhamnosus GR-1, las cuales se utilizaron como controles, contra 3 cepas diferentes de Staphylococcus saprophyticus. Este grfico de barras proporciona una presentacin visual que se muestra como una barra/columna apilada separada. Cada barra/columna apilada resulta de agrupar el IC o la actividad inhibidora ("IC (mm)") medida en milmetros para cada una de las cepas citadas anteriormente, as como para cada cepa de control mencionada, contra las cepas DSM20229, DSM4853 y DSM4852 de S. saprophyticus. En este grfico, la cepa probada para la actividad antagonista contra S. saprophyticus aparece a lo largo del eje horizontal; y la altura de la barra apilada corresponde al valor IC acumulativo de cada cepa probada. Por consiguiente, cada barra apilada representa la actividad IC acumulativa de cada cepa probada contra las cepas DSM20229, DSM4853 y DSM4852 de S. saprophyticus acumuladas una encima de la otra. La altura de la barra apilada resultante muestra el resultado combinado.</span>FIG. 3. Bar Graph with Stacked Columns showing the cumulative antagonist activity of L. plantarum CECT8675, CECT8676, CECT8677, strains <sup class="style-scope patent-text">c</sup> E <sup class="style-scope patent-text">c</sup> T8678 and commercial strains of L. plantarum P17630, L. reuteri RC-14 and L. rhamnosus GR-1, which were used as controls, against 3 different strains of Staphylococcus saprophyticus. This bar chart provides a visual presentation that is displayed as a separate stacked bar / column. Each stacked bar / column results from grouping the IC or inhibitory activity ("IC (mm)") measured in millimeters for each of the strains mentioned above, as well as for each control strain mentioned, against the strains DSM20229, DSM4853 and DSM4852 from S. saprophyticus. In this graph, the strain tested for antagonist activity against S. saprophyticus appears along the horizontal axis; and the height of the stacked bar corresponds to the cumulative IC value of each strain tested. Therefore, each stacked bar represents the cumulative IC activity of each strain tested against S. saprophyticus strains DSM20229, DSM4853 and DSM4852 stacked on top of each other. The height of the resulting stacked bar shows the combined result.</span>
  </p>
  <p id="p0156" num="0156" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La FIG. 4 muestra los halos (tambin conocidos como placas o zonas de inhibicin) de las cepas de L. plantarum CECT8675, CECT8676, CECT8677 y CECT8678 de la invencin y las cepas comerciales de L. plantarum P17630. Las cepas L. reuteri RC-14 y L. rhamnosus GR-1 se utilizaron como controles contra el patgeno Staphylococcus saprophyticus DSM4582. Como se muestra en la FIG. 4 los tamaos ms grandes de los halos, que representan las zonas claras o zonas de inhibicin del crecimiento del patgeno S. saprophyticus DSM4582, se obtuvieron para las cepas de la invencin en comparacin con las cepas de control, cuando se colocaron sobre una placa de S. saprophyticus DSM4582 crecido hasta la confluencia. Esto significa una actividad antagonista ms potente de las cepas de la invencin en comparacin con las cepas utilizadas comercialmente.</span>FIG. 4 shows the halos (also known as plaques or zones of inhibition) of the L. plantarum strains CECT8675, CECT8676, CECT8677 and CECT8678 of the invention and the commercial strains of L. plantarum P17630. The L. reuteri RC-14 and L. rhamnosus GR-1 strains were used as controls against the pathogen Staphylococcus saprophyticus DSM4582. As shown in FIG. 4 the largest sizes of the halos, which represent the clear zones or zones of inhibition of the growth of the pathogen S. saprophyticus DSM4582, were obtained for the strains of the invention in comparison with the control strains, when they were placed on a plate of S. saprophyticus DSM4582 grown to confluence. This means a more potent antagonistic activity of the strains of the invention compared to the strains used commercially.</span>
  </p>
  <p id="p0157" num="0157" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 5. Grfico de Barras con Columnas Apiladas que muestra la actividad acumulativa antagonista de L. plantarum CECT8675, CECT8676, CECT8677, cepas CECT8678, y las cepas comerciales de L. plantarum P17630, L. reuteri RC-14 y L. rhamnosus GR-1, que se utilizaron como controles contra 2 cepas diferentes de Proteus mirabilis. Cada barra/columna apilada resulta de agrupar la IC o la actividad inhibidora ("IC (mm)") medida en milmetros para cada una de las cepas antes citada as como para cada cepa de control probada, contra las cepas CECT5350 y CECT4168 de P. mirabilis. La cepa probada para la actividad antagonista contra P. mirabilis aparece a lo largo del eje horizontal; y la altura de la barra apilada corresponde al valor IC acumulativo de cada cepa probada. Por consiguiente, cada barra apilada representa la actividad IC acumulada de cada cepa probada contra las cepas CECT5350 y CECT4168 de P. mirabilis acumuladas una encima de la otra. La altura de la barra apilada resultante muestra el resultado combinado.</span>FIG. 5. Bar Graph with Stacked Columns showing the cumulative antagonist activity of L. plantarum CECT8675, CECT8676, CECT8677, CECT8678 strains, and the commercial strains of L. plantarum P17630, L. reuteri RC-14 and L. rhamnosus GR- 1, which were used as controls against 2 different strains of Proteus mirabilis. Each stacked bar / column results from grouping the IC or the inhibitory activity ("IC (mm)") measured in millimeters for each of the aforementioned strains as well as for each control strain tested, against the P strains CECT5350 and CECT4168. mirabilis. The strain tested for antagonistic activity against P. mirabilis appears along the horizontal axis; and the height of the stacked bar corresponds to the cumulative IC value of each strain tested. Therefore, each stacked bar represents the cumulative IC activity of each strain tested against P. mirabilis strains CECT5350 and CECT4168 stacked on top of each other. The height of the resulting stacked bar shows the combined result.</span>
  </p>
  <p id="p0158" num="0158" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 6. Grfico de Barras con Columnas Apiladas que muestra la actividad acumulativa antagonista de L. plantarum CECT8675, CECT8676, CECT8677, CECT8678, y las cepas comerciales L. plantarum P17630 L. reuteri RC-14 y L. rhamnosus GR-1 que se utilizaron como controles contra 2 cepas diferentes de E. coli. Cada barra/columna apilada es el resultado de agrupar la IC o la actividad inhibidora ("IC (mm)") medida en milmetros para cada una de las cepas probiticas citadas anteriormente, as como para cada cepa de control probada, contra las cepas CECT434 y DSM10650 de E. coli. En este grfico, la cepa probada para la actividad antagonista contra E. coli aparece a lo largo del eje horizontal; y la altura de la barra apilada corresponde al valor IC acumulativo de cada cepa probada. Por consiguiente, cada barra apilada representa la actividad IC acumulativa de cada cepa probada contra las cepas CECT434 y DSM10650 de E. coli acumuladas una encima de la otra.</span>FIG. 6. Bar Graph with Stacked Columns showing the cumulative antagonist activity of L. plantarum CECT8675, CECT8676, CECT8677, CECT8678, and the commercial strains L. plantarum P17630 L. reuteri RC-14 and L. rhamnosus GR-1 that were used as controls against 2 different strains of E. coli. Each stacked bar / column is the result of grouping the IC or inhibitory activity ("IC (mm)") measured in millimeters for each of the probiotic strains mentioned above, as well as for each control strain tested, against the CECT434 strains. and DSM10650 from E. coli. In this graph, the strain tested for antagonist activity against E. coli appears along the horizontal axis; and the height of the stacked bar corresponds to the cumulative IC value of each strain tested. Therefore, each stacked bar represents the cumulative IC activity of each strain tested against E. coli strains CECT434 and DSM10650 stacked on top of each other.</span>
  </p>
  <p id="p0159" num="0159" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La FIG. 7 muestra la actividad antagonista global frente a los patgenos ITU ms relevantes. Las cepas de la invencin muestran una actividad de espectro antagonista general superior.</span>FIG. 7 shows the global antagonist activity against the most relevant UTI pathogens. The strains of the invention show superior overall antagonist spectrum activity.</span>
  </p>
  <p id="p0160" num="0160" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 8. Grficos de Barras con Columnas para las cepas CECT8675, CECT8676, CECT8677, CECT8678 que muestran la compatibilidad de cada cepa con el extracto de arndano y con la vitamina C, ingredientes activos comnmente utilizados para formular productos para el tratamiento de ITU en un estudio in vitro. 
</span>FIG. 8. Bar Graphs with Columns for the strains CECT8675, CECT8676, CECT8677, CECT8678 showing the compatibility of each strain with cranberry extract and with vitamin C, active ingredients commonly used to formulate products for the treatment of UTI in a study. in vitro. </span>
  </p>
  <p id="p0161" num="0161" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 9. Uso combinado de un antibitico (fosfomicina) y probitico (L. plantarum CECT8677) contra Staphylococcus saprophyticus. Resultados expresados como log<sup class="style-scope patent-text">10 </sup>de las unidades de formacin de colonias (UFC) por mL de S. saprophyticus cuando se incuba A) sin antibitico o probitico (control positivo), B) con antibitico (fosfomicina) o C) con antibitico (fosfomicina) y probitico (L. plantarum CECT8677).</span>FIG. 9. Combined use of an antibiotic (fosfomycin) and a probiotic (L. plantarum CECT8677) against Staphylococcus saprophyticus. Results expressed as log <sup class="style-scope patent-text">10</sup> colony formation units (CFU) per mL of S. saprophyticus when incubated A) without antibiotic or probiotic (positive control), B) with antibiotic (fosfomycin) or C) with antibiotic (fosfomycin) and probiotic (L. plantarum CECT8677).</span>
  </p>
  <p id="p0162" num="0162" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 10. Crecimiento de patgenos ITU en presencia o ausencia de las cepas de lactobacilos. 10A, cintica de crecimiento de Staphyloccoccus saprophyticus; 10B, cintica de crecimiento de Escherichia coli; 10C, cintica de crecimiento de Proteus mirabillis. Ae estudi la cintica de crecimiento de los patgenos A) en ausencia de probitico como control, B) en presencia de L. plantarum CECT8675, C) en presencia de L. plantarum CECT8677 o D) en presencia de L. rhamnosus GR-1</span>FIG. 10. Growth of UTI pathogens in the presence or absence of lactobacilli strains. 10A, Staphyloccoccus saprophyticus growth kinetics; 10B, Escherichia coli growth kinetics; 10C, Proteus mirabillis growth kinetics. Ae studied the growth kinetics of pathogens A) in the absence of a probiotic as a control, B) in the presence of L. plantarum CECT8675, C) in the presence of L. plantarum CECT8677 or D) in the presence of L. rhamnosus GR-1</span>
  </p>
  <p id="p0163" num="0163" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplos</span>Examples</span>
  </p>
  <p id="p0164" num="0164" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 1. Aislamiento de los microorganismos</span>EXAMPLE 1. Isolation of microorganisms</span>
  </p>
  <p id="p0165" num="0165" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas CECT8675, CECT8676, CECT8677 y CECT8678 se aislaron a partir de heces frescas de nios de 0-9 aos. Las heces se disolvieron en tampn PBS (pH 7,4), se dividieron en alcuotas y se colocaron en placas sobre MRS suplementado con diversas combinaciones de antibiticos. Las cepas se cultivaron bajo condiciones de microaerofilia (5 % de CO<sup class="style-scope patent-text">2</sup>) a 37 o 30 C. El tiempo de incubacin dependi de la tasa de crecimiento, pero fue normalmente de 24 horas a 3 das. El aislamiento de las cepas individuales se llev a cabo con el mismo medio de seleccin, y luego se realiz la tincin de Gram para obtener una primera identificacin. Una vez cultivadas, las cepas aisladas se almacenaron mediante liofilizacin en PBS 0,1x con leche desnatada en polvo al 15 %.</span>Strains CECT8675, CECT8676, CECT8677 and CECT8678 were isolated from fresh feces of children 0-9 years of age. The feces were dissolved in PBS buffer (pH 7.4), aliquoted and plated on MRS supplemented with various combinations of antibiotics. The strains were grown under microaerophilic conditions (5% CO <sup class="style-scope patent-text">2</sup> ) at 37 or 30  C. The incubation time depended on the growth rate, but was normally 24 hours to 3 days. The isolation of the individual strains was carried out with the same selection medium, and then the Gram stain was carried out to obtain a first identification. Once cultured, the isolated strains were stored by lyophilization in 0.1x PBS with 15% skimmed milk powder.</span>
  </p>
  <p id="p0166" num="0166" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas se cultivaron inicialmente en medio MRS suplementado con 10 pg/ml de vancomicina (Sigma Chemical Co, Alemania) y se incubaron a 30 C en condiciones anaerbicas y pH 6,4. La tincin de Gram mostr una tincin Gram positiva clara, as como una morfologa de bacilos no formadores de esporas.</span>The strains were initially cultured in MRS medium supplemented with 10 pg / ml vancomycin (Sigma Chemical Co, Germany) and incubated at 30  C under anaerobic conditions and pH 6.4. The Gram stain showed a clear positive Gram stain, as well as a morphology of non-spore-forming bacilli.</span>
  </p>
  <p id="p0167" num="0167" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 2. Identificacin de gnero y especie</span>EXAMPLE 2. Identification of genus and species</span>
  </p>
  <p id="p0168" num="0168" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La identificacin a nivel de especie se realiz mediante la secuenciacin del gen ARNr 16S. Brevemente, el ADN de las cepas se extrajo con resina Chelex 100 de Bio-Rad Laboratories (Barcelona, Espaa). La secuencia completa del gen de ARNr 16S se amplific mediante la reaccin en cadena de la polimerasa (PCR) mediante el uso los cebadores universales para eubacterias 27F y 1492R como se describi anteriormente [LANE, D.J. 16/23S rRNA sequencing. In Nucleic acid techniques in bacterial systematics (ed. Stackebrandt and Goodfellow) 1991, pginas 177-204; MUYZER, G. y otros. Application of denaturing gradient gel electrophoresis (DGGE) and temperature gradient gel electrophoresis (TGGE) in microbial ecology. Antonie van Leeuwenhoeck. 1998. Vol 73, No 1, pginas 127-141]. La integridad de los productos de PCR se comprob en un gel de agarosa mediante el uso del colorante verde sYb R (Invitrogen, Life Technologies, Madrid, Espaa). Los productos de PCR se secuenciaron al utilizar los cebadores 27F, 357F, 907R y 1492 [LANE, D.J. supra; MuYz ER; G. y otros. supra; OLSEN, Q.J y otros. Microbial Ecology and Evolution: A Ribosomal RNA Approach. Annual Review of Microbiology. 1986. Vol. 4, No. 1, pginas 337-365), un kit de Secuenciacin de Ciclos v3.1 y un Analizador Gentico 3130 XL (de Applied Biosystems, Life Technologies, Madrid, Espaa). Las secuencias resultantes se alinearon y compararon con las presentes en el Centro Nacional de Informacin Biotecnolgica (NCBI) y RDP (Ribosomal Database Project, Proyecto de base de datos ribosomal). Las cepas se identificaron en funcin de las puntuaciones de acierto ms altas.</span>Identification at the species level was carried out by sequencing the 16S rRNA gene. Briefly, the DNA of the strains was extracted with Chelex 100 resin from Bio-Rad Laboratories (Barcelona, Spain). The complete sequence of the 16S rRNA gene was amplified by polymerase chain reaction (PCR) using the universal primers for eubacteria 27F and 1492R as previously described [LANE, D.J. 16 / 23S rRNA sequencing. In Nucleic acid techniques in bacterial systematics (ed. Stackebrandt and Goodfellow) 1991, pages 177-204; MUYZER, G. and others. Application of denaturing gradient gel electrophoresis (DGGE) and temperature gradient gel electrophoresis (TGGE) in microbial ecology. Antonie van Leeuwenhoeck. 1998. Vol 73, No 1, pages 127-141]. The integrity of the PCR products was checked on an agarose gel using the green dye sYb R (Invitrogen, Life Technologies, Madrid, Spain). The PCR products were sequenced using primers 27F, 357F, 907R and 1492 [LANE, D.J. supra; MuYz ER; G. and others. supra; OLSEN, Q.J and others. Microbial Ecology and Evolution: A Ribosomal RNA Approach. Annual Review of Microbiology. 1986. Vol. 4, No. 1, pages 337-365), a Cycle Sequencing kit v3.1 and a 3130 XL Genetic Analyzer (from Applied Biosystems, Life Technologies, Madrid, Spain). The resulting sequences were aligned and compared with those present in the National Center for Biotechnology Information (NCBI) and RDP (Ribosomal Database Project, Ribosomal Database Project). Strains were identified based on the highest hit scores.</span>
  </p>
  <p id="p0169" num="0169" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas CECT8675, CECT8676, CECT8677 y CECT8678 se identificaron como Lactobacillus plantarum. Posteriormente las cepas se depositaron en la Coleccin Espaola de Cultivos Tipo (CECT) con los nmeros de acceso CECT8675, CECT8676, CECT8677 y CECT8678.</span>Strains CECT8675, CECT8676, CECT8677 and CECT8678 were identified as Lactobacillus plantarum. Subsequently, the strains were deposited in the Spanish Collection of Type Cultures (CECT) with the access numbers CECT8675, CECT8676, CECT8677 and CECT8678.</span>
  </p>
  <p id="p0170" num="0170" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las secuencias de ARNr 16S obtenidas para las cepas CECT8675, CECT8676, CECT8677 y CECT8678, corresponden a SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 y SEQ ID NO: 4, respectivamente.</span>The 16S rRNA sequences obtained for the strains CECT8675, CECT8676, CECT8677 and CECT8678, correspond to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, respectively.</span>
  </p>
  <p id="p0171" num="0171" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 3. Genotipado de las cepas</span>EXAMPLE 3. Genotyping of the strains</span>
  </p>
  <p id="p0172" num="0172" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El genotipado de la cepa se realiz mediante la digestin genmica y la electroforesis en gel de campo pulsado (PFGE) y el ADN polimrfico amplificado al azar (RAPD). La PFGE de las cepas se realiz como se describi anteriormente [RODAS, A.M. y otros. Polyphasic study of wine Lactobacillus strains: taxonomic implications. Int. J. Syst. Evol. Microbiol, 2005. Vol. 55, No. 1, pginas 197-207) al utilizar las enzimas de restriccin Sfi-I y Sma-I. La RAPD se realiz de acuerdo con lo descrito por Nigatu y otros. (NIGATU, A. y otros. Randomly amplified polymorphic DNA (RAPD) for discrimination of Pediococcus pentosaceus and Pediococcus acidilactici and rapid grouping of Pediococcus isolates. Letters in Applied Microbiology. 1998. Vol 26, No. 6, pginas 412-6). Los patrones se compararon con L. plantarum P17630 del producto Isadin a Barcilus como una cepa disponible comercialmente de la misma especie. 
</span>The genotyping of the strain was performed by genomic digestion and pulsed field gel electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD). The PFGE of the strains was performed as previously described [RODAS, AM et al. Polyphasic study of wine Lactobacillus strains: taxonomic implications. Int. J. Syst. Evol. Microbiol, 2005. Vol. 55, No. 1, pages 197-207) by using the restriction enzymes Sfi-I and Sma-I. RAPD was performed according to what was described by Nigatu et al. (NIGATU, A. et al. Randomly amplified polymorphic DNA (RAPD) for discrimination of Pediococcus pentosaceus and Pediococcus acidilactici and rapid grouping of Pediococcus isolates. Letters in Applied Microbiology. 1998. Vol 26, No. 6, pages 412-6). The standards were compared to L. plantarum P17630 of the Isadin a Barcilus product as a commercially available strain of the same species. </span>
  </p>
  <p id="p0173" num="0173" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los patrones de PFGE se representan en la FIG. 1. Puede verse claramente que el patrn de las cepas CECT8675 y CECT8677 fue diferente al de las otras cepas; mientras que el patrn de restriccin de las cepas CECT8676, CECT8678 y P17630 fue muy similar entre ellas. Por lo tanto, RAPd se realiz como un mtodo complementario para distinguir las cepas CECT8676, CECT8678 y P17630, porque es una tcnica eficiente para genotipar las cepas de Lactobacillus plantarum (ver, por ejemplo, JOHANSSON, M.L. y otros. Randomly amplified polymorphic DNA (RAPD) for rapid typing of Lactobacillus plantarum strains. Appl. Microbiol. 1995. Vol. 21, No. 3, pginas 155-159). Los resultados se muestran en la FIG. 2 y permiten confirmar claramente que las cepas CECT8676, CECT8678 y P17630 tambin fueron diferentes.</span>The PFGE patterns are depicted in FIG. 1. It can be clearly seen that the pattern of the CECT8675 and CECT8677 strains was different from that of the other strains; while the restriction pattern of the CECT8676, CECT8678 and P17630 strains was very similar between them. Therefore, RAPd was performed as a complementary method to distinguish the CECT8676, CECT8678 and P17630 strains, because it is an efficient technique for genotyping Lactobacillus plantarum strains (see, for example, JOHANSSON, ML et al. Randomly amplified polymorphic DNA ( RAPD) for rapid typing of Lactobacillus plantarum strains. Appl. Microbiol. 1995. Vol. 21, No. 3, pages 155-159). The results are shown in FIG. 2 and clearly confirm that the strains CECT8676, CECT8678 and P17630 were also different.</span>
  </p>
  <p id="p0174" num="0174" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 4. Actividad antagonista contra los patgenos ms frecuentes que causan ITU</span>EXAMPLE 4. Antagonistic activity against the most frequent pathogens that cause UTI</span>
  </p>
  <p id="p0175" num="0175" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se estudi la capacidad de las cepas probiticas de la presente invencin para inhibir el crecimiento de los patgenos ms frecuentes que causan ITU, mediante la confrontacin de placas de semillas de patgenos con secciones cilndricas de las cepas probiticas. En particular, se analizaron diferentes cepas de los siguientes patgenos: Staphylococcus saprohyticus, Proteus mirabilis, Escherichia coli y Klebsiella pneumoniae.</span>The ability of the probiotic strains of the present invention to inhibit the growth of the most frequent pathogens that cause UTI was studied by comparing pathogen seed plates with cylindrical sections of the probiotic strains. In particular, different strains of the following pathogens were analyzed: Staphylococcus saprohyticus, Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae.</span>
  </p>
  <p id="p0176" num="0176" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas probiticas se sembraron uniformemente en placas de agar MRS y se dejaron crecer hasta la confluencia durante 24 h a 37 C y 5 % de CO<sup class="style-scope patent-text">2</sup>. Las cepas de patgenos se cultivaron durante la noche en placas de TSA (Tripticasa Soya Agar) a 37 C y 5 % de CO<sup class="style-scope patent-text">2</sup>. Se usaron colonias aisladas de estos patgenos para preparar las suspensiones en medio de solucin salina tamponada con fosfato (PBS) y se frotaron uniformemente en placas de TSA. Inmediatamente las secciones cilndricas de 6 mm de dimetro de la placa de agar confluente de las cepas probiticas probadas se colocaron carril a carril en la placa sembrada con patgenos, lo cual permiti la confrontacin de la placa sembrada con patgenos con el lado de agar crecido de una de las secciones cilndricas y con el lado no crecido de la otra seccin del cilindro y se incub durante la noche a 37 C y 5 % de CO<sup class="style-scope patent-text">2</sup>. Luego, se midieron las zonas de inhibicin al colocar la placa de agar sobre una regla plana. A continuacin, se calcul la actividad inhibidora del crecimiento (IC) al restar el dimetro del cilindro (DC) al dimetro de la zona de inhibicin (DZI) medido en milmetros y se dividi esta diferencia por 2, de acuerdo con la frmula IC = (DZI-DC)/ 2. La actividad inhibidora final se calcul como un valor medio de los valores de IC para las dos secciones de cilindro mencionadas anteriormente para cada cepa probitica, es decir, al promediar los duplicados. Los valores inferiores a 0,5 mm se consideraron sin inhibicin (n.i.). Todos los experimentos se realizaron por triplicados.</span>The probiotic strains were uniformly seeded on MRS agar plates and grown to confluence for 24 h at 37  C and 5% CO <sup class="style-scope patent-text">2</sup> . The pathogen strains were cultured overnight on TSA plates (Trypticase Soya Agar) at 37  C and 5% CO <sup class="style-scope patent-text">2</sup> . Isolated colonies of these pathogens were used to prepare the suspensions in phosphate buffered saline (PBS) medium and evenly smeared on TSA plates. Immediately the 6 mm diameter cylindrical sections of the confluent agar plate of the probiotic strains tested were placed lane by lane on the plate seeded with pathogens, which allowed the confrontation of the plate seeded with pathogens with the agar side grown from one of the cylindrical sections and with the ungrown side of the other section of the cylinder and incubated overnight at 37  C and 5% CO <sup class="style-scope patent-text">2</sup> . Then, the zones of inhibition were measured by placing the agar plate on a flat ruler. Next, the growth inhibitory activity (IC) was calculated by subtracting the diameter of the cylinder (DC) from the diameter of the zone of inhibition (DZI) measured in millimeters and this difference was divided by 2, according to the formula IC = (DZI-DC) / 2. The final inhibitory activity was calculated as a mean value of the IC values for the two cylinder sections mentioned above for each probiotic strain, that is, by averaging the duplicates. Values less than 0.5 mm were considered without inhibition (ni). All experiments were done in triplicates.</span>
  </p>
  <p id="p0177" num="0177" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados se detallan en las siguientes secciones 4.1 a 4.3 y en las Tablas 1-3. Con fines ilustrativos, se usaron los siguientes cdigos de actividad en dichas Tablas: "-" significa IC&lt;0,5 (= inhibicin no cuantificable); "+" significa 0,5&lt;IC&lt;1; "++" significa 1 &lt;IC&lt;2; "+++" significa 2&lt;IC&lt;3; y "++++" significa IC&gt;3. Finalmente, "n.r." significa "Valor no informado".</span>The results are detailed in the following sections 4.1 to 4.3 and in Tables 1-3. For illustrative purposes, the following activity codes were used in said Tables: "-" means IC &lt;0.5 (= non-quantifiable inhibition); "+" means 0.5 &lt;CI &lt;1; "++" means 1 &lt;IC &lt;2; "+++" means 2 &lt;IC &lt;3; and "++++" means IC&gt; 3. Finally, "n.r." means "Value not reported".</span>
  </p>
  <p id="p0178" num="0178" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En consecuencia, el producto Isadin a Barcilus se ha utilizado como referencia para comparar el rendimiento probitico de Lactobacillus utilizado para restaurar el equilibrio microbiano del ecosistema vaginal. Como se muestra en las TABLAS 1-3, la cepa probitica L. plantarum P17630 de Isadin a Barcilus administrada por va oral, la cual se ha demostrado que es eficaz en la restauracin de la flora vaginal de lactobacilos y la reduccin de su colonizacin por bacterias potencialmente patgenas, no es eficaz en la reduccin de la recurrencia de ITU, en vista de la falta de actividad antagonista contra los agentes patgenos ITU, S. saprophyticus, P. mirabilis y E. coli. Por tanto, un probitico comercial compuesto por una cepa de Lactobacillus, en particular, la cepa L. plantarum P 17630, en otras palabras, un lactobacillus de la misma especie que el de las cepas de la presente invencin no ha revelado un efecto antagonista contra los patgenos causantes de ITU. Finalmente, el alimento probitico comercial VSL #3 para el tratamiento diettico de pacientes con colitis ulcerosa, IBS, etc., que comprende tambin cepas de lactobacilos, no ha descrito la actividad antagonista de las cepas de la presente invencin.</span>Consequently, the Isadin a Barcilus product has been used as a reference to compare the probiotic performance of Lactobacillus used to restore the microbial balance of the vaginal ecosystem. As shown in TABLES 1-3, the probiotic strain L. plantarum P17630 of Isadin a Barcilus administered orally, which has been shown to be effective in restoring the vaginal flora of lactobacilli and reducing their colonization. by potentially pathogenic bacteria, it is not effective in reducing UTI recurrence, in view of the lack of antagonistic activity against UTI pathogens, S. saprophyticus, P. mirabilis and E. coli. Therefore, a commercial probiotic composed of a Lactobacillus strain, in particular the L. plantarum P 17630 strain, in other words, a lactobacillus of the same species as that of the strains of the present invention has not revealed an antagonistic effect against the pathogens causing UTI. Finally, the commercial probiotic food VSL # 3 for the dietary treatment of patients with ulcerative colitis, IBS, etc., which also comprises strains of lactobacilli, has not described the antagonistic activity of the strains of the present invention.</span>
  </p>
  <p id="p0179" num="0179" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4.1. Actividad antagonista contra Staphylococcus saprophyticus</span>4.1. Antagonistic activity against Staphylococcus saprophyticus</span>
  </p>
  <p id="p0180" num="0180" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se probaron cepas de lactobacilos frente a tres cepas de S. saprophyticus (CECT235, DSM4853 y DSM4852). Como se muestra en la TABLA 1, todas las cepas CECT8675, CECT8676, CECT8677 y CECT8678 de la presente invencin mostraron actividad antagonista contra las tres cepas probadas de S. saprophyticus. En contraste, la cepa comercial L. reuteri RC-14 no mostr inhibicin contra ninguna de las tres cepas probadas de S. saprophyticus. La cepa L. rhamnosus GR-1 pudo inhibir el crecimiento de solo una de las tres cepas probadas de S. saprophyticus; y las cepas comerciales L. plantarum P17630 y VSL #3 no pudieron inhibir una de las tres cepas de S. saprophyticus. 
 </span>Lactobacilli strains were tested against three strains of S. saprophyticus (CECT235, DSM4853 and DSM4852). As shown in TABLE 1, all strains CECT8675, CECT8676, CECT8677 and CECT8678 of the present invention showed antagonistic activity against the three tested strains of S. saprophyticus. In contrast, the commercial strain L. reuteri RC-14 did not show inhibition against any of the three tested strains of S. saprophyticus. The L. rhamnosus GR-1 strain was able to inhibit the growth of only one of the three tested strains of S. saprophyticus; and the commercial strains L. plantarum P17630 and VSL # 3 could not inhibit one of the three strains of S. saprophyticus. </span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TABLA 1</span>TABLE 1</span>
  </p>
  <p id="p0182" num="0182" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e9/0a/3f/0ac5faebc50c4c/imgf000020_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000020_0001" he="246" wi="1938" file="imgf000020_0001.tif" img-format="tif" width="7752" height="984" alt="Figure imgf000020_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e9/0a/3f/0ac5faebc50c4c/imgf000020_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e9/0a/3f/0ac5faebc50c4c/imgf000020_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000020_0001" he="246" wi="1938" file="imgf000020_0001.tif" img-format="tif" width="7752" height="984" alt="Figure imgf000020_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e9/0a/3f/0ac5faebc50c4c/imgf000020_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0185" num="0185" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La FIG. 3 muestra la actividad acumulativa antagonista frente a las cepas de S. saprophyticus de las cepas de la invencin y de las cepas probiticas comerciales L. plantarum P17630, L. reuteri RC-14 y L. rhamnosus GR-1. Las cuatro cepas de la invencin mostraron una mayor actividad contra S. saprophyticus en comparacin con las cepas comerciales.</span>FIG. 3 shows the cumulative antagonist activity against the S. saprophyticus strains of the strains of the invention and of the commercial probiotic strains L. plantarum P17630, L. reuteri RC-14 and L. rhamnosus GR-1. The four strains of the invention showed greater activity against S. saprophyticus compared to the commercial strains.</span>
  </p>
  <p id="p0186" num="0186" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La FIG. 4 muestra los halos (tambin conocidos como placas o zonas de inhibicin) contra S. saprophyticus tanto de las cepas de la invencin como de las cepas comerciales utilizadas como controles. Como se muestra en la FIG. 4 los tamaos ms grandes de los halos se obtuvieron para las cepas de la invencin, la actividad antagonista ms potente de las cepas de la invencin en comparacin con las cepas comerciales utilizadas para comparar.</span>FIG. 4 shows the halos (also known as plaques or zones of inhibition) against S. saprophyticus both of the strains of the invention and of the commercial strains used as controls. As shown in FIG. 4 the largest sizes of the halos were obtained for the strains of the invention, the most potent antagonist activity of the strains of the invention compared to the commercial strains used for comparison.</span>
  </p>
  <p id="p0187" num="0187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4.2. Actividad antagonista contra Proteus m irabilis</span>4.2. Antagonistic activity against Proteus m irabilis</span>
  </p>
  <p id="p0188" num="0188" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se probaron las cepas de lactobacilos frente a dos cepas de P. mirabilis (CECT5350 y CECT4168).</span>Lactobacilli strains were tested against two P. mirabilis strains (CECT5350 and CECT4168).</span>
  </p>
  <p id="p0189" num="0189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se muestra en la TABLA 2 a continuacin, todas las cepas probadas de la presente invencin mostraron una actividad antagonista contra las dos cepas probadas de P. mirabilis. Este fue tambin el caso de L. plantarum P17630. Sin embargo, como se muestra en la FIG. 5, la actividad antagonista acumulativa de las cepas de la invencin fue mayor que la de P17630. La cepa comercial L. reuteri RC-14 no mostr actividad antagonista.</span>As shown in TABLE 2 below, all the tested strains of the present invention showed antagonistic activity against the two tested strains of P. mirabilis. This was also the case for L. plantarum P17630. However, as shown in FIG. 5, the cumulative antagonist activity of the strains of the invention was greater than that of P17630. The commercial strain L. reuteri RC-14 did not show antagonistic activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TABLA 2</span>TABLE 2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/30/b0/c501449a90e1cd/imgf000020_0002.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000020_0002" he="240" wi="1440" file="imgf000020_0002.tif" img-format="tif" width="5760" height="960" alt="Figure imgf000020_0002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/30/b0/c501449a90e1cd/imgf000020_0002.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/30/b0/c501449a90e1cd/imgf000020_0002.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000020_0002" he="240" wi="1440" file="imgf000020_0002.tif" img-format="tif" width="5760" height="960" alt="Figure imgf000020_0002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/30/b0/c501449a90e1cd/imgf000020_0002.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0194" num="0194" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4.3. Actividad antagonista contra Escherichia co li y Klebsiella pneumoniae</span>4.3. Antagonistic activity against Escherichia co li and Klebsiella pneumoniae</span>
  </p>
  <p id="p0195" num="0195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas de lactobacilos se probaron frente a dos cepas de E. coli (CECT434 y DSM10650) y la cepa de K. pneumonia DSM11678.</span>Lactobacilli strains were tested against two E. coli strains (CECT434 and DSM10650) and the K. pneumonia strain DSM11678.</span>
  </p>
  <p id="p0196" num="0196" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se muestra en la TABLA 3, todas las cepas de la presente invencin mostraron una actividad antagonista contra las dos cepas de E. coli ensayadas. Este no fue el caso de las otras cepas comerciales comnmente utilizadas para tratar las enfermedades vaginales, las cuales inhibieron una o ninguna de las cepas de E. coli probadas. Esto demuestra que aunque estas cepas comerciales pueden ser tiles para el tratamiento de enfermedades tales como la vaginitis (L. plantarum P17630) y vaginosis (L. rhamnosus GR-1 y L. reuteri RC-14), 
no son necesariamente eficaces para el tratamiento de ITU. La FIG. 6 representa la mayor actividad antagonista acumulativa contra las dos cepas de E. coli de las cepas de la invencin en comparacin con las cepas comerciales. Ventajosamente, todas las cepas de la presente invencin tambin mostraron una actividad antagonista frente a la cepa de K. pneumoniae ensayada, lo cual no fue el caso de L. rhamnosus GR-1 y L. reuteri RC-14.</span>As shown in TABLE 3, all the strains of the present invention showed antagonistic activity against the two E. coli strains tested. This was not the case for the other commercial strains commonly used to treat vaginal diseases, which inhibited one or none of the E. coli strains tested. This shows that although these commercial strains can be useful for the treatment of diseases such as vaginitis (L. plantarum P17630) and vaginosis (L. rhamnosus GR-1 and L. reuteri RC-14),  they are not necessarily effective for treating UTIs. FIG. 6 represents the highest cumulative antagonist activity against the two E. coli strains of the strains of the invention compared to the commercial strains. Advantageously, all the strains of the present invention also showed antagonistic activity against the K. pneumoniae strain tested, which was not the case for L. rhamnosus GR-1 and L. reuteri RC-14.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TABLA 3</span>TABLE 3</span>
  </p>
  <p id="p0199" num="0199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/34/8a/a5b705435591db/imgf000021_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000021_0001" he="240" wi="1939" file="imgf000021_0001.tif" img-format="tif" width="7756" height="960" alt="Figure imgf000021_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/34/8a/a5b705435591db/imgf000021_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/34/8a/a5b705435591db/imgf000021_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000021_0001" he="240" wi="1939" file="imgf000021_0001.tif" img-format="tif" width="7756" height="960" alt="Figure imgf000021_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/34/8a/a5b705435591db/imgf000021_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0201" num="0201" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 5. Compatibilidad de las cepas con el tratamiento antibitico de la ITU</span>EXAMPLE 5. Compatibility of the strains with the antibiotic treatment of UTI</span>
  </p>
  <p id="p0202" num="0202" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evalu in vitro la capacidad de las cepas CECT8675, CECT8676, CECT8677 y CECT8678 de crecer en presencia de la fosfomicina, la cual se utiliza como terapia antibitica de primera lnea para el tratamiento de ITU. Se estudi la concentracin inhibitoria mnima (CIM) de la fosfomicina para dichas cepas de acuerdo con la norma ISO 10932: 2010 (IDF 223: 2010) Leche y productos lcteos - Determinacin de la concentracin inhibitoria mnima (CIM) de los antibiticos aplicables a las bifidobacterias y a las bacterias de cido lctico no enteroccicas (LAB) 2010) para concentraciones de hasta 1024 mg/L. El crecimiento de las cuatro cepas ensayadas no se inhibi por la presencia de la fosfomicina.</span>The ability of the strains CECT8675, CECT8676, CECT8677 and CECT8678 to grow in the presence of fosfomycin, which is used as first-line antibiotic therapy for the treatment of UTI, was evaluated in vitro. The minimum inhibitory concentration (MIC) of fosfomycin for these strains was studied according to ISO 10932: 2010 (IDF 223: 2010) Milk and dairy products - Determination of the minimum inhibitory concentration (MIC) of antibiotics applicable to bifidobacteria and non-enterococcal lactic acid bacteria (LAB) 2010) for concentrations up to 1024 mg / L. The growth of the four strains tested was not inhibited by the presence of fosfomycin.</span>
  </p>
  <p id="p0203" num="0203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De manera similar, se estudi la tolerancia de las cepas a la norfloxacina, una fluoroquinolona sinttica de primera generacin que se usa ocasionalmente para tratar las ITU comunes y complicadas, mediante la misma metodologa. El crecimiento de todas las cepas no se inhibi en concentraciones tan altas como 1000 mg/L.</span>Similarly, the tolerance of the strains to norfloxacin, a first-generation synthetic fluoroquinolone that is occasionally used to treat common and complicated UTIs, was studied using the same methodology. The growth of all strains was not inhibited at concentrations as high as 1000 mg / L.</span>
  </p>
  <p id="p0204" num="0204" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 6. Compatibilidad con los ingredientes activos utilizados para tratar las ITU</span>EXAMPLE 6. Compatibility with the active ingredients used to treat UTIs</span>
  </p>
  <p id="p0205" num="0205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se estudi la compatibilidad de las cepas de la invencin con los ingredientes activos comnmente utilizados para formular productos para el tratamiento de las ITU tales como el arndano y la vitamina C, in vitro.</span>The compatibility of the strains of the invention with the active ingredients commonly used to formulate products for the treatment of UTIs such as cranberry and vitamin C, in vitro, was studied.</span>
  </p>
  <p id="p0206" num="0206" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se prepararon diluciones que contenan 3 mg/mL de extracto de arndano (titulado en proantocianidina &gt; 50 % de acuerdo con la Farmacopea Europea) o 1 mg/mL de vitamina C en solucin salina tamponada con fosfato (PBS, pH=7,4) y se esterilizaron por filtracin a travs de 0,22 pl. Se aadi un mililitro de estas soluciones a 8 mL de medio de cultivo estril Man, Rogosa y Sharpe (MRS). Se us la misma cantidad de PBS sin ingredientes activos como control. Luego, tambin se aadi al medio un mililitro de cultivos crecidos durante la noche de las cepas de la invencin (estandarizados a una concentracin equivalente a un valor de McFarland de 1). Las cepas se incubaron a continuacin durante 24 horas a 37 C en 5 % de CO<sup class="style-scope patent-text">2</sup>. El nmero de clulas viables en el medio se determin en el tiempo 0 h y despus de 24 h mediante el recuento en placa en medio slido MRS.</span>Dilutions containing 3 mg / mL of cranberry extract (titer in proanthocyanidin&gt; 50% according to the European Pharmacopoeia) or 1 mg / mL of vitamin C in phosphate buffered saline (PBS, pH = 7.4) were prepared and sterilized by filtration through 0.22 l. One milliliter of these solutions was added to 8 mL of Man, Rogosa and Sharpe (MRS) sterile culture medium. The same amount of PBS without active ingredients was used as a control. Then, one milliliter of overnight grown cultures of the strains of the invention (standardized to a concentration equivalent to a McFarland value of 1) was also added to the medium. The strains were then incubated for 24 hours at 37  C in 5% CO <sup class="style-scope patent-text">2</sup> . The number of viable cells in the medium was determined at time 0 h and after 24 h by plate counting on solid MRS medium.</span>
  </p>
  <p id="p0207" num="0207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como puede verse en la FIG. 8 todas las cepas pudieron crecer en el mismo rango independientemente de la presencia de los ingredientes activos, extracto de arndano y vitamina C, lo cual no inhibi el crecimiento de ninguna de las cepas CECT8675, CECT8676, CECT8677 y CECT8678, entre las cuales, las cepas CECT8675 y CECT8677 fueron los que mostraron mayor capacidad de crecimiento.</span>As can be seen in FIG. 8 all the strains could grow in the same range regardless of the presence of the active ingredients, cranberry extract and vitamin C, which did not inhibit the growth of any of the strains CECT8675, CECT8676, CECT8677 and CECT8678, among which, the Strains CECT8675 and CECT8677 were those that showed the highest growth capacity.</span>
  </p>
  <p id="p0208" num="0208" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 7. Formacin de agregados</span>EXAMPLE 7. Formation of aggregates</span>
  </p>
  <p id="p0209" num="0209" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La capacidad de autoagregacin es una de las etapas iniciales que conducen a la formacin de biopelculas protectoras contra los patgenos. La capacidad para formar agregados se evalu mediante el control de la disminucin de la densidad ptica a 620 nm de los cultivos durante la noche debido a la formacin de agregados y la precipitacin. El valor porcentual de la capacidad de agregacin (% AC) se obtuvo mediante el uso de la siguiente frmula: %AC=(1(DOtf/DOt0)/100, donde DOtf y DOt<sup class="style-scope patent-text">0 </sup>son la densidad ptica en los tiempos final e inicial, respectivamente. La DO en los tiempos iniciales se ajust de modo que todos los cultivos contenan un nmero 
equivalente de ufc/ml. Los cultivos combinados se prepararon mediante la mezcla de una cantidad apropiada de cepas individuales para obtener el total deseado de ufc/ml que contena el 50 % de cada cepa.</span>Self-aggregating ability is one of the initial stages leading to the formation of protective biofilms against pathogens. The ability to form aggregates was evaluated by monitoring the decrease in optical density at 620 nm of the overnight cultures due to aggregate formation and precipitation. The percentage value of the aggregation capacity (% AC) was obtained by using the following formula:% AC = (1 (DOtf / DOt0) / 100, where DOtf and DOt <sup class="style-scope patent-text">0</sup> are the optical density at the final and initial times , respectively. The OD in the initial times was adjusted so that all cultures contained a number  equivalent of cfu / ml. Pooled cultures were prepared by mixing an appropriate amount of individual strains to obtain the desired total cfu / ml containing 50% of each strain.</span>
  </p>
  <p id="p0210" num="0210" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados, como se muestra en la Tabla 4 a continuacin, revelaron una buena capacidad de agregacin para las cepas CECT8675, CECT8676 y CECT8677, que eran aproximadamente 2 veces ms altas que las de las cepas VSL #3 y L. plantarum P17630.</span>The results, as shown in Table 4 below, revealed good aggregation capacity for the CECT8675, CECT8676 and CECT8677 strains, which were approximately 2 times higher than those of the VSL # 3 and L. plantarum P17630 strains.</span>
  </p>
  <p id="p0211" num="0211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TABLA 4. Capacidad de agregacin (%)</span>TABLE 4. Aggregation capacity (%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/91/ac/0e/bda5a789cc6dfb/imgf000022_0002.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000022_0002" he="187" wi="898" file="imgf000022_0002.tif" img-format="tif" width="3592" height="748" alt="Figure imgf000022_0002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/91/ac/0e/bda5a789cc6dfb/imgf000022_0002.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/91/ac/0e/bda5a789cc6dfb/imgf000022_0002.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000022_0002" he="187" wi="898" file="imgf000022_0002.tif" img-format="tif" width="3592" height="748" alt="Figure imgf000022_0002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/91/ac/0e/bda5a789cc6dfb/imgf000022_0002.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0216" num="0216" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 8. Produccin de cidos Grasos de Cadena Corta (AGCC)</span>EXAMPLE 8. Production of Short Chain Fatty Acids (SCFA)</span>
  </p>
  <p id="p0217" num="0217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La produccin de AGCC se ensay al incubar las cepas en medio basal suplementario con fibras cada una (inulina, pectina y fructooligosacridos) en una cantidad especfica, en condiciones de microaerofilia (5 % CO<sup class="style-scope patent-text">2</sup>) a 37 C. La cantidad de AGCC se determin mediante Cromatografa Lquida de Alta Resolucin (HPLC) como se describi anteriormente [BOSCH, M. y otros. Lactobacillus plantarum CECT7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. J. Sci. Food Agric. 2014. Vol 94, No. 15, pginas 803-809].</span>The production of SCFA was tested by incubating the strains in supplemental basal medium with fibers each (inulin, pectin and fructooligosaccharides) in a specific amount, under microaerophilic conditions (5% CO <sup class="style-scope patent-text">2</sup> ) at 37  C. The amount of SCFA was determined by High Performance Liquid Chromatography (HPLC) as previously described [BOSCH, M. et al. Lactobacillus plantarum CECT7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. J. Sci. Food Agric. 2014. Vol 94, No. 15, pages 803-809].</span>
  </p>
  <p id="p0218" num="0218" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todas las cepas pudieron producir butirato. La mayor produccin se observ para las cepas CECT8677 y CECT8678, seguidas de las cepas CECT8676 y CECT8675. Todas las cepas fueron mejores productoras de butirato que L. plantarum P17630.</span>All strains were able to produce butyrate. The highest production was observed for the CECT8677 and CECT8678 strains, followed by the CECT8676 and CECT8675 strains. All the strains were better producers of butyrate than L. plantarum P17630.</span>
  </p>
  <p id="p0219" num="0219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 9. Capacidad para sobrevivir a enfermedades gastrointestinales y vaginales</span>EXAMPLE 9. Ability to survive gastrointestinal and vaginal diseases</span>
  </p>
  <p id="p0220" num="0220" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Con el fin de evaluar la resistencia de las cepas CECT8675, CECT8676, CECT8677 y CECT8678 al tracto gastrointestinal (TGI), se realizaron ensayos en condiciones que imitan el entorno del TGI de los mamferos. De este modo, se cuantific la supervivencia despus del tratamiento con lisozima, perxido de hidrgeno, ambiente cido y sales biliares.</span>In order to evaluate the resistance of the strains CECT8675, CECT8676, CECT8677 and CECT8678 to the gastrointestinal tract (GIT), tests were performed under conditions that mimic the environment of the mammalian GIT. In this way, survival was quantified after treatment with lysozyme, hydrogen peroxide, acidic environment and bile salts.</span>
  </p>
  <p id="p0221" num="0221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se colocaron veinte mililitros de cultivos probiticos crecidos durante la noche de cada cepa en una placa de 96 pocillos que contena 200 pL de medio MRS suplementado con 300 pg/ml de lisozima (Condicin de lisozima en la Tabla 5), MRS suplementado con 30 pg/ml de H<sup class="style-scope patent-text">2</sup>O<sup class="style-scope patent-text">2 </sup>(Condicin de perxido de hidrgeno en la Tabla 4), MRS suplementado con 0,3 % (p/v) de sales biliares (SIGMA B8756-10G, 096K1213) (Condicin de perxido de hidrgeno en la Tabla 5) o medio MRS ajustado a pH 2 (Ambiente cido en la Tabla 5). La relacin de supervivencia se determin para cada cepa mediante la medicin del aumento de la densidad ptica a 620 nm en un lector de ELISA despus de un tiempo de incubacin entre 0 y 6 horas, y se expres como el porcentaje de crecimiento en comparacin con el de la cepa correspondiente en MRS no suplementado (utilizado como control positivo). Los resultados se muestran en la Tabla 5 a continuacin.</span>Twenty milliliters of overnight grown probiotic cultures of each strain were placed in a 96-well plate containing 200 pL of MRS medium supplemented with 300 pg / ml of lysozyme (Lysozyme condition in Table 5), MRS supplemented with 30 pg / ml of H <sup class="style-scope patent-text">2</sup> O <sup class="style-scope patent-text">2</sup> (Condition of hydrogen peroxide in Table 4), MRS supplemented with 0.3% (w / v) of bile salts (SIGMA B8756-10G, 096K1213) (Condition of hydrogen peroxide in the Table 5) or MRS medium adjusted to pH 2 (Acidic environment in Table 5). The survival ratio was determined for each strain by measuring the increase in optical density at 620 nm in an ELISA reader after an incubation time between 0 and 6 hours, and was expressed as the percentage of growth compared to the of the corresponding strain in unsupplemented MRS (used as positive control). The results are shown in Table 5 below.</span>
  </p>
  <p id="p0222" num="0222" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TABLA 5. Relacin de supervivencia a las condiciones de TGI (%)</span>TABLE 5. Survival ratio to GIT conditions (%)</span>
  </p>
  <p id="p0224" num="0224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/89/2b/4c/3c1cc8f81ff74d/imgf000022_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000022_0001" he="133" wi="1939" file="imgf000022_0001.tif" img-format="tif" width="7756" height="532" alt="Figure imgf000022_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/89/2b/4c/3c1cc8f81ff74d/imgf000022_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/89/2b/4c/3c1cc8f81ff74d/imgf000022_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000022_0001" he="133" wi="1939" file="imgf000022_0001.tif" img-format="tif" width="7756" height="532" alt="Figure imgf000022_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/89/2b/4c/3c1cc8f81ff74d/imgf000022_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0226" num="0226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todas las cepas pudieron crecer en las diferentes condiciones de TGI ensayadas.</span>All the strains were able to grow under the different TGI conditions tested.</span>
  </p>
  <p id="p0227" num="0227" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Adems, para evaluar la resistencia de las cepas CECT8675, CECT8676, CECT8677 y CECT8678 al ambiente vaginal, se realizaron ensayos en donde dichas cepas se incubaron en medio que simulaba el fluido vaginal. El 
simulador de fluido vaginal utilizado fue el descrito por Owen y otros. [OWEN, D.H. y otros. A vaginal fluid simulan! Contraception. 1999. Vol. 59, No. 2, pginas. 91-95] a la cual se aadi lisozima (4-16 mg/L). La composicin final de dicho simulador de fluidos vaginales es de 3,5 g/l de NaCl, 1,4 g/l de KOH, 0,22 g/l de Ca(OH)<sup class="style-scope patent-text">2 </sup>, 0,02 g/l de BSA, 2 g/l de cido lctico, 1 g/l de cido actico, 0,16 g/l de glicerol, 0,4 g/l de urea y 5 g/l de glucosa; el pH se ajust adicionalmente a 4,2 al utilizar cido lctico. Las cepas se incubaron a 37 C y 5 % de CO<sup class="style-scope patent-text">2</sup>.</span>In addition, to evaluate the resistance of the strains CECT8675, CECT8676, CECT8677 and CECT8678 to the vaginal environment, tests were carried out in which said strains were incubated in a medium that simulated vaginal fluid. The  The vaginal fluid simulator used was that described by Owen et al. [OWEN, DH and others. A vaginal fluid simulate! Contraception. 1999. Vol. 59, No. 2, pages. 91-95] to which lysozyme (4-16 mg / L) was added. The final composition of said vaginal fluid simulator is 3.5 g / l of NaCl, 1.4 g / l of KOH, 0.22 g / l of Ca (OH) <sup class="style-scope patent-text">2</sup> , 0.02 g / l of BSA , 2 g / l of lactic acid, 1 g / l of acetic acid, 0.16 g / l of glycerol, 0.4 g / l of urea and 5 g / l of glucose; the pH was further adjusted to 4.2 by using lactic acid. The strains were incubated at 37  C and 5% CO <sup class="style-scope patent-text">2</sup> .</span>
  </p>
  <p id="p0228" num="0228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todas las cepas CECT8675, CECT8676, CECT8677 y CECT8678 tambin pudieron crecer en el fluido vaginal. Por lo tanto, se confirm que todas las cepas pueden vencer el TGI y urogenital y de este modo ejercer su efecto beneficioso en las ubicaciones deseadas del cuerpo.</span>All strains CECT8675, CECT8676, CECT8677 and CECT8678 were also able to grow in vaginal fluid. Therefore, it was confirmed that all strains can overcome GIT and urogenital and thus exert their beneficial effect at the desired locations in the body.</span>
  </p>
  <p id="p0229" num="0229" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 10. Efecto combinado de la fosfomicina y las cepas probiticas</span>EXAMPLE 10. Combined effect of fosfomycin and probiotic strains</span>
  </p>
  <p id="p0230" num="0230" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El objetivo fue estudiar la capacidad de las cepas probiticas de la presente invencin para incrementar la eficacia de la fosfomicina para inhibir los patgenos asociados con ITU. Se determin la actividad contra Staphylococcus saprophyticus. Se prepararon los cultivos de S. saprophyticus CECT235 y de la cepa probitica L. plantarum CECT8677 en medio Triptona Soya Agar (TSA) y medio Man, Rogosa y Sharpe (MRS), respectivamente, en placa durante la noche. Despus del crecimiento durante la noche de ambas bacterias, se prepararon suspensiones de S. saprophyticus y CECT8677 estandarizadas a 3E+06 CFU/mL en solucin salina tampn fosfato 0,1 M (PBS).</span>The objective was to study the ability of the probiotic strains of the present invention to increase the efficacy of fosfomycin to inhibit pathogens associated with UTI. Activity against Staphylococcus saprophyticus was determined. The cultures of S. saprophyticus CECT235 and of the probiotic strain L. plantarum CECT8677 were prepared in Tryptone Soy Agar (TSA) and Man, Rogosa and Sharpe (MRS) medium, respectively, on plate overnight. After overnight growth of both bacteria, suspensions of S. saprophyticus and CECT8677 standardized at 3E + 06 CFU / mL in 0.1M phosphate buffered saline (PBS) were prepared.</span>
  </p>
  <p id="p0231" num="0231" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Luego, se prepararon tubos de acuerdo con las siguientes condiciones experimentales:</span>Then, tubes were prepared according to the following experimental conditions:</span>
  </p>
  <p id="p0232" num="0232" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1) Control positivo: Tubo que contiene 7 mL de medio IST  2 mL de PBS  1 mL de la suspensin de S. saprophyticus previamente preparada.</span>1) Positive control: Tube containing 7 mL of IST medium 2 mL of PBS 1 mL of the S. saprophyticus suspension previously prepared.</span>
  </p>
  <p id="p0233" num="0233" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2) Tratamiento antibitico: Tubo que contiene 7 mL de medio IST  1 mL de PBS  1 mL de fosfomicina (concentracin final de 1 mg/L en el tubo)  1 mL de la suspensin de S. saprophyticus previamente preparada. 3) Tratamiento combinado: Tubo que contiene 7 mL de medio IST  1 mL de fosfomicina (concentracin final de 1 mg/L en el tubo)  1 mL de suspensin probitica (CECT8677) previamente preparada  1 mL de la suspensin de S. saprophyticus previamente preparada.</span>2) Antibiotic treatment: Tube containing 7 mL of IST medium 1 mL of PBS 1 mL of fosfomycin (final concentration of 1 mg / L in the tube) 1 mL of the previously prepared S. saprophyticus suspension. 3) Combined treatment: Tube containing 7 mL of IST medium 1 mL of fosfomycin (final concentration of 1 mg / L in the tube) 1 mL of previously prepared probiotic suspension (CECT8677) 1 mL of previously prepared S. saprophyticus suspension .</span>
  </p>
  <p id="p0234" num="0234" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El medio IST consisti en 11 g de casena hidrolizada, 3 g de peptona, 2 g de glucosa, 3 g de cloruro de sodio, 1 g de almidn soluble, 2 g de hidrogenofosfato disdico, 1 g de acetato de sodio, 0,2 g de magnesio, glicerofosfato, 0,1 g de gluconato de calcio, 0,001 g de sulfato de cobalto (II), 0,001 de sulfato de cobre (II), 0,001 g de sulfato de zinc, 0,001 g de sulfato de hierro (II), 0,002 g de cloruro de manganeso (II), 0,001 g de menadiona, 0,001 g de cianocobalamina, 0,02 g de clorhidrato de L-cistena, 0,02 g de L-triptfano, 0,003 g de pirodoxina, 0,003 g de pantotenato, 0,003 g de nicotinamida, 0,0003 g de biotina, 0,00004 g de tiamina, 0,01 g de adenina, 0,01 g de guanina, 0,01 g de xantina, 0,01 g de uracilo y agua hasta 1 L.</span>The IST medium consisted of 11 g of hydrolyzed casein, 3 g of peptone, 2 g of glucose, 3 g of sodium chloride, 1 g of soluble starch, 2 g of disodium hydrogen phosphate, 1 g of sodium acetate, 0.2 g of magnesium, glycerophosphate, 0.1 g of calcium gluconate, 0.001 g of cobalt (II) sulfate, 0.001 of copper (II) sulfate, 0.001 g of zinc sulfate, 0.001 g of iron (II) sulfate , 0.002 g of manganese (II) chloride, 0.001 g of menadione, 0.001 g of cyanocobalamin, 0.02 g of L-cysteine hydrochloride, 0.02 g of L-tryptophan, 0.003 g of pyrodoxin, 0.003 g of pantothenate , 0.003 g of nicotinamide, 0.0003 g of biotin, 0.00004 g of thiamine, 0.01 g of adenine, 0.01 g of guanine, 0.01 g of xanthine, 0.01 g of uracil and water up to 1 L.</span>
  </p>
  <p id="p0235" num="0235" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los tubos se incubaron a 37 C en CO<sup class="style-scope patent-text">2 </sup>al 5 % y se tomaron alcuotas de 1 mL en tiempos de 10 h y 24 h para el recuento en la placa. Se utiliz una alcuota para el recuento en la placa en medio de agar IST con el fin de contar el nmero total de bacterias presentes en el tubo. Se utiliz otra alcuota para el recuento en la placa en agar MRS que contena 16 pg/mL de vancomicina para el recuento especfico de bacterias probiticas. En los tubos que contenan tanto S. saprophyticus como CECT8677, la concentracin de S. saprophyticus se determin al restar el nmero de bacterias probiticas al recuento total de bacterias en medio IST.</span>The tubes were incubated at 37  C in <sup class="style-scope patent-text">5% CO 2</sup> and aliquots of 1 mL were taken at times of 10 h and 24 h for the plate count. An aliquot was used for the plate count on IST agar medium in order to count the total number of bacteria present in the tube. Another aliquot was used for the plate count on MRS agar containing 16 pg / mL vancomycin for the specific count of probiotic bacteria. In tubes containing both S. saprophyticus and CECT8677, the concentration of S. saprophyticus was determined by subtracting the number of probiotic bacteria from the total bacterial count in IST medium.</span>
  </p>
  <p id="p0236" num="0236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados se presentan en la FIG. 9. Como se muestra en la misma, la presencia de fosfomicina no fue suficiente para reducir significativamente la concentracin de S. saprophyticus. Sin embargo, cuando tambin se aadi el probitico, la presencia de S. saprophyticus se redujo drsticamente. Por lo tanto, el uso combinado de antibiticos y probiticos puede considerarse una opcin de manejo eficaz para tratar las infecciones por S. saprophyticus.</span>The results are presented in FIG. 9. As shown therein, the presence of fosfomycin was not sufficient to significantly reduce the concentration of S. saprophyticus. However, when the probiotic was also added, the presence of S. saprophyticus was drastically reduced. Therefore, the combined use of antibiotics and probiotics can be considered an effective management option to treat S. saprophyticus infections.</span>
  </p>
  <p id="p0237" num="0237" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 11. Formulacin del producto en cpsulas</span>EXAMPLE 11. Formulation of the product in capsules</span>
  </p>
  <p id="p0238" num="0238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cpsulas se formularon al combinar 100 mg de las cepas probiticas liofilizadas CECT8675 y CECT8677 (1-2E+09 ufc por cpsula), 240 mg de extracto de arndano, 40 mg de vitamina C (cido ascrbico), 70 mg de maltodextrina. Las cpsulas eran de hidroxipropil metilcelulosa (en esta descripcin se hace referencia como aglutinante) y dixido de titanio (E7171) (pigmento).</span>The capsules were formulated by combining 100 mg of freeze-dried probiotic strains CECT8675 and CECT8677 (1-2E + 09 cfu per capsule), 240 mg of cranberry extract, 40 mg of vitamin C (ascorbic acid), 70 mg of maltodextrin. The capsules were made of hydroxypropyl methylcellulose (referred to as a binder in this description) and titanium dioxide (E7171) (pigment).</span>
  </p>
  <p id="p0239" num="0239" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 12. Formulacin del producto en parches</span>EXAMPLE 12. Formulation of the product in patches</span>
  </p>
  <p id="p0240" num="0240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los parches se formularon al combinar 100 mg de las cepas probiticas liofilizadas CECT8675 y CECT8677 (1-2E+09 ufc por parche), 50 mg de extracto de arndano, 40 mg de vitamina C (cido ascrbico) y 70 mg de maltodextrina (en esta descripcin referida como aditivo). 
</span>The patches were formulated by combining 100 mg of the freeze-dried probiotic strains CECT8675 and CECT8677 (1-2E + 09 cfu per patch), 50 mg of cranberry extract, 40 mg of vitamin C (ascorbic acid) and 70 mg of maltodextrin (in this description referred to as an additive). </span>
  </p>
  <p id="p0241" num="0241" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 13. Formulacin del producto en viales</span>EXAMPLE 13. Formulation of the product in vials</span>
  </p>
  <p id="p0242" num="0242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El producto probitico combina los ingredientes presentes en un tapn de administracin y un vial. Los tapones de administracin contenan 100 mg de las cepas probiticas liofilizadas CECT8675 y CECT8677 (1-2 E+09 ufc por tapn de suministro), estearato de magnesio (2,2 mg) (en esta descripcin, referido como agente antiaglomerante y antiadherente) y dixido de silicio (0,5 mg) (referido en esta descripcin como agente antiaglutinante). El vial contiene 10 mL de agua y 250 mg de extracto de arndano, 0,2 mg de cido srbico (conservante), sabor a fresa (0,2 mg), cido ctrico (0,05 mg) y sucralosa 3 mg (edulcorante).</span>The probiotic product combines the ingredients present in an administration cap and a vial. The administration caps contained 100 mg of the freeze-dried probiotic strains CECT8675 and CECT8677 (1-2 E + 09 cfu per dispensing cap), magnesium stearate (2.2 mg) (in this description, referred to as an anti-caking and anti-stick agent) and silicon dioxide (0.5 mg) (referred to in this description as an anticaking agent). The vial contains 10 mL of water and 250 mg of blueberry extract, 0.2 mg of sorbic acid (preservative), strawberry flavor (0.2 mg), citric acid (0.05 mg) and sucralose 3 mg (sweetener ).</span>
  </p>
  <p id="p0243" num="0243" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 14. Estudio longitudinal de la actividad antagnica de las cepas</span>EXAMPLE 14. Longitudinal study of the antagonistic activity of the strains</span>
  </p>
  <p id="p0244" num="0244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La actividad antagonista de la cepa de lactobacilos tambin se estudi en medios lquidos para tener informacin detallada de su actividad contra los patgenos ITU ms comunes a lo largo del tiempo. Se inocularon tubos que contenan 7 mL de medio lquido ms sensible a ISO (IST) suplementado con 10 g/L de glucosa con 1 mL de PBS que contena 1E 05 UFC/mL de patgeno. Las cepas patgenas utilizadas en este ensayo fueron S. saprophyticus CECT235, E. coli CECT5350 y P. mirabilis CECT434.</span>The antagonist activity of the lactobacilli strain was also studied in liquid media to obtain detailed information on its activity against the most common UTI pathogens over time. Tubes containing 7 mL of more ISO sensitive liquid medium (IST) supplemented with 10 g / L of glucose were inoculated with 1 mL of PBS containing 1E 05 CFU / mL of pathogen. The pathogenic strains used in this assay were S. saprophyticus CECT235, E. coli CECT5350, and P. mirabilis CECT434.</span>
  </p>
  <p id="p0245" num="0245" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Posteriormente, los tubos se inocularon con 1 mL de PBS que contena 1E 07 CFU/mL de probitico. Como control se utilizaron tubos inoculados con la misma cantidad de PBS, pero que no contenan probiticos. Las cepas de lactobacilos estudiadas fueron L. plantarum CECT 8675 y CECT 8677 y L. rhamnosus GR-1. La actividad antagonista de las cepas de lactobacilos contra S. saprophyticus se representa en la FIG. 10 A. Los resultados demuestran que la adicin de los lactobacilos al medio redujo la cantidad de clulas vivas de S. saprophyticus en comparacin con el medio de control que no contena probiticos. Entre las diferentes cepas probiticas ensayadas, tanto L. plantarum CECT 8675 como CECT 8677 mostraron la mayor actividad antimicrobiana, y fueron las que redujeron con mayor eficiencia la concentracin de S. saprophyticus despus de 48h. De manera notable, L. plantarum CECT8677 pudo reducir la concentracin de patgeno incluso durante las primeras 24 h, mientras que L. plantarum CECT8677 pudo erradicar la presencia de S. saprophyticus en el medio despus de 48 h.</span>Subsequently, the tubes were inoculated with 1 mL of PBS containing 1E 07 CFU / mL of probiotic. As a control, tubes inoculated with the same amount of PBS, but which did not contain probiotics, were used. The lactobacilli strains studied were L. plantarum CECT 8675 and CECT 8677 and L. rhamnosus GR-1. The antagonistic activity of the lactobacilli strains against S. saprophyticus is depicted in FIG. 10 A. The results demonstrate that the addition of the lactobacilli to the medium reduced the number of live S. saprophyticus cells compared to the control medium containing no probiotics. Among the different probiotic strains tested, both L. plantarum CECT 8675 and CECT 8677 showed the highest antimicrobial activity, and were the ones that most efficiently reduced the concentration of S. saprophyticus after 48h. Notably, L. plantarum CECT8677 was able to reduce the pathogen concentration even during the first 24 h, while L. plantarum CECT8677 was able to eradicate the presence of S. saprophyticus in the medium after 48 h.</span>
  </p>
  <p id="p0246" num="0246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todos los lactobacilos probados tambin pudieron reducir el crecimiento de E. coli (FIG. 10B). En este caso todas las cepas mostraron un efecto bacteriosttico durante las primeras 24 horas y una leve actividad bactericida despus de este perodo. La cepa L. plantarum CECT8677 fue la que mostr la mayor actividad antimicrobiana.</span>All the lactobacilli tested were also able to reduce the growth of E. coli (FIG. 10B). In this case, all the strains showed a bacteriostatic effect during the first 24 hours and a slight bactericidal activity after this period. The L. plantarum CECT8677 strain was the one that showed the highest antimicrobial activity.</span>
  </p>
  <p id="p0247" num="0247" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La actividad antagonista de las cepas de lactobacilos contra P. mirabillis se representa en la FIG. 10C. Las cepas L. plantarum CECT8675 y CECT8677 fueron las cepas que mostraron la mayor actividad durante las primeras 24 h. Luego de este perodo L. plantarum CECT8677 fue la cepa con mayor efecto antimicrobiano, la cual redujo la presencia de P. mirabilli a concentraciones an menores a las del inicio del ensayo.</span>The antagonist activity of the lactobacilli strains against P. mirabillis is depicted in FIG. 10C. The L. plantarum strains CECT8675 and CECT8677 were the strains that showed the highest activity during the first 24 h. After this period, L. plantarum CECT8677 was the strain with the greatest antimicrobial effect, which reduced the presence of P. mirabilli to concentrations even lower than those at the beginning of the trial.</span>
  </p>
  <p id="p0248" num="0248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En resumen, los resultados confirman que tanto L. plantarum CECT8675 como CECT8677 muestran una buena actividad frente a los patgenos ITU, por lo cual son buenos candidatos para el tratamiento de enfermedades asociadas.</span>In summary, the results confirm that both L. plantarum CECT8675 and CECT8677 show good activity against UTI pathogens, which is why they are good candidates for the treatment of associated diseases.</span>
  </p>
  <p id="p0249" num="0249" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLO 15. Fermentacin y postratamiento de las cepas</span>EXAMPLE 15. Fermentation and post-treatment of the strains</span>
  </p>
  <p id="p0250" num="0250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La biomasa post-tratamiento utilizada como materia prima se obtuvo mediante un proceso de fabricacin que incluy las etapas de fermentacin y liofilizacin. Se prepar un cultivo madre al inocular 80 mL de medio de cultivo <sup class="style-scope patent-text">m </sup>R<sup class="style-scope patent-text">s </sup>con las cepas de L. plantarum. El medio inoculado se ferment a 37 C en condiciones de microaerofilias durante 48 h. El cultivo resultante se us para inocular 600 litros de medio de cultivo MRS en una relacin de aproximadamente 1-2 % de inculo por volumen total de medio de caldo. El medio resultante se enfri a 3-5 C y se centrifug para eliminar la mayor parte del agua presente en el caldo. Se aadieron crioprotectores al cultivo concentrado y la mezcla resultante se liofiliz a -45 C.</span>The post-treatment biomass used as raw material was obtained through a manufacturing process that included the fermentation and lyophilization stages. Mother culture was prepared inoculating 80 mL of culture medium <sup class="style-scope patent-text">m</sup> R <sup class="style-scope patent-text">s</sup> with L. plantarum strains. The inoculated medium was fermented at 37  C under microaerophilic conditions for 48 h. The resulting culture was used to inoculate 600 liters of MRS culture medium at a ratio of approximately 1-2% inoculum per total volume of broth medium. The resulting medium was cooled to 3-5  C and centrifuged to remove most of the water present in the broth. Cryoprotectants were added to the concentrated culture and the resulting mixture was lyophilized at -45  C.</span>
  </p>
  <p id="p0251" num="0251" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Referencias bibliogrficas</span>Bibliographic references</span>
  </p>
  <p id="p0252" num="0252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ARAYA, M., y otros. Guidelines for the Evaluation of Probiotics in Food - Joint FAO/WHO Working Group, FAO/WHO, Editor 2002, Food and Agriculture Organization of the United Nations and World Health Organization: Ontario, Canada.</span>ARAYA, M., and others. Guidelines for the Evaluation of Probiotics in Food - Joint FAO / WHO Working Group, FAO / WHO, Editor 2002, Food and Agriculture Organization of the United Nations and World Health Organization: Ontario, Canada.</span>
  </p>
  <p id="p0253" num="0253" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REID, G. y otros. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J. Urol. 1987, Vol. 138, pginas 330-335.</span>REID, G. and others. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J. Urol. 1987, Vol. 138, pages 330-335.</span>
  </p>
  <p id="p0254" num="0254" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HOOTON, T.M. Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, Vol. 366, No. 11, pginas 1028-1037.</span>HOOTON, T.M. Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, Vol. 366, No. 11, pages 1028-1037.</span>
  </p>
  <p id="p0255" num="0255" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GRABE, M. y otros. European Association of Urology (EAU). Guidelines on urological infections. EAU. 2013.</span>GRABE, M. and others. European Association of Urology (EAU). Guidelines on urological infections. UAE. 2013.</span>
  </p>
  <p id="p0256" num="0256" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SALVATORE, S. y otros. Urinary Tract Infections in Women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, Vol. 156, pginas 131-136. 
</span>SALVATORE, S. and others. Urinary Tract Infections in Women. Eur. J. Obstet. Gynecol. Play Biol. 2011, Vol. 156, pages 131-136. </span>
  </p>
  <p id="p0257" num="0257" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FOXMAN, B. y BROWN, P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect. Dis. Clin. North. Am. 2003, Vol. 17, No. 2, pginas 227-241.</span>FOXMAN, B. and BROWN, P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect. Dis. Clin. North. Am. 2003, Vol. 17, No. 2, pages 227-241.</span>
  </p>
  <p id="p0258" num="0258" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HOOTON, T.M. y otros. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 1996, Vol. 335, No. 7, pginas 468-474.</span>HOOTON, T.M. and others. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 1996, Vol. 335, No. 7, pages 468-474.</span>
  </p>
  <p id="p0259" num="0259" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">JACKSON, S.L. y otros. Predictors of urinary tract infection after menopause: a prospective study. Am. J. Med. 2004, Vol. 117, No. 12, pginas 903-11.</span>JACKSON, S.L. and others. Predictors of urinary tract infection after menopause: a prospective study. Am. J. Med. 2004, Vol. 117, No. 12, pages 903-11.</span>
  </p>
  <p id="p0260" num="0260" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ULLERYD, P. y otros. Febrile urinary tract infection in men. Int. J. Antimicrob. Agents. 2003, Vol. 22, Suppl. 2, pginas 89-93.</span>ULLERYD, P. and others. Febrile urinary tract infection in men. Int. J. Antimicrob. Agents. 2003, Vol. 22, Suppl. 2, pages 89-93.</span>
  </p>
  <p id="p0261" num="0261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GUPTA, K. y otros. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 2011, Vol. 52, No. 1, e103-e120.</span>GUPTA, K. and others. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 2011, Vol. 52, No. 1, e103-e120.</span>
  </p>
  <p id="p0262" num="0262" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ERIKSSON, A. y otros. The relative importance of Staphylococcus Saprophyticus as a urinary tract pathogen: distribution of bacteria among urinary samples analyzed during 1 year at a major Swedish laboratory. APMIS. 2012, Vol. 121, pginas 72-78.</span>ERIKSSON, A. and others. The relative importance of Staphylococcus Saprophyticus as a urinary tract pathogen: distribution of bacteria among urinary samples analyzed during 1 year at a major Swedish laboratory. APMIS. 2012, Vol. 121, pages 72-78.</span>
  </p>
  <p id="p0263" num="0263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GARCA-GARCA, M.I. y otros. In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J. Chemotherapy. 2007, Vol. 19, pginas 263-270.</span>GARCA-GARCA, M.I. and others. In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J. Chemotherapy. 2007, Vol. 19, pages 263-270.</span>
  </p>
  <p id="p0264" num="0264" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ANDREU, A., y otros. Etiologa y sensibilidad a los antimicrobianos de los uropatgenos causantes de la infeccin urinaria baja adquirida en la comunidad. Estudio nacional multicntrico. Enferm. Infecc. Microbiol. Clin. 2005, Vol. 23, No. 1, pginas 4-9.</span>ANDREU, A., and others. Etiology and antimicrobial sensitivity of the uropathogens causing community-acquired lower urinary tract infection. National multicenter study. Sick Infecc. Microbiol. Clin. 2005, Vol. 23, No. 1, pages 4-9.</span>
  </p>
  <p id="p0265" num="0265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KAHLMETER, G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project. Journal of Antimicrobial Chemotherapy. 2003, Vol. 51, pginas 69-76.</span>KAHLMETER, G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project. Journal of Antimicrobial Chemotherapy. 2003, Vol. 51, pages 69-76.</span>
  </p>
  <p id="p0266" num="0266" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HUMMERS-PRADIER, E. y otros. Urinary tract infections in adult general practice patients. British Journal of general practice. 2002, Vol. 52, pginas 752-761.</span>HUMMERS-PRADIER, E. and others. Urinary tract infections in adult general practice patients. British Journal of general practice. 2002, Vol. 52, pages 752-761.</span>
  </p>
  <p id="p0267" num="0267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SENGUPTA, K. y otros. A Randomized, double blind, controlled, dose dependent clinical trial to evaluate the efficacy of a proanthocyanidin standardized whole cranberry (Vaccinium macrocarpon) powder on infections of the urinary tract. Current Bioactive Compounds. 2011, Vol. 7, No 1, pginas 39-42.</span>SENGUPTA, K. and others. A Randomized, double blind, controlled, dose dependent clinical trial to evaluate the efficacy of a proanthocyanidin standardized whole cranberry (Vaccinium macrocarpon) powder on infections of the urinary tract. Current Bioactive Compounds. 2011, Vol. 7, No 1, pages 39-42.</span>
  </p>
  <p id="p0268" num="0268" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BARBOSA-CESNIK, C. y otros. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clinical Infectious Diseases. 2011, Vol. 52, No. 1, pginas 23-30.</span>BARBOSA-CESNIK, C. and others. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clinical Infectious Diseases. 2011, Vol. 52, No. 1, pages 23-30.</span>
  </p>
  <p id="p0269" num="0269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KONTIOKARI, T. y otros. Randomized trial of cranberry-lingonberry juice and Lactobacillus G drink for the prevention of urinary tract infections in women. BMJ. 2001. Vol. 322, pginas 1-5.</span>KONTIOKARI, T. and others. Randomized trial of cranberry-lingonberry juice and Lactobacillus G drink for the prevention of urinary tract infections in women. BMJ. 2001. Vol. 322, pages 1-5.</span>
  </p>
  <p id="p0270" num="0270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">JEPSON, R.G. y CRAIG, J.C. Cranberries for preventing urinary tract infections (Revisin). Cochrane Database Syst. Rev. 2008. Vol. 23, No. 1.</span>JEPSON, R.G. and CRAIG, J.C. Cranberries for preventing urinary tract infections (Review). Cochrane Database Syst. Rev. 2008. Vol. 23, No. 1.</span>
  </p>
  <p id="p0271" num="0271" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">LARSSON, P.G. y otros. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Ingectious Diseases. 2011. Vol. 11, pgina 223 BAERHEIM, A. y otros. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand. J. Prim. Health Care. 1994. Vol. 12, pginas 239-243.</span>LARSSON, P.G. and others. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Ingectious Diseases. 2011. Vol. 11, page 223 BAERHEIM, A. and others. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand. J. Prim. Health Care. 1994. Vol. 12, pages 239-243.</span>
  </p>
  <p id="p0272" num="0272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MARTINEZ, R.C.R. y otros. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double blind, placebo control trial. Canadian Journal of Microbiology. 2009, Vol. 55, pginas 133-138.</span>MARTINEZ, R.C.R. and others. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double blind, placebo control trial. Canadian Journal of Microbiology. 2009, Vol. 55, pages 133-138.</span>
  </p>
  <p id="p0273" num="0273" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ANUKAM, K. y otros. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes and infection. 2006. Vol. 8. pginas 1450-1454.</span>ANUKAM, K. and others. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes and infection. 2006. Vol. 8. pages 1450-1454.</span>
  </p>
  <p id="p0274" num="0274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BEEREPOT, M.A. y otros. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in post-menopausal women. Archives of Internal Medicine. Mayo de 2012, Vol. 172, No. 9, pginas 704-712.</span>BEEREPOT, M.A. and others. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in post-menopausal women. Archives of Internal Medicine. May 2012, Vol. 172, No. 9, pages 704-712.</span>
  </p>
  <p id="p0275" num="0275" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EP 1137423 B1 (UREX BIOTECH, INC.) 04.10.2001, reivindicacin 4. 
</span>EP 1137423 B1 (UREX BIOTECH, INC.) 04.10.2001, claim 4.
</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(9)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Spanish</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM308095568" lang="EN" load-source="google" class="style-scope patent-text">
  <claim-statement class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REIVINDICACIONES
  </span></span></claim-statement>
  <claim id="clm-0001" num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composicin que comprende una cantidad eficaz de al menos una cepa de Lactobacillus plantarum, en donde al menos la cepa de Lactobacillus plantarum se selecciona del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677, la cepa CECT8678 y un mutante de cualquiera de las cepas depositadas, en donde el mutante se obtuvo mediante el uso de la cepa depositada como material de partida y mediante mutagnesis, y en donde el mutante obtenido retiene o potencia al menos la capacidad de la cepa depositada de antagonizar el patgeno urogenital Staphylococcus saprophyticus.</span>1. A composition comprising an effective amount of at least one Lactobacillus plantarum strain, wherein at least the Lactobacillus plantarum strain is selected from the group consisting of: strain CECT8675, strain CECT8676, strain CECT8677, strain CECT8678 and a mutant of any of the deposited strains, wherein the mutant was obtained by using the deposited strain as starting material and by mutagenesis, and wherein the obtained mutant retains or enhances at least the ability of the deposited strain to antagonize the urogenital pathogen Staphylococcus saprophyticus.</span>
    </claim-text>
  </claim>
  <claim id="clm-0002" num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. La composicin de acuerdo con la reivindicacin 1, en donde al menos la cepa de Lactobacillus plantarum se selecciona del grupo que consiste en: la cepa CECT8675, la cepa CECT8676, la cepa CECT8677 y la cepa CECT8678.</span>The composition according to claim 1, wherein at least the Lactobacillus plantarum strain is selected from the group consisting of: the CECT8675 strain, the CECT8676 strain, the CECT8677 strain and the CECT8678 strain.</span>
    </claim-text>
  </claim>
  <claim id="clm-0003" num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. La composicin de acuerdo con cualquiera de las reivindicaciones 1-2, en donde al menos la cepa se ha fermentado en un medio artificial y sometida a un postratamiento despus de la fermentacin, para obtener clulas bacterianas, y en donde las clulas bacterianas resultantes estn en un medio lquido o en una forma slida.</span>3. The composition according to any of claims 1-2, wherein at least the strain has been fermented in an artificial medium and subjected to post-treatment after fermentation, to obtain bacterial cells, and wherein the resulting bacterial cells they are in a liquid medium or in a solid form.</span>
    </claim-text>
  </claim>
  <claim id="clm-0004" num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. La composicin de acuerdo con la reivindicacin 3, en donde el postratamiento se selecciona del grupo que consiste en: secado, congelacin, liofilizacin, secado en lecho fluido, secado por aspersin y refrigeracin en medio lquido.</span>The composition according to claim 3, wherein the post-treatment is selected from the group consisting of: drying, freezing, lyophilization, fluid bed drying, spray drying and cooling in a liquid medium.</span>
    </claim-text>
  </claim>
  <claim id="clm-0005" num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. La composicin de acuerdo con cualquiera de las reivindicaciones 1-4, para su uso como medicamento o como probitico.</span>5. The composition according to any of claims 1-4, for use as a medicine or as a probiotic.</span>
    </claim-text>
  </claim>
  <claim id="clm-0006" num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. La composicin para su uso de acuerdo con la reivindicacin 5 en la prevencin y/o tratamiento de una enfermedad relacionada con alteraciones de la microbiota urogenital.</span>6. The composition for use according to claim 5 in the prevention and / or treatment of a disease related to alterations of the urogenital microbiota.</span>
    </claim-text>
  </claim>
  <claim id="clm-0007" num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. La composicin para su uso de acuerdo con la reivindicacin 6, en donde la enfermedad es una infeccin del tracto urinario.</span>The composition for use according to claim 6, wherein the disease is a urinary tract infection.</span>
    </claim-text>
  </claim>
  <claim id="clm-0008" num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. La composicin para su uso de acuerdo con cualquiera de las reivindicaciones 5-7, en combinacin con una cantidad eficaz de un agente antimicrobiano.</span>The composition for use according to any of claims 5-7, in combination with an effective amount of an antimicrobial agent.</span>
    </claim-text>
  </claim>
  <claim id="clm-0009" num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. Un producto farmacutico, un producto veterinario, un alimento mdico, un producto alimenticio, un suplemento alimenticio o un producto de higiene personal, que comprende una cantidad eficaz de la composicin como se define en cualquiera de las reivindicaciones 1-8, junto con cantidades apropiadas de excipientes aceptables. 
</span>9. A pharmaceutical product, a veterinary product, a medical food, a food product, a food supplement or a personal hygiene product, comprising an effective amount of the composition as defined in any of claims 1-8, together with appropriate amounts of acceptable excipients.
</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (5)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20010101171A/en"><a id="link" href="#" class="style-scope state-modifier">KR20010101171A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-11</span>
                    <span class="td style-scope patent-result">2001-11-14</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Oral administration of lactobacillus for the treatment and prevention of urogenital infection 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006045347A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2006045347A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-10-22</span>
                    <span class="td style-scope patent-result">2006-05-04</span>
                    <span class="td style-scope patent-result">Medinova Ag</span>
                    <span class="td style-scope patent-result">Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PL210465B1/en"><a id="link" href="#" class="style-scope state-modifier">PL210465B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-06-04</span>
                    <span class="td style-scope patent-result">2012-01-31</span>
                    <span class="td style-scope patent-result">Inst Biotechnologii Surowic I Szczepionek Biomed Spoka Akcyjna</span>
                    <span class="td style-scope patent-result">Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ITRM20110475A1/en"><a id="link" href="#" class="style-scope state-modifier">ITRM20110475A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-09-09</span>
                    <span class="td style-scope patent-result">2013-03-10</span>
                    <span class="td style-scope patent-result">Probiotical Spa</span>
                    <span class="td style-scope patent-result">
  BACTERIA OF LACTIC AND / OR BIFIED BACTERIA BACTERIA, OPTIONALLY ADDED TO N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTETTO, HAVING INHIBITION ACTIVITIES / REDUCTION OF THE GROWTH OF DIFFERENT E.COLI BIOTYPES, INCLUDING E.COLI O157: H7 E
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ITMI20130794A1/en"><a id="link" href="#" class="style-scope state-modifier">ITMI20130794A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-05-14</span>
                    <span class="td style-scope patent-result">2014-11-15</span>
                    <span class="td style-scope patent-result">Probiotical Spa</span>
                    <span class="td style-scope patent-result">
  COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF BACTERIAL VAGINOSIS.
 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (5)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CL2017001273A1/en"><a id="link" href="#" class="style-scope state-modifier">CL2017001273A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-05-17</span>
                    <span class="td style-scope patent-result">2018-03-16</span>
                    <span class="td style-scope patent-result">Univ San Sebastian</span>
                    <span class="td style-scope patent-result">
  Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101930438B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101930438B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-12</span>
                    <span class="td style-scope patent-result">2018-12-18</span>
                    <span class="td style-scope patent-result">() </span>
                    <span class="td style-scope patent-result">Novel Lactobacillus plantarum strain ATG-K2, ATG-K6 or ATG-K8, and composition comprising thereof for preventing or treating vaginosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20230129480A/en"><a id="link" href="#" class="style-scope state-modifier">KR20230129480A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-01-05</span>
                    <span class="td style-scope patent-result">2023-09-08</span>
                    <span class="td style-scope patent-result"> /</span>
                    <span class="td style-scope patent-result">
  Strains, compositions and methods of use
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2024061444A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2024061444A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-09-20</span>
                    <span class="td style-scope patent-result">2024-03-28</span>
                    <span class="td style-scope patent-result">Uab "Avodes"</span>
                    <span class="td style-scope patent-result">Sponge for the vaginal canal 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116004464A/en"><a id="link" href="#" class="style-scope state-modifier">CN116004464A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-01-06</span>
                    <span class="td style-scope patent-result">2023-04-25</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Lactobacillus plantarum and application thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2865269T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2865269T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-10-15</span>
                    <span class="td style-scope patent-result">
  Lactobacillus salivarius strain, a composition that includes it and uses of it
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2873075T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2873075T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-11-03</span>
                    <span class="td style-scope patent-result">
  Lactobacillus plantarum probiotic strains for urinary tract infections
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2949659T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2949659T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-10-02</span>
                    <span class="td style-scope patent-result">
  Synergistic bacterial compositions and production and use procedures thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2652464T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2652464T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-02-02</span>
                    <span class="td style-scope patent-result">
  Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2500166T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2500166T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-30</span>
                    <span class="td style-scope patent-result">
  Probiotic oral dosage forms
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2761333T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2761333T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-05-19</span>
                    <span class="td style-scope patent-result">
  Pharmaceutical compositions containing Pediococcus and methods to reduce the symptoms of gastroenterological syndromes
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2324532T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2324532T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-10</span>
                    <span class="td style-scope patent-result">
  PROBIOTIC BACTERIA: LACTOBACILLUS FERMENTUM.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2268226T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2268226T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-03-16</span>
                    <span class="td style-scope patent-result">
  BIFIDOBACTERIUM LONGUN BASTERIES AND PREPARATIONS THAT CONTAIN THEM.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2611277T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2611277T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-05-08</span>
                    <span class="td style-scope patent-result">
  Peptides against a rotavirus infection
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2568955T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2568955T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-05-05</span>
                    <span class="td style-scope patent-result">
  Metabolically active microorganisms and methods for their production
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2742410T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2742410T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-02-14</span>
                    <span class="td style-scope patent-result">
  Lactobacillus pentosus strain as a probiotic
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20060056991A/en"><a id="link" href="#" class="style-scope state-modifier">KR20060056991A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-05-25</span>
                    <span class="td style-scope patent-result">Bacterial strains, compositions including same and probiotic use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2683190T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2683190T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-09-25</span>
                    <span class="td style-scope patent-result">
  Probiotic for excessive childhood crying
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101287126B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101287126B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-07-17</span>
                    <span class="td style-scope patent-result">Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN105307654A/en"><a id="link" href="#" class="style-scope state-modifier">CN105307654A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-02-03</span>
                    <span class="td style-scope patent-result">Compositions and methods for treating microbiota-related psychotropic conditions and diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2734994T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2734994T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-12-13</span>
                    <span class="td style-scope patent-result">
  Chitin or its derivatives for the prevention and / or treatment of parasitosis
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN107405354A/en"><a id="link" href="#" class="style-scope state-modifier">CN107405354A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-11-28</span>
                    <span class="td style-scope patent-result">Treat the composition and method of ARI 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN113474447A/en"><a id="link" href="#" class="style-scope state-modifier">CN113474447A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-10-01</span>
                    <span class="td style-scope patent-result">Strains, compositions and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2551408T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2551408T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-18</span>
                    <span class="td style-scope patent-result">
  Use of d-fagomin as an inhibitor of bacterial adhesion to epithelial cells
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN107427697A/en"><a id="link" href="#" class="style-scope state-modifier">CN107427697A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-01</span>
                    <span class="td style-scope patent-result">Treatment diarrhoea and the method for promotion intestinal health in non-human animal 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10456430B1/en"><a id="link" href="#" class="style-scope state-modifier">US10456430B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-10-29</span>
                    <span class="td style-scope patent-result">Lactobacillus composition for prevention and treatment of bacterial vaginosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2678395T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2678395T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-08-10</span>
                    <span class="td style-scope patent-result">
  New strain of Lactobacillus casei capable of degrading the immunotoxic gluten peptide
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101833832B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101833832B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-02-28</span>
                    <span class="td style-scope patent-result">A composition comprising specific lactic acid bacteria for protecting and treating vaginosis disease and the use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH11180888A/en"><a id="link" href="#" class="style-scope state-modifier">JPH11180888A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-07-06</span>
                    <span class="td style-scope patent-result">Antimicrobial, infection preventive and food product against helicobacter pylori bacteria 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2615808T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2615808T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-08</span>
                    <span class="td style-scope patent-result">
  Microorganisms and compositions that comprise them for use in the treatment or prevention of mastitis
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3064072A1/en"><a id="link" href="#" class="style-scope state-modifier">EP15382051.9A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2015-02-11</span>
                    <span class="td style-scope patent-result">Probiotic lactobacillus strains for use in treating urinary tract infections 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016128414A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2016/052747</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2016-02-09</span>
                    <span class="td style-scope patent-result">Probiotic strains for urinary tract infections 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu"></span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Anatomy</div>
          
            <div class="item style-scope dropdown-menu">Chemical class</div>
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          
            <div class="item style-scope dropdown-menu">Chemical group</div>
          
            <div class="item style-scope dropdown-menu">Diseases</div>
          
            <div class="item style-scope dropdown-menu">Drugs</div>
          
            <div class="item style-scope dropdown-menu">Effects</div>
          
            <div class="item style-scope dropdown-menu">Human genes</div>
          
            <div class="item style-scope dropdown-menu">Inorganic materials</div>
          
            <div class="item style-scope dropdown-menu">Methods</div>
          
            <div class="item style-scope dropdown-menu">Natural products</div>
          
            <div class="item style-scope dropdown-menu">Nutrition</div>
          
            <div class="item style-scope dropdown-menu">Polymers</div>
          
            <div class="item style-scope dropdown-menu">Proteins</div>
          
            <div class="item style-scope dropdown-menu">Species</div>
          
            <div class="item style-scope dropdown-menu">Substances</div>
          
            <div class="item style-scope dropdown-menu">Toxicity</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lactobacillus plantarum</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">83</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lactobacillus plantarum</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lactobacillus plantarum</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">urinary tract infection</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">117</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">probiotic</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">80</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">probiotics</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">80</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">probiotic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">67</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mixture</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">94</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pathogen</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">70</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Staphylococcus saprophyticus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">60</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pathogenic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Toxicity style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mutagenesis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mutagenesis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">starting material</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">84</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">product</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">42</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">food</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">35</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bacterial effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dietary supplement</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">liquid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">solid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antimicrobial</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">18</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fluid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pharmaceutical excipient</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">diseases, disorders, signs and symptoms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drying</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">14</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">prevention</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">14</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pharmaceutical preparation</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pharmaceutical product</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Microbiota</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">freeze drying</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">alteration</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">freezing</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">freezing</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">spray drying</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fermentation</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fermentation</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cooling</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2638806602" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2638806602" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=359394104" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>